


Article

Sulfondiimidamides as new functional groups for synthetic and medicinal chemistry



The double aza variants of sulfonamides—sulfondiimidamides—are elusive functional groups with extremely limited precedent. We establish that these new groups are stable, that they can be prepared efficiently, are amenable to modification, and that S-chiral versions are possible. Exploiting an unsymmetrical sulfurdiimide reagent unlocks their three-component assembly, using organometallic reagents and amines as the building blocks. Broad variation at all three nitrogen atoms and at the carbon substituent is possible. We also synthesize a sulfondiimidamide analogue of the COX-2 inhibitor celecoxib.

Ze-Xin Zhang, Michael C. Willis

michael.willis@chem.ox.ac.uk

Highlights

Efficient three-component assembly of sulfondiimidamides; new analogs of sulfonamides

Use of unsymmetrical sulfurdiimide reagents is key to success of the synthesis

Broad variation at all three nitrogen atoms and the carbon substituent

Preparation of enantiomerically enriched, chiral at sulfur, examples

Article

Sulfondiimidamides as new functional groups for synthetic and medicinal chemistry

Ze-Xin Zhang¹ and Michael C. Willis^{1,2,*}

SUMMARY

Due to their three-dimensional structure, chemical and metabolic stability, polarity, and hydrogen-bonding ability, sulfonamides occupy a privileged position among the functional groups used to design bioactive molecules. The mono aza variants, sulfonimidamides, a functional group known since the 1930s, possess an extra nitrogen atom, which delivers an additional point of diversity and introduces chirality at sulfur. However, the double aza analogs, sulfondiimidamides, are elusive molecules with severely limited accessibility. We show that sulfondiimidamides are viable molecules and that by using an unsymmetrical sulfurdiiimide as a linchpin, in combination with organometallic reagents and amines, that their three-component assembly is possible. Variation of the substrates, and the controlled manipulation of nitrogen functionality, allows a broad range of substituents to be introduced at all three nitrogen atoms and at carbon.

INTRODUCTION

The discovery of the first “sulfa drug,” Prontosil,¹ in the 1930s predated the first isolation of a naturally occurring sulfonamide by some 50+ years.^{2,3} Given the diverse applications enjoyed by sulfonamides, ranging from medicines⁴ to agrochemicals⁵ to materials,⁶ these functional groups provide an excellent example of how a designed functional group,⁷ as opposed to one commonly found in nature, can have broad impacts on society.⁸ Sulfonamides continue to play an important role in the design of new medicines and feature in 10%–15% of annual Food and Drug Administration (FDA) approvals.⁹ Elexacaftor, a component of Trikafta, approved by the FDA in 2019 for the treatment of cystic fibrosis, is a pertinent recent example (Figure 1A).¹⁰ Replacing one of the oxygen atoms of a sulfonamide with a nitrogen atom produces a sulfonimidamide (Figure 1B) and from a discovery chemistry perspective defines a new region of chemical space.^{11,12} This is beginning to be exploited,¹³ with bioactive sulfonimidamides being used in a diverse range of applications.^{14–20} Sulfonimidamides are a designed functional group,²¹ and are unknown in nature.²² One of the key attributes of sulfonimidamides comes from variation of the imidic N-substituent (R¹ in Figure 1B), as this provides opportunities to modulate the physiochemical properties of these molecules¹³ as well as delivering a further vector to be explored in the study of structure-activity relationships (SARs).¹² The introduction of basic nitrogen atoms to increase biological potency is a popular tactic in medicinal chemistry and has been applied in varied settings.²³ However, the further substitution of oxygen for nitrogen in the context of sulfonamides and sulfonimidamides, to generate the double aza-analogs called sulfondiimidamides, is unknown in medicinal chemistry.^{24,25} In fact, sulfondiimidamides are essentially unexplored functional groups;^{26,27} they lack viable synthetic routes,²⁸ and there are scant data concerning their stability and further manipulation.²⁹ Given the central

The bigger picture

A functional group is an arrangement of atoms that defines the key topology and reactivity of a molecule. The ability to modify these two parameters in useful and predictive ways is the foundation of synthetic organic chemistry and accounts for the wide-ranging applications enjoyed by organic molecules. For example, medicinal chemists often tune the substituents attached to specific functional groups as they explore chemical space, searching for biologically active molecules.

Sulfonamides have a long history in medicinal chemistry, with the first biologically important examples, the “sulfa drugs,” being described in the 1930s. Here, we report a new functional group, the sulfondiimidamides, which are the double aza analogs of sulfonamides. We show that these new molecules are stable, that they can be efficiently prepared, and that precise manipulation and functionalization of these groups is possible. Sulfondiimidamides provide an exciting new scaffold for exploring chemical space.






Figure 1. Examples of S(VI) derivatives and this work

(A) Examples of biologically active sulfonamides and sulfonimidamides.

(B) Sulfonamides and their mono- and di-aza derivatives.

(C) This work: a three-component synthesis of sulfondiimidamides.

role of sulfonamides in medicinal chemistry and the recent surge of interest in sulfonimidamides, this absence is striking. This newly designed functional group—a sulfondiimidamide—offers a potent mix of additional structural diversity, tuneable basicity, and unexplored chemical space, with the corresponding patent freedoms that this brings.

The small number of sulfondiimidamides reported are not amenable to discovery chemistry, featuring either symmetrical di-alkyl or di-triflyl N-substituents.^{26,27,30} In addition, the syntheses offer little scope for structural variation and employ unattractive, hazardous reagents. We envisioned a divergent synthesis, in which a central sulfur diimide linchpin is combined with a carbon fragment and an amine fragment in a three-component assembly (Figure 1C). Organometallic reagents, such as Grignard reagents and organolithiums, would form the carbon fragment. This type of approach would exploit the vast array of commercial amines and aryl, heteroaryl, and alkyl halides (as the organometallics precursors), and would allow access to a diverse range of sulfondiimidamides. The proposed synthesis would require an oxidative adjustment to allow the union of two nucleophilic fragments to the central linchpin reagent.

¹Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford OX1 3TA, UK

²Lead contact

*Correspondence: michael.willis@chem.ox.ac.uk
<https://doi.org/10.1016/j.chempr.2022.02.013>




Figure 2. The synthesis of sulfondiimidoyl fluorides **4**, using sulfurdiimide reagent **1**, and proceeding via sulfenamides **3**

The yield in parenthesis is for the relevant sulfenamide (**3**), and the final yield is for the fluoride **4**. Both are isolated yields. Ns, 4- $\text{NO}_2\text{C}_6\text{H}_4\text{SO}_2$.

^a“Turbo Grignard” reagent ($\text{R-MgCl} \cdot \text{LiCl}$) employed. ^bOrganolithium reagent employed.

RESULTS AND DISCUSSION

Synthesis of sulfondiimidoyl fluorides

To achieve the structural diversity that we targeted and allow for further synthetic manipulation, we required an unsymmetrical sulfurdiimide reagent in which the two N-substituents could be selectively modified. Accordingly, we designed sulfurdiimide reagent **1**, featuring N-SiMe₃ and N-*t*-octyl substituents for initial evaluation (Figure 2). Reagent **1** could be prepared from the corresponding *t*-octyl sulfinylamine, recently reported by our laboratory for the synthesis of sulfondiimines,³¹ by adapting a procedure from Zibarev and co-workers.³² Although diimide **1** could be isolated, it was more practical to combine it directly with an organometallic reagent to deliver N-*t*-octyl sulfinamidines **2**. Conveniently, the N-SiMe₃ substituent was removed during work-up. Installation of a 4-nosyl (Ns) substituent on nitrogen then yielded the first intermediates that were routinely isolated, the N-Ns N-*t*-octyl sulfinamidines **3**. The conversion of sulfenamides **3** into sulfondiimidoyl fluorides **4** was achieved efficiently by first deprotonating with NaH, followed by the addition of NFSI as a F⁺ source, which affected oxidative fluorination. Attempts to achieve this transformation using weaker bases such as K₂CO₃, NEt₃, or no base at all, were unsuccessful, with starting material being recovered (see supplemental information; Table S1, for details). This route allowed a broad range of Grignard and organolithium reagents to be used, but not organozinc reagents, which were found to be insufficiently reactive. Electronically and sterically varied aryl reagents (**4a–4h**), 3-pyridyl groups (**4i** and **4j**), simple alkyl (**4k–4m**), as well as vinyl (**4n**) examples,

were all successfully employed. We were also able to include the complex arenes related to the pharmaceuticals sildenafil³³ (**4o**) and celecoxib (**4p**).³⁴ In general, sulfondiimidoyl fluorides **4** were stable, isolable molecules.

Conversion of sulfondiimidoyl fluorides into sulfondiimidamides

To achieve the conversion of the sulfondiimidoyl fluorides into the corresponding sulfondiimidamides, we investigated a range of Lewis acids, using fluoride **4a** and morpholine as the test substrates (see [supplemental information](#); [Table S2](#), for details). Of the Lewis acids investigated, $\text{Ca}(\text{NTf}_2)_2$ was superior,^{35,36} affording excellent yields and clean reaction profiles; common side reactions with alternative Lewis acids included hydrolysis to a sulfonimidamide as well as a competing $\text{S}_{\text{N}}\text{Ar}$ reaction. Using the $\text{Ca}(\text{NTf}_2)_2$ conditions, the sulfondiimidoyl fluorides shown in [Figure 2](#) were coupled with morpholine, leading to the corresponding sulfondiimidamides (**5a–5m**, **5o**, and **5p**) in generally high yields ([Figure 3A](#)). The one exception was the vinyl example (**4n**), which led to multiple unidentified products. Sulfondiimidamides **5a–5m**, **5o**, and **5p** featured a selection of aryl, heteroaryl, and alkyl carbon substituents, and all delivered stable molecules that were readily purified and characterized. Gram-scale, preparative reactions were possible, with 4.5 g of sulfondiimidamide **5a** being obtained in 90% yield. We next explored the variety of amines that could be used in these reactions; sulfondiimidamides **5q–5v** show that a broad range of cyclic secondary amines featuring varied substituents, including several motifs that are attractive in medicinal chemistry, can be combined with sulfondiimidoyl fluoride **4a** in high yields. In particular, the piperidine fragments from antiplatelet (clopidogrel, **5r**) and antipsychotic (risperidone, **5s**) agents, and piperazines that feature in the atypical antipsychotics perospirone and ziprasidone (**5t**), and the anti-Parkinson's compound Piribedal (**5u**), all performed well, in addition to the piperazine moiety that is the active pharmaceutical ingredient (API) in the antidepressant amoxapine (**5v**). An acyclic secondary amine (**5w**), 3-aminopyridine (**5x**), and tetramethyl guanidine (**5y**) could also be effectively introduced. The use of an enantiomerically enriched pyrrolidine generated the diastereomeric sulfondiimidamides **5z** and **5z'**, which could be separated by flash chromatography, and are the first examples of enantiomerically enriched, chiral at sulfur sulfondiimidamides to be isolated. The $\text{Ca}(\text{NTf}_2)_2$ -promoted amination was poorly effective for primary amines, and ammonia, with minimal reactivity being observed, presumably due to catalyst deactivation from the strongly binding nucleophiles. We sought a more effective method that would allow additional amines to be used and turned to the use of an imidazolium derivative.³⁷ Imidazole could be employed as a nucleophile using $\text{Ca}(\text{NTf}_2)_2$ conditions to deliver sulfondiimidamide **5aa** in 88% yield ([Figure 3B](#)); this example also delivered crystals suitable for diffraction studies, and the resultant X-ray structure is shown, and confirms, the structural assignment. Imidazole derivative **5aa** proved to be a versatile intermediate; treatment with MeOTf activates the imidazole as a leaving group³⁷ and allows a more diverse range of amines to be introduced. Combining the *in-situ*-generated imidazolium with two equivalents of the N-nucleophiles (without additional base) allows simple primary amines (**5ab**), including cyclic (**5ac**), allylic (**5ad**), and sterically demanding (**5ae**) examples to be employed. Amino heterocycles (**5af–5ah**) and azoles (**5ai** and **5aj**) could also be effectively introduced. Sulfondiimidamide **5ak** features an oxazolidone, and **5al/5al'** are further examples of separable S-chiral derivatives. The final example, **5am**, is a primary sulfondiimidamide generated using ammonia as the nucleophile.

Synthetic manipulations of sulfondiimidamides

The sulfondiimidamides shown in [Figure 3](#) establish that a wide range of carbon and nitrogen fragments can be introduced. We next explored reactions to demonstrate that intact sulfondiimidamides are amenable to functionalization ([Figure 4](#)). The primary-amidic sulfondiimidamide **5am** could be smoothly converted to the corresponding




Figure 3. Conversion of sulfondiimidoyl fluorides into sulfondiimidamides

(A) The synthesis of sulfondiimidamides **5** from sulfondiimidoyl fluorides **4**. Reaction conditions: **4** (1.0 equiv), amine (2.2 equiv), Ca(NTf₂)₂ (1.1 equiv), t-Amyl-OH, 60°C, 10–36 h. Isolated yields.

(B) The synthesis of sulfondiimidamides **5** from imidazole sulfondiimidamide derivative **5aa** and X-ray crystal structure of **5aa**. Reaction conditions: **5aa** (1.0 equiv), MeOTf (1.05 equiv), CH₂Cl₂, 0°C, room temperature (RT) for 30 min, then amine (2.1 equiv), RT, 30 min. ^aMorpholine (4.0 equiv), 75°C. ^bTMG (3.0 equiv), 80°C. ^c70°C. ^dImidazole (6.0 equiv), 65°C. ^eNH₃ 2M in *i*-PrOH (4.0 equiv).




Figure 4. Functionalization and manipulation of sulfondiimides

(A) Functionalization of primary sulfondiimide 5am.

(B) Removal of the t-octyl group from 5a, followed by manipulation of the imidic N-substituents.

(C) Functionalization of N-CN derivative 6e.

(D) Use of triisopropylsilyl sulfynilamine reagent 7 for the synthesis of N-silyl sulfondiimide 12 and the conversion of 12 to NH-derivative 6c.

amide and urea derivatives (**6a** and **6b**, Figure 4A). The imidic N-substituents could also be manipulated. For example, treatment of N-*t*-octyl N-nosyl derivative **5a** with TFA in methylene chloride led to *t*-octyl cleavage and formation of imidic NH-derivative **6c** (Figure 4B). The imidic NH of **6c** was converted to a variety of functional groups; for example, treatment with cyanogen bromide provided N-CN derivative **6d**, the nosyl group of which was removed by treatment with dodecane thiol and DBU,³¹ efficiently providing N-H N-CN derivative **6e**. Related two-stage procedures were used to introduce sulfonamide (**6g**), amide (**6i**), and urea (**6k**) functionality, each time partnered with a N-H substituent. Given the prominence of imidic N-CN substituents in known bioactive molecules,^{38,39} we used N-CN derivative **6e** to further probe the compatibility of the sulfondiimidamide motif to the types of synthetic manipulations needed to introduce additional function (Figure 4C). Accordingly, aryl (**6l**),⁴⁰ carbamate (**6m**), propargyl (**6n**), benzyl (**6o**), and SCF₃ groups⁴¹ (**6p**) were efficiently introduced, demonstrating tolerance to a range of reaction conditions, including transition metal catalysts, bases, oxidants, and reactive alkylating agents. These are in addition to the acidic conditions used to prepare N-H derivative **6c**.

To achieve maximum flexibility in the range of substituents that can be tolerated in our approach to sulfondiimidamides, we have also developed a complementary route that exploits an alternative sulfurdiimide reagent (Figure 4D). Unsymmetrical (bis-silyl)sulfurdiimide **8** can be prepared as before, but using tri-isopropylsilyl sulfinyamine **7** as the substrate.⁴² The forward sequence then mirrors our earlier route, with organometallic addition (**8** → **9**), N-nosylation (**9** → **10**), S-fluorination (**10** → **11**), and then amine addition leading to sulfondiimidamide **12**. Importantly, from silyl-protected sulfondiimidamide **12**, the imidic N-H can be liberated by treatment with fluoride (TBAF), which is formally basic, in contrast to the acidic conditions needed to remove the *t*-octyl group, providing **6c** in 97% yield.

Synthesis of a celecoxib analog

As a demonstration of the utility of the developed chemistry, we prepared a direct sulfondiimidamide analog of the sulfonamide-containing non-steroidal anti-inflammatory drug (NSAID) celecoxib (Figure 5). Celecoxib inhibits COX-2, and given the reported success of N-CN substituted sulfoximines against this enzyme,³⁹ we selected an achiral bis(N-CN) sulfondiimidamide as our target. N-*t*-octyl, N-Ns sulfondiimidoyl fluoride **4p** was obtained as described in Figure 2 and then subjected to the three-step sequence of fluoride displacement with diallylamine, *t*-octyl cleavage, and installation of an imidic CN substituent to provide intermediate sulfondiimidamide **13**. From here, nosyl removal followed by installation of a second CN substituent delivered the diallyl-protected derivative **14**. De-allylation was then achieved using Pd(0) conditions to furnish the target structure (**15**) in a 93% yield for the final step. An alternative approach to sulfondiimidamide **15**, involving the ammonia displacement of a suitable imidazolium derivative (of the type generated from **5aa** in Figure 3B) was also considered, but the stability of the imidazole derivative to the acidic conditions needed to remove the imidic *t*-Oct-substituent precluded this route. One of the drivers for exploring sulfonimidamides in medicinal chemistry has been exploiting the oxygen to nitrogen exchange¹⁵ as a method to tune physiochemical properties.^{43,44} The additional oxygen to nitrogen switch present in sulfondiimidamides will allow further flexibility in these parameters. Accordingly, we have calculated select properties for celecoxib bis(N-CN)-sulfondiimidamide analog **15**, together with the parent molecule, celecoxib (**16**), and the related N-CN sulfonimidamide derivative (**17**) (Figure 5B). The calculations were performed using the SwissADME platform (see supplemental information for details)⁴⁵ and give an indication of the variations that will be possible with this approach.




Figure 5. Synthesis of a sulfondiimidamide analogue of celecoxib

(A) Synthesis of bis(N-CN)-sulfondiimidamide celecoxib analog **15**.

(B) Comparison of calculated physical properties of **15** and related celecoxib-analogues.

Conclusions

In conclusion, we have shown that an efficient three-component assembly can be used to prepare sulfondiimidamides, that sulfondiimidamides can tolerate a variety of standard reaction conditions, that they are amenable to synthetic manipulation, and that this newly designed functional group is capable of supporting a variety of medicinal chemistry-relevant substituents. These features, together with the prominent role played by sulfur functional groups in the development of new medicines and agrochemicals, suggest that sulfondiimidamides will become a motif routinely employed in discovery chemistry.

EXPERIMENTAL PROCEDURES

Resource availability

Lead contact

Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Michael Willis (michael.willis@chem.ox.ac.uk).

Materials availability

Reagents generated in this study will be made available on request, but we may require a payment and/or a completed materials transfer agreement if there is potential for commercial application.

Data and code availability

There is no dataset or code associated with this publication. Details of methods, [experimental procedures](#), and characterization data are available in the [supplemental information](#). Nuclear magnetic resonance (NMR) spectra are available ([Data S1](#)).

Crystallographic data for the structure reported in this article have been deposited at the Cambridge Crystallographic Data Centre, under deposition number CCDC: 2091794 (5aa).

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.chempr.2022.02.013>.

ACKNOWLEDGMENTS

This work was supported by the EPSRC (EP/K024205/1) and by the China Scholarship Council (to Z.-X.Z.). Antoine de Gombert and Richard Cooper (both University of Oxford) are thanked for X-ray structure analysis.

AUTHOR CONTRIBUTIONS

Z.-X.Z. and M.C.W. conceived the project. Z.-X.Z. performed the experimental studies. Z.-X.Z. and M.C.W. wrote the manuscript. Both authors contributed to the analysis and interpretation of the data and commented on the final draft of the manuscript. M.C.W. directed the project.

DECLARATION OF INTERESTS

The authors have submitted a patent application related to this work.

Received: November 19, 2021

Revised: January 16, 2022

Accepted: February 15, 2022

Published: March 17, 2022

REFERENCES

- Domagk, G. (1936). Chemotherapie der Streptokokken-Infektionen. *Klin Wochenschr* 15, 1585–1590. <https://doi.org/10.1007/BF01780820>.
- Takahashi, A., Ikeda, D., Nakamura, H., Naganawa, H., Kurasawa, S., Okami, Y., Takeuchi, T., and Iitaka, Y. (1989). Altemicidin, a new acaricidal and antitumor substance. II. Structure determination. *J. Antibiot. (Tokyo)* 42, 1562–1566. <https://doi.org/10.7164/antibiotics.42.1562>.
- Mujumdar, P., and Poulsen, S.-A. (2015). Natural product primary sulfonamides and primary sulfamates. *J. Nat. Prod.* 78, 1470–1477. <https://doi.org/10.1021/np501015m>.
- Scott, K.A., and Njardarson, J.T. (2018). Analysis of US FDA-approved drugs containing sulfur atoms. *Top. Curr. Chem. (Cham)* 376, 5. <https://doi.org/10.1007/s41061-018-0184-5>.
- Devendar, P., and Yang, G.F. (2017). Sulfur-containing agrochemicals. *Top. Curr. Chem. (Cham)* 375, 82. <https://doi.org/10.1007/s41061-017-0169-9>.
- Wang, J., Lakraychi, A.E., Liu, X., Sieuw, L., Morari, C., Poizat, P., and Vlad, A. (2021). Conjugated sulfonamides as a class of organic lithium-ion positive electrodes. *Nat. Mater.* 20, 665–673. <https://doi.org/10.1038/s41563-020-00869-1>.
- Mondal, S., and Malakar, S. (2020). Synthesis of sulfonamide and their synthetic and therapeutic applications: recent advances. *Tetrahedron* 76, 131662. <https://doi.org/10.1016/j.tet.2020.131662>.
- Kalgutkar, A.S., Jones, R., and Sawant, A. (2010). Chapter 5. Sulfonamide as an essential functional group in drug design. In *Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET (The Royal Society of Chemistry)*, pp. 210–274. <https://doi.org/10.1039/9781849731102-00210>.
- Ilardi, E.A., Vitaku, E., and Njardarson, J.T. (2014). Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery. *J. Med. Chem.* 57, 2832–2842. <https://doi.org/10.1021/jm401375q>.
- Flick, A.C., Leverett, C.A., Ding, H.X., McInturff, E., Fink, S.J., Mahapatra, S., Carney, D.W., Lindsey, E.A., DeForest, J.C., France, S.P., et al. (2021). Synthetic approaches to the new drugs approved during 2019. *J. Med. Chem.* 64, 3604–3657. <https://doi.org/10.1021/acs.jmedchem.1c00208>.
- Mäder, P., and Kattner, L. (2020). Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an emerging functional group in medicinal chemistry. *J. Med. Chem.* 63, 14243–14275. <https://doi.org/10.1021/acs.jmedchem.0c00960>.
- Izzo, F., Schäfer, M., Lienau, P., Ganzer, U., Stockman, R., and Lücking, U. (2018). Exploration of novel chemical space: synthesis and in vitro evaluation of N-functionalized tertiary sulfonimidamides. *Chemistry* 24, 9295–9304. <https://doi.org/10.1002/chem.201801557>.
- Chinthakindi, P.K., Naicker, T., Thota, N., Govender, T., Kruger, H.G., and Arvidsson, P.I. (2017). Sulfonimidamides in medicinal and agricultural chemistry. *Angew. Chem. Int. Ed.* 56, 4100–4109. <https://doi.org/10.1002/anie.201610456>.
- Frings, M., Bolm, C., Blum, A., and Gnam, C. (2017). Sulfoximines from a medicinal chemist's perspective: physicochemical and in vitro parameters relevant for drug discovery. *Eur. J. Med. Chem.* 126, 225–245. <https://doi.org/10.1016/j.ejmech.2016.09.091>.
- Sehgelmeble, F., Janson, J., Ray, C., Rosqvist, S., Gustavsson, S., Nilsson, L.I., Minidis, A., Holenz, J., Rotticci, D., Lundkvist, J., and Arvidsson, P.I. (2012). Sulfonimidamides as sulfonamides bioisosteres: rational evaluation through synthetic, in vitro, and in vivo studies with γ -secretase inhibitors. *ChemMedChem* 7, 396–399. <https://doi.org/10.1002/cmdc.201200014>.
- Gege, C., Bravo, F.J., Uhlig, N., Hagmaier, T., Schmachtenberg, R., Elis, J., Burger-Kentischer, A., Finkelmeier, D., Hamprecht, K., Grunwald, T., et al. (2021). A helicase-primase

- drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections. *Sci. Transl. Med.* 13, eabf8668. <https://doi.org/10.1126/scitranslmed.abf8668>.
17. Biftu, T., and Khan, T.A. (2014) Treating diabetes with dipeptidyl peptidase-IV inhibitors. WO patent WO2014/018355A1.
18. Langkopf, E., and Blum. (2016) Azabenzimidazole derivatives as AMP protein kinase agonists. WO patent WO2016/023789A1.
19. Chowdhury, S., Dehnhardt, C.M., Focken, T., Grimwood, M.E., Hemeon, I.W., McKerrall, S., and Sutherland, D. (2017) Substituted benzamides and methods of use thereof. WO patent WO2017/172802A1.
20. Trainor, G.L. (2021) Tricyclic modulators of PP2A. WO patent WO2021/170913A1.
21. Nandi, G.C., and Arvidsson, P.I. (2018). Sulfonimidamides: synthesis and applications in preparative organic chemistry. *Adv. Synth. Catal.* 360, 2976–3001. <https://doi.org/10.1002/adsc.201800273>.
22. Waldman, A.J., Ng, T.L., Wang, P., and Balskus, E.P. (2017). Heteroatom-heteroatom bond formation in natural product biosynthesis. *Chem. Rev.* 117, 5784–5863. <https://doi.org/10.1021/acs.chemrev.6b00621>.
23. Pennington, L.D., and Moustakas, D.T. (2017). The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization. *J. Med. Chem.* 60, 3552–3579. <https://doi.org/10.1021/acs.jmedchem.6b01807>.
24. Lücking, U. (2019). Neglected sulfur(VI) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development. *Org. Chem. Front.* 6, 1319–1324. <https://doi.org/10.1039/C8QO001233D>.
25. Tilby, M.J., and Willis, M.C. (2021). How do we address neglected sulfur pharmacophores in drug discovery? *Expert Opin. Drug Discov.* 16, 1227–1231. <https://doi.org/10.1080/17460441.2021.1948008>.
26. Laughlin, R.G. (1968). The synthesis and properties of aliphatic sulfonamide methylamines and bis(methylamines). *J. Am. Chem. Soc.* 90, 2651–2656. <https://doi.org/10.1021/ja01012a033>.
27. Garlyauskajyte, R.Y., Sereda, S.V., and Yagupolskii, L.M. (1994). The unusual reactivity of the mono- and bis- N-(trifluoromethylsulfonyl)-substituted azaanalogues of arenesulfonochlorides. *Tetrahedron* 50, 6891–6906. [https://doi.org/10.1016/S0040-4020\(01\)81341-7](https://doi.org/10.1016/S0040-4020(01)81341-7).
28. Bremerich, M., Conrads, C.M., Langlet, T., and Bolm, C. (2019). Additions to N-sulfinylamines as an approach for the metal-free synthesis of sulfonimidamides: O-benzotriazolyl sulfonimidates as activated intermediates. *Angew. Chem. Int. Ed.* 58, 19014–19020. <https://doi.org/10.1002/anie.201911075>.
29. Stalke, D. (2012). Polyimido sulfur anions and ylides. *Chem. Commun. (Camb)* 48, 9559–9573. <https://doi.org/10.1039/c2cc33221c>.
30. Schwengers, S.A., De, C.K., Grossmann, O., Grimm, J.A.A., Sadlowski, N.R., Gerosa, G.G., and List, B. (2021). Unified approach to imidodiphosphate-type Brønsted acids with tunable confinement and acidity. *J. Am. Chem. Soc.* 143, 14835–14844. <https://doi.org/10.1021/jacs.1c07067>.
31. Zhang, Z.X., Davies, T.Q., and Willis, M.C. (2019). Modular sulfonidimine synthesis using a stable sulfinylamine reagent. *J. Am. Chem. Soc.* 141, 13022–13027. <https://doi.org/10.1021/jacs.9b06831>.
32. Lork, E., Mews, R., Shakirov, M.M., Watson, P.G., and Zibarev, A.V. (2002). The first N-alkyl-N'-polyfluorohetaryl sulfur diimide. *J. Fluor. Chem.* 115, 165–168. [https://doi.org/10.1016/S0022-1139\(02\)00047-7](https://doi.org/10.1016/S0022-1139(02)00047-7).
33. Chung Leung, G.Y., Ramalingam, B., Loh, G., and Chen, A. (2020). Efficient and practical synthesis of sulfonamides utilizing SO₂ gas generated on demand. *Org. Process Res. Dev.* 24, 546–554. <https://doi.org/10.1021/acs.oprd.9b00552>.
34. Penning, T.D., Talley, J.J., Bertenshaw, S.R., Carter, J.S., Collins, P.W., Docter, S., Graneto, M.J., Lee, L.F., Malecha, J.W., Miyashiro, J.M., et al. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). *J. Med. Chem.* 40, 1347–1365. <https://doi.org/10.1021/jm960803q>.
35. Mukherjee, P., Woroch, C.P., Cleary, L., Rusznak, M., Franzese, R.W., Reese, M.R., Tucker, J.W., Humphrey, J.M., Etuk, S.M., Kwan, S.C., et al. (2018). Sulfonamide synthesis via calcium triflimide activation of sulfonyl fluorides. *Org. Lett.* 20, 3943–3947. <https://doi.org/10.1021/acs.orglett.8b01520>.
36. Mahapatra, S., Woroch, C.P., Butler, T.W., Carneiro, S.N., Kwan, S.C., Khasnavis, S.R., et al. (2020). SuFEx activation with Ca(NTf₂)₂: a unified strategy to access sulfamides, sulfamates, and sulfonamides from S(VI) fluorides. *Org. Lett.* 22, 4389–4394. <https://doi.org/10.1021/acs.orglett.0c01397>.
37. Zasukha, S.V., Timoshenko, V.M., Tolmachev, A.A., Pivnytska, V.O., Gavrylenko, O., Zherish, S., Shermolovich, Y., and Grygorenko, O.O. (2019). Sulfonimidamides and Imidosulfuric diamides: compounds from an underexplored part of biologically relevant chemical space. *Chemistry* 25, 6928–6940. <https://doi.org/10.1002/chem.201900440>.
38. Zhu, Y., Loso, M.R., Watson, G.B., Sparks, T.C., Rogers, R.B., Huang, J.X., Gerwick, B.C., Babcock, J.M., Kelley, D., Hegde, V.B., et al. (2011). Discovery and characterization of sulfoxaflo, a novel insecticide targeting sap-feeding pests. *J. Agric. Food Chem.* 59, 2950–2957. <https://doi.org/10.1021/jf102765x>.
39. Park, S.J., Baars, H., Mersmann, S., Buschmann, H., Baron, J.M., Amann, P.M., Czaja, K., Hollert, H., Bluhm, K., Redelstein, R., et al. (2013). N-Cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicity. *ChemMedChem* 8, 217–220. <https://doi.org/10.1002/cmdc.201200403>.
40. Vantourout, J.C., Li, L., Bendito-Moll, E., Chhabra, S., Arrington, K., Bode, B.E., Isidro-Llobet, A., Kowalski, J.A., Nilsson, M.G., Wheelhouse, K.M.P., et al. (2018). Mechanistic insight enables practical, scalable, room temperature Chan–Lam N-arylation of N-aryl sulfonamides. *ACS Catal.* 8, 9560–9566. <https://doi.org/10.1021/acscatal.8b03238>.
41. Bohnen, C., and Bolm, C. (2015). N-Trifluoromethylthiolated sulfoximines. *Org. Lett.* 17, 3011–3013. <https://doi.org/10.1021/acs.orglett.5b01384>.
42. Ding, M., Zhang, Z.X., Davies, T.Q., and Willis, M.C. (2022). A Silyl Sulfinylamine Reagent Enables the Modular Synthesis of Sulfonimidamides via Primary Sulfinamides. *Org. Lett.* 24, 1711–1715. <https://doi.org/10.1021/acs.orglett.2c00347>.
43. Hann, M.M., and Keserü, G.M. (2012). Finding the sweet spot: the role of nature and nurture in medicinal chemistry. *Nat. Rev. Drug Discov.* 11, 355–365. <https://doi.org/10.1038/nrd3701>.
44. Gleeson, M.P., Hersey, A., Montanari, D., and Overington, J. (2011). Probing the links between in vitro potency, ADMET and physicochemical parameters. *Nat. Rev. Drug Discov.* 10, 197–208. <https://doi.org/10.1038/nrd3367>.
45. Daina, A., Michielin, O., and Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* 7, 42717. <https://doi.org/10.1038/srep42717>.

Chem, Volume 8

Supplemental information

**Sulfondiimidamides as new functional groups
for synthetic and medicinal chemistry**

Ze-Xin Zhang and Michael C. Willis

Supplemental Information - Contents

1. Optimization Details	
1.1 Optimization of Sulfondiimidoyl Fluoride Synthesis (Table S1)	S2
1.2 Optimization of Sulfondiimidamide Synthesis (Table S2)	S3
2. Experimental	
2.1 General Considerations	S4
2.2 Synthetic Procedures and Characterization Data	
2.2.1 Preparation of <i>N</i> -Sulfinyl- <i>tert</i> -Octylamine	S6
2.2.2 General Procedure A for Sulfinamidine Synthesis	S7
2.2.3 General Procedure B for Sulfondiimidoyl Fluoride Synthesis	S25
2.2.4 General Procedure C for Sulfondiimidamide Synthesis	S42
2.2.5 General Procedure D for Sulfondiimidamide Synthesis	S69
2.2.6 Functionalisation of Primary Sulfondiimidamide 5am	S81
2.2.7 <i>t</i> -Octyl Deprotection of Sulfondiimidamide 5a	S83
2.2.8 Functionalisation of Sulfondiimidamide 6c	S84
2.2.9 Functionalisation of Sulfondiimidamide 6e	S91
2.2.10 Sulfondiimidamide Synthesis using Tri- <i>isopropylsilyl</i> Sulfinylamine	S96
2.2.11 Synthesis of Sulfondiimidamide Analogue of Celecoxib	S101
3. Calculated Physical Properties	S107
4. References	S109

1. Optimization Details

1.1 Optimization of Sulfondiimidoyl Fluoride Synthesis

Table S1. Optimization of sulfondiimidoyl fluoride **4a** synthesis


Reaction scheme: **3a** (4-fluorophenyl N-t-octylsulfonamide) $\xrightarrow[\text{Solvent, 0 } ^\circ\text{C to rt}]{\text{Base (1.1 eq.), then F}^+}$ **4a** (4-fluorophenyl N-t-octylsulfondiimidoyl fluoride)

Entry ^a	Solvent	Base	F ⁺ (eq.)	Yield
1	DMF (0.5 M)	NaH	NFSI (1.5 eq.)	57%
2	Et ₂ O (0.5 M)	NaH	NFSI (1.5 eq.)	10%
3	MeCN (0.5 M)	NaH	NFSI (1.5 eq.)	11%
4	1,4-dioxane (0.5 M)	NaH	NFSI (1.5 eq.)	7%
5	EtOAc (0.5 M)	NaH	NFSI (1.5 eq.)	36%
6	THF (0.5 M)	NaH	NFSI (1.5 eq.)	68% (70%^b)
7	THF (0.5 M)	NaH	NFSI (2.0 eq.)	66%
8	THF (0.1 M)	NaH	NFSI (2.0 eq.)	61%
9	THF (0.5 M)	NaH	NFSI (4.0 eq.)	64%
10	THF (0.5 M)	NaH	NFSI (2.0 eq.)	63%
11	THF (0.2 M)	NaH	Selectfluor (3.0 eq.)	0% ^c
12	THF (0.1 M)	K ₂ CO ₃	NFSI (1.1 eq)	0% ^c
13	THF (0.5 M)	Et ₃ N	NFSI (1.5 eq.)	0% ^c
14	THF (0.5 M)	-	NFSI (1.5 eq.)	0% ^c

a. Reaction conditions: sulfinamidide **3a** (1.0 equiv.), base (1.1 equiv.), solvent, 0 °C for 5 min, then rt for 25 min. Then NFSI or Selectfluor, rt, 30 min. Aqueous workup. 20 h. Isolated yields. **b.** 15-crown-5 (1.1 equiv.) used as the additive. **c.** Starting material recovered.

1.2 Optimization of Sulfondiimidamide Synthesis

Table S2. Optimization of sulfondiimidamide 5a synthesis



Entry ^a	Lewis acid	Solvent	T	Yield of 5a	Yield of 5a'	Yield of 5a''
1	In(OTf) ₃	<i>t</i> -AmylOH	60 °C	0%	77%	0%
2	Cu(OTf) ₂	<i>t</i> -AmylOH	60 °C	0%	0%	0%
3	Ca(OTf) ₂	<i>t</i> -AmylOH	60 °C	29%	0%	8%
4	Ca(NTf₂)₂	<i>t</i>-AmylOH	60 °C	93%	0%	0%
5	Mg(NTf ₂) ₂	<i>t</i> -AmylOH	60 °C	55%	0%	0%
6	Ba(NTf ₂) ₂	<i>t</i> -AmylOH	60 °C	64%	0%	0%
7	Ca(NTf ₂) ₂	MeOH	60 °C	40%	0%	0%
8	Ca(NTf ₂) ₂	MeCN	60 °C	87%	0%	0%
9	Ca(NTf ₂) ₂	THF	60 °C	87%	0%	0%
10 ^b	-	MeCN	60 °C	0%	0%	84%
11	Ca(NTf ₂) ₂	<i>t</i> -AmylOH	40 °C	73%	0%	0%
12	Ca(NTf ₂) ₂ (0.5 eq.)	<i>t</i> -AmylOH	60 °C	47%	0%	5%

a. Reaction conditions: sulfondiimidoyl fluoride **4a** (1.0 equiv.), Lewis acid, morpholine (2.2 equiv.), solvent (0.5 M), 24 h. Isolated yields. **b.** DBU (2.0 equiv.) used as the additive, 15 h.

2. Experimental

2.1 General Considerations

Handling techniques: Reactions were performed under inert nitrogen atmosphere with anhydrous solvent unless otherwise stated. All glassware was oven-dried at $>100\text{ }^{\circ}\text{C}$ and allowed to cool to room temperature under a positive pressure of nitrogen before use. Reactions were monitored by TLC until deemed complete using aluminum backed silica plates. Plates were visualised under ultraviolet light ($\lambda_{\text{max}} = 254\text{ nm}$) and/or by staining with KMnO_4 solution. Cooling of reaction mixtures to $0\text{ }^{\circ}\text{C}$ was achieved using an ice-water bath. Cooling of reaction mixtures to $-78\text{ }^{\circ}\text{C}$ was achieved using a dry ice-acetone bath. ‘Room temperature’ refers to an ambient temperature of $21 \pm 2\text{ }^{\circ}\text{C}$.

Reagents: Reagents were purchased from Sigma-Aldrich Chemical Co. Ltd., Alfa Aesar, Tokyo Chemical Industry UK or Fluorochem Ltd. and were used as supplied. *N*-Sulfinyl-*tert*-octylamine was prepared according to literature method.¹ Anhydrous solvents were purified by filtration through dried alumina columns using the University of Oxford internal solvent drying system (Innovative Technology Inc. PS-400-7) and sparged with nitrogen before use. All inert gases were sourced from the University of Oxford internal supplies and dried through CaCl_2 drying columns. Grignard reagents were titrated against a solution of salicylaldehyde phenylhydrazone.² Flash column chromatography was carried out using matrix 60 silica gel. ‘Petrol’ refers to the fraction of petroleum ether which boils in the range $40\text{--}60\text{ }^{\circ}\text{C}$.

NMR Spectroscopy: ^1H -NMR spectra were obtained on a Bruker AVIII400 (400 MHz) spectrometer. ^{13}C -NMR spectra were obtained on a Bruker AVIII400 (101 MHz). ^{19}F -NMR spectra were obtained on a Bruker AVIII400 (377 MHz) spectrometer. All reported ^1H and ^{13}C chemical shifts (δ_{H} , δ_{C}) are referenced to the residual signal of deuterated solvents (CDCl_3 : $\delta_{\text{H}} = 7.26\text{ ppm}$, $\delta_{\text{C}} = 77.16\text{ ppm}$; $(\text{CD}_3)_2\text{SO}$: $\delta_{\text{H}} = 2.50\text{ ppm}$, $\delta_{\text{C}} = 39.52\text{ ppm}$; $(\text{CD}_3)_2\text{CO}$: $\delta_{\text{H}} = 2.05\text{ ppm}$, $\delta_{\text{C}} = 206.26\text{ ppm}$; CD_3CN : $\delta_{\text{H}} = 1.94\text{ ppm}$, $\delta_{\text{C}} = 118.26\text{ ppm}$; C_6D_6 : $\delta_{\text{H}} = 7.16\text{ ppm}$, $\delta_{\text{C}} = 128.06\text{ ppm}$). ^{19}F chemical shifts (δ_{F}) are referenced externally to CFCl_3 ($\delta_{\text{F}} = 0.0\text{ ppm}$). Chemical shifts (δ) are reported in parts per million (ppm) to the nearest 0.01 ppm for ^1H NMR, and 0.1 ppm for ^{13}C and ^{19}F NMR. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are reported as followings: s (singlet), d (doublet), t (triplet), q (quartet), pent. (pentet), m (multiplet), br. (broad signal), app. (apparent).

Mass Spectroscopy: Low resolution ESI mass spectra were recorded on a Waters LCT Premier spectrometer. High resolution mass spectrometry measurements were recorded on a Bruker

Daltonics MicroTOF (ESI) spectrometer or on a Micromass LCT (FI) spectrometer by the internal service at Chemistry Research Laboratory, University of Oxford. Samples for mass spectra were prepared as 1 mg/mL solution in MeOH (LRMS, HRMS-ESI) or submitted neat (HRMS-FI).


IR Spectroscopy: Infrared spectra were recorded as thin films on a Bruker Tensor 27 FT-IR spectrometer.

Melting point: Melting points were measured using a Stuart Scientific Melting Point Apparatus SMP1.

Optical rotation: Optical rotations were measured on a Schmidt Haensch UniPol L2000 polarimeter at 589 nm, 25 °C. $[\alpha]_D^T$ is expressed in $\text{deg cm}^3 \text{ g}^{-1} \text{ dm}^{-1}$ and c is expressed in $\text{g}/100 \text{ cm}^3$.

2.2 Synthetic Procedures and Characterisation Data

2.2.1 Preparation of *N*-sulfinyl-*tert*-octylamine



Tert-Octylamine (5.17 g, 40.0 mmol, 1.00 equiv.) was dissolved in anhydrous diethyl ether (200 mL) in a 500 mL 3-necked round bottom flask. Anhydrous triethylamine (11.49 mL, 82.4 mmol, 2.06 equiv.) was added and the reaction was cooled to 0 °C. Freshly distilled thionyl chloride (2.99 mL, 41.2 mmol, 1.03 equiv.) was added dropwise. The reaction was stirred at 0 °C for 2 h. Filtration through Celite® (washed with anhydrous diethyl ether) and removal of solvent under reduced pressure afforded *N*-sulfinyl-*tert*-octylamine as a yellow oil (6.65 g, 38.0 mmol, 95%).

Notes

1. *N*-Sulfinyl-*tert*-octylamine should be stored in the freezer (-20 °C) and can be used without loss of performance for at least 2 months. Prolonged contact with air or storage at room temperature should be avoided.
2. **CAUTION: Hydrolysis of sulfinylamines results in the formation of toxic sulfur dioxide gas.** Evolution of SO₂ from *N*-sulfinyl-*tert*-octylamine has not been noted by the authors in the normal course of use, but avoidance of contact with water or prolonged storage at room temperature is advised.
3. *tert*-Octylamine was purchased from Sigma-Aldrich and used without further purification.
4. The product may be further purified by vacuum distillation at 65 °C/5 mbar, but this was not necessary. Use of high temperatures during distillation may result in decomposition of the product.

The data was consistent with the literature ^[1].


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 1.73 (s, 2H), 1.60 (s, 6H), 1.02 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 67.7, 55.5, 32.2, 31.5, 31.2

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 2888, 1382, 1252, 1152, 1073, 954;

HRMS (EI⁺) calcd. for C₈H₁₈NOS⁺ [M+H]⁺: 176.1104; found: 176.1106.

2.2.2 General Procedure A for Sulfinamidine Synthesis




N-Sulfinyl-*tert*-octylamine (1.00 equiv.) was dissolved in anhydrous THF (0.5 M) in an oven-dried round-bottom flask and was purged with nitrogen gas. The mixture was cooled to -30 °C before LiHMDS solution (1.00 M in THF, 1.00 equiv.) was added. After being stirred at -30 °C for 5 min, the reaction was warmed to 0 °C and stirred for another 5 min. TMSCl (1.00 equiv.) was added and the reaction was stirred at 0 °C for 10 min. Then the corresponding organometallic reagent (1.20 equiv.) was added. The reaction was stirred at 0 °C for 10 min before being quenched with sat. aq. tetrasodium EDTA solution. Ethyl acetate was added and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate twice. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude mixture was dissolved in anhydrous CH₂Cl₂ (0.2 M) in an oven-dried round-bottom flask. Then Et₃N (1.20 equiv.) and NsCl (1.10 equiv.) were added. The reaction was stirred at room temperature for 1 h. The reaction was then quenched with sat. aq. NaCl solution and extracted with CH₂Cl₂ three times. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and purified by flash column chromatography to afford sulfinamidine **3**.

Notes:

1. *Tert*-octyl-protected primary sulfinamidines **2** are sensitive to moisture and heat. For this reason, during the work-up stage volatiles were removed in a rotary evaporator with the bath temperature set to 30 °C or lower. In addition, *tert*-octyl-protected primary sulfinamidines were not purified by flash column chromatography and instead were used as a crude mixture immediately in the following nosylation step without further purification.
2. If the organometallic reagents were prepared at -78 °C, the *in-situ* generated sulfurdiimide reagent was added to the organometallic reagents at -78 °C. The reaction was then warmed to 0 °C and stirred at 0 °C for 10 min before being quenched with sat. aq. tetrasodium EDTA solution.
3. If the final sulfinamidine product is not sufficiently pure after flash column chromatography,

the impure solid product can be further purified by washing with diethyl ether or additional flash column chromatography.

***N*-(*S*-(4-Fluorophenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3a)**



N-Sulfinyl-*tert*-octylamine (2.75 g, 15.68 mmol, 1.00 equiv.) was dissolved in anhydrous THF (31.4 mL) in an oven-dried 250 mL round-bottom flask and was purged with nitrogen gas. The mixture was cooled to -30 °C before LiHMDS solution (15.68 mL, 1.00 M in THF, 15.68 mmol, 1.00 equiv.) was added. After being stirred at -30 °C for 5 min, the reaction was warmed to 0 °C and stirred for another 5 min. TMSCl (1.99 mL, 15.68 mmol, 1.00 equiv.) was added and the reaction was stirred at 0 °C for 10 min. 4-Fluorophenylmagnesium bromide solution (19.20 mL, 0.98 M in THF, 18.82 mmol, 1.20 equiv.) was then added and the reaction was stirred at 0 °C for 10 min. The reaction mixture was then quenched with sat. aq. tetrasodium EDTA solution (300 mL). Ethyl acetate (150 mL) was added and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate (2 × 80 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude mixture was dissolved in anhydrous CH₂Cl₂ (78.0 mL) in an oven-dried 250 mL round-bottom flask before Et₃N (2.62 mL, 18.82 mmol, 1.20 equiv.) and NsCl (3.82 g, 17.25 mmol, 1.10 equiv.) were added. The reaction was stirred at room temperature for 1 h until completion (judged by TLC). The reaction was quenched with sat. aq. NaCl solution (250 mL) and extracted with CH₂Cl₂ (3 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 30:1 to 20:1) to afford *sulfinamidine* **3a** as a white solid (6.23 g, 13.69 mmol, 87%).

mp 118-120 °C;

R_f 0.57 (CH₂Cl₂/ethyl acetate, 15:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.21 (d, *J* = 8.8 Hz, 2H), 7.96 (d, *J* = 8.8 Hz, 2H), 7.67-7.47 (m, 2H), 7.19-6.89 (m, 2H), 4.48 (s, 1H), 1.65 (d, *J* = 15.0 Hz, 1H), 1.61 (d, *J* = 15.0 Hz, 1H), 1.48 (s, 3H), 1.44 (s, 3H), 0.97 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.7 (d, J = 254.7 Hz), 150.2, 149.2, 133.5 (d, J = 3.1 Hz), 129.4 (d, J = 9.1 Hz), 127.3, 124.0, 116.8 (d, J = 22.9 Hz), 60.6, 55.6, 31.8, 31.7, 30.7, 29.1 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -106.7 (tt, J = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1490, 1349, 1290, 1145, 1088, 982, 618;

HRMS (ESI⁺) calcd. for C₂₀H₂₇FN₃O₄S₂⁺ [M+H]⁺: 456.1422, found: 456.1421.

***N*-(S-(4-Chlorophenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (**3b**)**



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.27 g, 7.23 mmol, 1.00 equiv.), THF (14.5 mL), LiHMDS solution (7.23 mL, 1.00 M in THF, 7.23 mmol, 1.00 equiv.), TMSCl (0.92 mL, 7.23 mmol, 1.00 equiv.), 4-chlorophenylmagnesium bromide solution (9.85 mL, 0.88 M in 2-methyltetrahydrofuran, 8.67 mmol, 1.20 equiv.), CH₂Cl₂ (36.0 mL), Et₃N (1.21 mL, 8.68 mmol, 1.20 equiv.) and NsCl (1.76 g, 7.95 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 50:1 to 30:1 to 20:1) afforded *sulfinamidine* **3b** as a white solid (3.01 g, 6.39 mmol, 88%).

mp 110-112 °C;

R_f 0.40 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.23 (d, J = 8.9 Hz, 2H), 7.96 (d, J = 8.9 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.39 (d, J = 8.8 Hz, 2H), 4.49 (s, 1H), 1.67 (d, J = 14.9 Hz, 1H), 1.63 (d, J = 14.9 Hz, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 0.99 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.2, 149.2, 138.7, 136.6, 129.8, 128.4, 127.3, 124.1, 60.7, 55.7, 31.81, 31.75, 30.7, 29.2 (note: for *gem*-dimethyl carbons in *tert*-octyl group,

NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1349, 1290, 1145, 1088, 982, 745, 620;

HRMS (ESI⁺) calcd. for C₂₀H₂₇ClN₃O₄S₂⁺ [M+H]⁺: 472.1126, found: 472.1125.

***N*-(*S*-(3-Chlorophenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3c)**



Preparation of Grignard reagent

3-Chlorophenylmagnesium chloride lithium chloride complex solution was prepared according to the following procedure. To a solution of 1-bromo-3-chlorobenzene (1.61 g, 8.40 mmol, 1.20 equiv.) in anhydrous THF (8.4 mL) in an oven-dried 100 mL round-bottom flask was added isopropylmagnesium chloride lithium chloride complex solution (Turbo Grignard Reagent, 6.72 mL, 1.25 M in THF, 8.40 mmol, 1.20 equiv.) dropwise at 0 °C. The reaction was stirred at the same temperature for 3.5 h.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.23 g, 7.00 mmol, 1.00 equiv.), THF (14.0 mL), LiHMDS solution (7.00 mL, 1.00 M in THF, 7.00 mmol, 1.00 equiv.), TMSCl (0.89 mL, 7.00 mmol, 1.00 equiv.), 3-chlorophenyl magnesium chloride lithium chloride complex solution (8.40 mmol, 1.20 equiv.), CH₂Cl₂ (35.0 mL), Et₃N (1.17 mL, 8.40 mmol, 1.20 equiv.) and NsCl (1.71 g, 7.70 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 50:1 to 30:1) afforded *sulfinamidine* **3c** as a white solid (2.15 g, 4.56 mmol, 65%).

mp 104-106 °C;

R_f 0.45 (CH₂Cl₂/ethyl acetate, 20:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.23 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H), 7.52-7.47 (m, 2H), 7.46-7.41 (m, 1H), 7.40-7.34 (m, 1H), 4.59 (s, 1H), 1.71 (d, J = 14.9 Hz, 1H), 1.66 (d, J = 14.9 Hz, 1H), 1.53 (s, 3H), 1.51 (s, 3H), 1.02 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.1, 149.3, 139.8, 135.8, 132.1, 130.7, 127.3, 127.2, 125.3, 124.1, 60.9, 55.7, 31.9, 31.8, 30.9, 29.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1462, 1383, 1349, 1290, 1251, 1147, 1087, 957, 855, 732, 678, 618;

HRMS (ESI⁺) calcd. for C₂₀H₂₇ClN₃O₄S₂⁺ [M+H]⁺: 472.1126, found: 472.1125.

***N*-(*S*-(4-Cyanophenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3d)**



Preparation of Grignard reagent

4-Cyanophenylmagnesium chloride lithium chloride complex solution was prepared according to the following procedure. To a solution of 4-bromobenzonitrile (1.53 g, 8.40 mmol, 1.20 equiv.) in anhydrous THF (8.4 mL) in an oven-dried 100 mL round-bottom flask was added isopropylmagnesium chloride lithium chloride complex solution (Turbo Grignard Reagent, 6.89 mL, 1.22 M in THF, 8.40 mmol, 1.20 equiv.) dropwise at 0 °C. The reaction was stirred at room temperature for 1.5 h.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.23 g, 7.00 mmol, 1.00 equiv.), THF (14.0 mL), LiHMDS solution (7.00 mL, 1.00 M in THF, 7.00 mmol, 1.00 equiv.), TMSCl (0.89 mL, 7.00 mmol, 1.0 equiv.), 4-cyanophenyl magnesium chloride lithium chloride complex solution (8.40 mmol, 1.20 equiv.), CH₂Cl₂ (35.0 mL), Et₃N (1.17 mL, 8.40 mmol, 1.20 equiv.) and NsCl (1.71 g, 7.70 mmol, 1.10 equiv.). Purification by flash column chromatography

(CH₂Cl₂/ethyl acetate, 25:1 to 15:1 to 10:1) afforded *sulfinamidine* **3d** as a white solid (2.16 g, 4.68 mmol, 67%).

mp 126-128 °C;

*R*_f 0.34 (CH₂Cl₂/ethyl acetate, 15:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.27 (d, *J* = 8.8 Hz, 2H), 8.02 (d, *J* = 8.8 Hz, 2H), 7.82 (d, *J* = 8.8 Hz, 2H), 7.76 (d, *J* = 8.8 Hz, 2H), 4.54 (s, 1H), 1.68 (d, *J* = 14.9 Hz, 1H), 1.64 (d, *J* = 14.9 Hz, 1H), 1.51 (s, 3H), 1.46 (s, 3H), 1.00 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.9, 149.5, 143.7, 133.2, 128.0, 127.4, 124.2, 117.2, 116.0, 61.1, 55.8, 31.9, 31.8, 30.7, 29.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1349, 1289, 1144, 1087, 982, 855, 732, 618;

HRMS (ESI⁺) calcd. for C₂₁H₂₇N₄O₄S₂⁺ [M+H]⁺: 463.1468, found: 463.1462.

***N*-(*S*-(3-Cyanophenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (**3e**)**



Preparation of Grignard reagent

3-Cyanophenylmagnesium chloride lithium chloride complex solution was prepared according to the following procedure. To a solution of 3-bromobenzonitrile (1.53 g, 8.40 mmol, 1.20 equiv.) in anhydrous THF (8.4 mL) in an oven-dried 100 mL round-bottom flask was added isopropylmagnesium chloride lithium chloride complex solution (Turbo Grignard Reagent) (6.83 mL, 1.23 M in THF, 8.40 mmol, 1.20 equiv.) dropwise at 0 °C. The reaction was stirred at room temperature for 2.5 h.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.23 g, 7.00 mmol, 1.00 equiv.), THF (14.0 mL), LiHMDS solution (7.00 mL, 1.00 M in THF, 7.00 mmol, 1.00 equiv.), TMSCl (0.89 mL, 7.00 mmol, 1.00 equiv.), 3-cyanophenyl magnesium chloride lithium chloride complex solution (8.40 mmol, 1.20 equiv.), CH₂Cl₂ (35.0 mL), Et₃N (1.17 mL, 8.40 mmol, 1.20 equiv.) and NsCl (1.71 g, 7.70 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 25:1 to 15:1 to 10:1) afforded *sulfinamidine 3e* as a white solid (2.86 g, 6.19 mmol, 88%).

mp 102-104 °C;

R_f 0.57 (CH₂Cl₂/ethyl acetate, 15:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.27 (d, *J* = 8.9 Hz, 2H), 8.00 (d, *J* = 8.9 Hz, 2H), 7.93-7.87 (m, 2H), 7.78 (dt, *J* = 7.7, 1.3 Hz, 1H), 7.60 (td, *J* = 7.7, 0.7 Hz, 1H), 4.66 (s, 1H), 1.69 (d, *J* = 14.9 Hz, 1H), 1.65 (d, *J* = 14.9 Hz, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 1.01 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.9, 149.5, 140.6, 135.2, 131.4, 130.8, 130.5, 127.4, 124.2, 117.1, 114.2, 61.1, 55.7, 31.9, 31.8, 30.6, 29.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1349, 1291, 1145, 1087, 981, 855, 732, 684, 619;

HRMS (ESI⁺) calcd. for C₂₁H₂₇N₄O₄S₂⁺ [M+H]⁺: 463.1468, found: 463.1463.

***N*-(*S*-(4-Methoxyphenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3f)**



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.26 g, 7.17 mmol, 1.00 equiv.), THF (14.3 mL), LiHMDS solution (7.17 mL, 1.00 M in THF, 7.23 mmol, 1.00 equiv.), TMSCl (0.91 mL, 7.17 mmol, 1.00 equiv.), 4-methoxyphenylmagnesium bromide solution (17.20 mL, 0.50 M in THF, 8.60 mmol, 1.20 equiv.), CH₂Cl₂ (35.9 mL), Et₃N (1.20 mL, 8.60 mmol, 1.20

equiv.) and NsCl (1.75 g, 7.89 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 30:1 to 20:1 to 10:1) afforded *sulfinamidine* **3f** as a white solid (2.54 g, 5.44 mmol, 76%).

mp 108-110 °C;

R_f 0.2 (petrol/ethyl acetate, 2:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.19 (d, *J* = 8.8 Hz, 2H), 7.94 (d, *J* = 8.8 Hz, 2H), 7.48 (d, *J* = 9.0 Hz, 2H), 6.88 (d, *J* = 9.0 Hz, 2H), 4.35 (s, 1H), 3.80 (s, 3H), 1.68 (d, *J* = 15.0 Hz, 1H), 1.63 (d, *J* = 15.0 Hz, 1H), 1.52 (s, 3H), 1.49 (s, 3H), 1.00 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 162.5, 150.5, 149.1, 128.7, 128.5, 127.3, 124.0, 114.9, 60.4, 55.8, 55.7, 31.83, 31.79, 30.9, 29.2 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1526, 1494, 1348, 1287, 1257, 1143, 1085, 1017, 980, 731, 616;

HRMS (ESI⁺) calcd. for C₂₁H₃₀N₃O₅S₂⁺ [M+H]⁺: 468.1621, found: 468.1620.

4-Nitro-*N*-(*S*-(*o*-tolyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)benzenesulfonamide (**3g**)



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.23 g, 7.00 mmol, 1.00 equiv.), THF (14.0 mL), LiHMDS solution (7.00 mL, 1.00 M in THF, 7.00 mmol, 1.00 equiv.), TMSCl (0.89 mL, 7.00 mmol, 1.00 equiv.), 2-methylphenylmagnesium bromide solution (13.10 mL, 0.64 M in THF, 8.40 mmol, 1.20 equiv.), CH₂Cl₂ (14.0 mL), Et₃N (1.95 mL, 14.00 mmol, 2.00 equiv.) and NsCl (2.33 g, 10.50 mmol, 1.50 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 60:1 to 30:1 to 20:1) afforded *sulfinamidine* **3g** as a white solid (2.58 g, 5.72 mmol, 82%).

mp 110-112 °C;

R_f 0.36 (CH₂Cl₂/ethyl acetate, 30:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.08 (d, J = 8.9 Hz, 2H), 7.94 (dd, J = 7.4, 1.9 Hz, 1H), 7.75 (d, J = 8.9 Hz, 2H), 7.38-7.29 (m, 2H), 7.09-7.05 (m, 1H), 4.49 (s, 1H), 2.36 (s, 3H), 1.70 (d, J = 14.9 Hz, 1H), 1.65 (d, J = 14.9 Hz, 1H), 1.57 (s, 3H), 1.51 (s, 3H), 0.99 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.1, 148.9, 136.6, 136.2, 132.3, 131.6, 127.2, 127.1, 125.6, 123.7, 60.8, 55.7, 31.82, 31.75, 30.5, 29.2, 19.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1526, 1348, 1286, 1143, 1088, 968, 731, 616;

HRMS (ESI⁺) calcd. for C₂₁H₃₀N₃O₄S₂⁺ [M+H]⁺: 452.1672, found: 452.1669.

***N*-(*S*-(3,5-Difluorophenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3h)**



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.02 g, 5.82 mmol, 1.00 equiv.), THF (11.6 mL), LiHMDS solution (5.82 mL, 1.00 M in THF, 5.82 mmol, 1.00 equiv.), TMSCl (0.74 mL, 5.82 mmol, 1.00 equiv.), 3,5-difluorophenylmagnesium bromide solution (29.10 mL, 0.24 M in THF, 6.98 mmol, 1.20 equiv.), CH₂Cl₂ (29.1 mL), Et₃N (0.97 mL, 6.98 mmol, 1.20 equiv.) and NsCl (1.42 g, 6.40 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 50:1 to 25:1) afforded *sulfinamidine* **3h** as a white solid (2.36 g, 4.99 mmol, 86%).

mp 110-112 °C;

R_f 0.50 (CH₂Cl₂/ethyl acetate, 25:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.26 (d, J = 8.9 Hz, 2H), 7.99 (d, J = 8.9 Hz, 2H), 7.17-7.12 (m, 2H), 6.92 (tt, J = 8.3, 2.3 Hz, 1H), 4.68 (s, 1H), 1.69 (d, J = 14.9 Hz, 1H), 1.65 (d, J = 14.9 Hz, 1H), 1.50 (s, 3H), 1.47 (s, 3H), 1.01 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 163.0 (dd, J = 255.2, 11.8 Hz), 149.9, 149.4, 142.2 (t, J = 8.5 Hz), 127.4, 124.2, 111.8-110.2 (second-order multiplet), 107.6 (t, J = 25.1 Hz), 61.1, 55.7, 31.83, 31.75, 30.6, 29.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom); **¹⁹F NMR** (377 MHz, CDCl₃): δ (ppm) = -104.7 – -104.8 (second-order multiplet);

The second-order multiplet in the ¹³C and ¹⁹F NMR spectra arise due to virtual coupling;

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1600, 1528, 1437, 1349, 1291, 1146, 1125, 1088, 990, 855, 731, 619;

HRMS (ESI⁺) calcd. for C₂₀H₂₆F₂N₃O₄S₂⁺ [M+H]⁺: 474.1327, found: 474.1319.

***N*-(6-Methoxy-*N*-(2,4,4-trimethylpentan-2-yl)pyridine-3-sulfinimidoyl)-4-nitrobenzenesulfonamide (3i)**



Preparation of organometallic reagent

(6-Methoxypyridin-3-yl)lithium solution was prepared according to the following procedure. To a solution of 5-bromo-2-methoxypyridine (1.74 g, 9.25 mmol, 1.20 equiv.) in anhydrous THF (18.5 mL) in an oven-dried 100 mL round-bottom flask was added *n*-butyllithium solution (3.70 mL, 2.50 M in hexanes, 9.25 mmol, 1.20 equiv.) dropwise at -78 °C. The reaction was stirred at the same temperature for 40 min.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.35 g, 7.71 mmol, 1.00 equiv.), THF (15.4 mL), LiHMDS solution (7.71 mL, 1.00 M in THF, 7.71 mmol, 1.00 equiv.), TMSCl (0.98 mL, 7.71 mmol, 1.00 equiv.), (6-methoxypyridin-3-yl)lithium solution (9.25 mmol, 1.20 equiv.), CH₂Cl₂ (38.5 mL), Et₃N (1.29 mL, 9.25 mmol, 1.20 equiv.) and NsCl (1.88 g, 8.47

mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 25:1 to 15:1 to 5:1) afforded *sulfinamidine* **3i** as a white solid (2.89 g, 6.18 mmol, 80%).

mp 120-122 °C;

R_f 0.38 (CH₂Cl₂/ethyl acetate, 10:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.28 (dd, *J* = 2.7, 0.7 Hz, 1H), 8.21 (d, *J* = 8.8 Hz, 2H), 7.94 (d, *J* = 8.8 Hz, 2H), 7.71 (dd, *J* = 8.9, 2.7 Hz, 1H), 6.73 (dd, *J* = 8.9, 0.7 Hz, 1H), 4.60 (s, 1H), 3.91 (s, 3H), 1.66 (d, *J* = 15.0 Hz, 1H), 1.64 (d, *J* = 15.0 Hz, 1H), 1.51 (s, 3H), 1.48 (s, 3H), 1.00 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.3, 150.2, 149.2, 146.7, 137.0, 127.3, 126.7, 124.1, 112.0, 60.7, 55.6, 54.4, 31.82, 31.76, 30.7, 29.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1588, 1527, 1478, 1371, 1349, 1285, 1145, 1087, 1015, 979, 732, 619;

HRMS (ESI⁺) calcd. for C₂₀H₂₉N₄O₅S₂⁺ [M+H]⁺: 469.1574, found: 469.1570.

4-Nitro-*N*-(*N*-(2,4,4-trimethylpentan-2-yl)pyridine-3-sulfinimidoyl)benzenesulfonamide (**3j**)



Preparation of Grignard reagent

3-Pyridylmagnesium chloride lithium chloride complex solution was prepared according to the following procedure. To a solution of 3-bromopyridine (1.32 g, 8.40 mmol, 1.20 equiv.) in anhydrous THF (8.4 mL) in an oven-dried 100 mL round-bottom flask was added isopropyl magnesium chloride lithium chloride complex solution (Turbo Grignard Reagent, 6.83 mL, 1.23 M in THF, 8.40 mmol, 1.20 equiv.) dropwise at 0 °C. The reaction was stirred at 0 °C for 1 h. Then the mixture was warmed to room temperature and stirred for another 0.5 h.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.23 g, 7.00 mmol, 1.00 equiv.), THF (14.0 mL), LiHMDS solution (7.00 mL, 1.00 M in THF, 7.00 mmol, 1.00 equiv.), TMSCl (0.89 mL, 7.00 mmol, 1.0 equiv.), 3-pyridylmagnesium chloride lithium chloride complex solution (8.40 mmol, 1.20 equiv.), CH₂Cl₂ (35.0 mL), Et₃N (1.17 mL, 8.40 mmol, 1.20 equiv.) and NsCl (1.71 g, 7.70 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 5:1 to 1:1 to 1:2) afforded *sulfinamidine 3j* as a white solid (2.31 g, 5.27 mmol, 75%).

mp 114-116 °C;

R_f 0.26 (CH₂Cl₂/ethyl acetate, 1:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.76 (s, 1H), 8.67 (d, *J* = 4.8 Hz, 1H), 8.23 (d, *J* = 8.8 Hz, 2H), 7.98 (d, *J* = 8.8 Hz, 2H), 7.97-7.93 (m, 1H), 7.38 (dd, *J* = 8.3, 4.8 Hz, 1H), 4.82 (s, 1H), 1.70 (d, *J* = 15.0 Hz, 1H), 1.65 (d, *J* = 15.0 Hz, 1H), 1.52 (s, 3H), 1.48 (s, 3H), 1.00 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 152.4, 149.9, 149.3, 148.1, 135.3, 135.1, 127.3, 124.2, 124.1, 61.0, 55.6, 31.8, 31.7, 30.7, 29.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1526, 1349, 1289, 1145, 1087, 974, 731, 616;

HRMS (ESI⁺) calcd. for C₁₉H₂₇N₄O₄S₂⁺ [M+H]⁺: 439.1368, found: 439.1469.

***N*-(*S*-Cyclopropyl-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3k)**



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.21 g, 6.91 mmol, 1.00 equiv.), THF (13.8 mL), LiHMDS solution (6.91 mL, 1.00 M in THF, 6.91 mmol, 1.00 equiv.), TMSCl (0.88 mL, 6.91 mmol, 1.00 equiv.), cyclopropylmagnesium bromide solution (9.87 mL, 0.84 M in 2-methyltetrahydrofuran, 8.29 mmol, 1.20 equiv.), CH₂Cl₂ (34.5 mL), Et₃N (1.16 mL, 8.29 mmol, 1.20 equiv.) and NsCl (1.68 g, 7.59 mmol, 1.10 equiv.). Purification by flash column

chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfinamidine 3k* as a white solid (2.32 g, 5.79 mmol, 84%).

mp 122-124 °C;

R_f 0.44 (petrol/ethyl acetate, 1:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.27 (d, *J* = 8.9 Hz, 2H), 8.03 (d, *J* = 8.9 Hz, 2H), 4.10 (s, 1H), 2.50 (tt, *J* = 7.8, 4.7 Hz, 1H), 1.57 (d, *J* = 15.0 Hz, 1H), 1.52 (d, *J* = 15.0 Hz, 1H), 1.39 (s, 3H), 1.35 (s, 3H), 1.28-1.20 (m, 1H), 0.98 (s, 9H), 0.92-0.77 (m, 2H), 0.63-0.55 (m, 1H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.8, 149.2, 127.4, 124.1, 59.6, 55.4, 31.9, 31.7, 31.1, 30.9, 28.9, 4.6, 1.7;


Notes:

1. For *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;
2. For 2 secondary carbons in cyclopropane ring, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1526, 1349, 1285, 1142, 1089, 981, 855, 731, 616;

HRMS (ESI⁺) calcd. for C₁₇H₂₈N₃O₄S₂⁺ [M+H]⁺: 402.1516, found: 402.1514.

***N*-(*S*-Ethyl-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3l)**



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.33 g, 7.62 mmol, 1.00 equiv.), THF (15.2 mL), LiHMDS solution (7.62 mL, 1.00 M in THF, 7.62 mmol, 1.00 equiv.), TMSCl (0.97 mL, 7.62 mmol, 1.00 equiv.), ethylmagnesium bromide solution (9.62 mL, 0.95 M in THF, 9.14 mmol, 1.20 equiv.), CH₂Cl₂ (38.1 mL), Et₃N (1.28 mL, 9.14 mmol, 1.20 equiv.) and NsCl (1.86 g, 8.38 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 20:1 to 10:1 to 5:1) afforded *sulfinamidine 3l* as a white solid (1.80 g, 4.63 mmol, 61%).

mp 122-124 °C;

R_f 0.50 (CH₂Cl₂/ethyl acetate, 4:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.27 (d, *J* = 8.9 Hz, 2H), 8.05 (d, *J* = 8.9 Hz, 2H), 4.41 (s, 1H), 3.15 (q, *J* = 7.4 Hz, 2H), 1.58 (d, *J* = 14.9 Hz, 1H), 1.53 (d, *J* = 14.9 Hz, 1H), 1.39 (s, 3H), 1.36 (s, 3H), 1.15 (t, *J* = 7.4 Hz, 3H), 0.97 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.7, 149.3, 127.3, 124.1, 59.8, 55.6, 48.8, 31.8, 31.7, 31.0, 28.8, 8.8 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1349, 1285, 1142, 1089, 979, 855, 744, 615;

HRMS (ESI⁺) calcd. for C₁₆H₂₈N₃O₄S₂⁺ [M+H]⁺: 390.1516, found: 390.1518.

***N*-(*S*-Butyl-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (3m)**



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.23 g, 7.00 mmol, 1.00 equiv.), THF (14.0 mL), LiHMDS solution (7.00 mL, 1.00 M in THF, 7.00 mmol, 1.00 equiv.), TMSCl (0.89 mL, 7.00 mmol, 1.00 equiv.), butylmagnesium chloride solution (4.29 mL, 1.96 M in THF, 8.40 mmol, 1.20 equiv.), CH₂Cl₂ (35.0 mL), Et₃N (1.17 mL, 8.40 mmol, 1.20 equiv.) and NsCl (1.71 g, 7.70 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 25:1 to 10:1) afforded *sulfinamidine* **3m** as a white solid (2.11 g, 5.06 mmol, 72%).

mp 122-124 °C;

R_f 0.46 (CH₂Cl₂/ethyl acetate, 9:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.28 (d, *J* = 8.9 Hz, 2H), 8.05 (d, *J* = 8.9 Hz, 2H), 4.33 (s, 1H), 3.19-3.07 (m, 2H), 1.58 (d, *J* = 14.9 Hz, 1H), 1.53 (d, *J* = 14.9 Hz, 1H), 1.53-1.45 (m, 2H), 1.39 (s, 3H), 1.37 (s, 3H), 1.36-1.29 (m, 2H), 0.98 (s, 9H), 0.82 (t, *J* = 7.3 Hz, 3H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.8, 149.3, 127.3, 124.1, 59.9, 55.7, 54.6, 31.8, 31.7, 31.0, 28.9, 25.9, 21.4, 13.6 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1524, 1346, 1290, 1145, 1088, 955, 919, 854, 770;

HRMS (ESI⁺) calcd. for C₁₈H₃₁N₃O₄S₂Na⁺ [M+ Na]⁺: 440.1648, found: 440.1649.

4-Nitro-*N*-(*N*-(2,4,4-trimethylpentan-2-yl)-*S*-vinylsulfinimidoyl)benzenesulfonamide (3n)



Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (1.31 g, 7.50 mmol, 1.00 equiv.), THF (15.0 mL), LiHMDS solution (7.50 mL, 1.00 M in THF, 7.50 mmol, 1.00 equiv.), TMSCl (0.95 mL, 7.50 mmol, 1.00 equiv.), vinylmagnesium bromide solution (10.10 mL, 0.89 M in THF, 9.00 mmol, 1.20 equiv.), CH₂Cl₂ (37.5 mL), Et₃N (1.25 mL, 9.00 mmol, 1.20 equiv.) and NsCl (1.83 g, 8.25 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 20:1 to 10:1 to 5:1) afforded *sulfinamidine* **3n** as a white solid (2.04 g, 5.27 mmol, 70%).

mp 92-94 °C;

R_f 0.30 (CH₂Cl₂/ethyl acetate, 10:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.27 (d, *J* = 8.9 Hz, 2H), 8.03 (d, *J* = 8.9 Hz, 2H), 6.50 (dd, *J* = 16.0, 9.2 Hz, 1H), 5.99 (dd, *J* = 16.0, 1.4 Hz, 1H), 5.90 (dd, *J* = 9.2, 1.4 Hz, 1H), 4.31 (s, 1H), 1.62 (d, *J* = 15.0 Hz, 1H), 1.54 (d, *J* = 15.0 Hz, 1H), 1.43 (s, 3H), 1.39 (s, 3H), 0.98 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.4, 149.3, 135.3, 127.3, 125.8, 124.1, 60.1, 55.3, 31.8, 31.7, 31.0, 29.1 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1526, 1349, 1287, 1143, 1088, 979, 855, 618;

HRMS (ESI⁺) calcd. for C₁₆H₂₆N₃O₄S₂⁺ [M+H]⁺: 388.1359, found: 388.1361.

***N*-(*S*-(3-Cyano-4-ethoxyphenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)-4-nitrobenzenesulfonamide (**3o**)**



Preparation of organometallic reagent

(3-Cyano-4-ethoxyphenyl)lithium solution was prepared according to the following procedure. To a solution of 5-bromo-2-ethoxybenzonitrile (9.08 g, 40.30 mmol, 1.50 equiv.) in anhydrous THF (40.3 mL) in an oven-dried 250 mL round-bottom flask was added *n*-butyllithium solution (16.67 mL, 2.42 M in hexanes, 40.30 mmol, 1.50 equiv.) dropwise at -78 °C. The reaction was stirred at the same temperature for 20 min.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (4.73 g, 27.00 mmol, 1.00 equiv.), THF (27.0 mL), LiHMDS solution (27.00 mL, 1.00 M in THF, 27.00 mmol, 1.00 equiv.), TMSCl (3.43 mL, 27.00 mmol, 1.00 equiv.), (3-cyano-4-ethoxyphenyl)lithium solution (40.30 mmol, 1.50 equiv.), CH₂Cl₂ (135.0 mL), Et₃N (6.02 mL, 43.20 mmol, 1.60 equiv.) and NsCl (8.98 g, 40.50 mmol, 1.50 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 20:1 to 10:1) afforded *sulfinamidine* **3o** as a white solid (7.11 g, 14.05 mmol, 52%).

mp 128-130 °C;

R_f 0.50 (CH₂Cl₂/ethyl acetate, 9:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.25 (d, *J* = 8.9 Hz, 2H), 7.99 (d, *J* = 8.9 Hz, 2H), 7.78-7.73 (m, 2H), 6.99 (d, *J* = 8.9 Hz, 1H), 4.54 (s, 1H), 4.18 (qd, *J* = 7.0, 1.0 Hz, 2H), 1.67 (d, *J* = 15.0 Hz, 1H), 1.63 (d, *J* = 15.0 Hz, 1H), 1.50 (s, 3H), 1.49 (t, *J* = 7.0 Hz, 3H), 1.46 (s, 3H), 1.00 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 163.1, 150.1, 149.4, 133.2, 132.8, 129.9, 127.4, 124.2, 114.8, 113.0, 103.6, 65.9, 60.8, 55.7, 31.84, 31.76, 30.7, 29.4, 14.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1473, 1383, 1349, 1286, 1252, 1147, 1087, 956;

HRMS (ESI⁺) calcd. for C₂₃H₃₁N₄O₅S₂⁺ [M+H]⁺: 507.1730, found: 507.1729.

4-Nitro-*N*-(*S*-(4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)-*N*-(2,4,4-trimethylpentan-2-yl)sulfinimidoyl)benzenesulfonamide (3p)



Preparation of organometallic reagent

(4-(5-(*p*-Tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)lithium solution was prepared according to the following procedure. To a solution of 1-(4-bromophenyl)-5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazole (2.42 g, 6.37 mmol, 1.20 equiv.) in anhydrous THF (12.7 mL) in an oven-dried 100 mL round-bottom flask was added *n*-butyllithium solution (2.55 mL, 2.50 M in hexanes, 6.37 mmol, 1.20 equiv.) dropwise at -78 °C. The reaction was stirred at the same temperature for 40 min.

Preparation of sulfinamidine

Prepared according to **General Procedure A** using *N*-sulfinyl-*tert*-octylamine (0.91 g, 5.22 mmol, 1.00 equiv.), THF (10.4 mL), LiHMDS solution (5.22 mL, 1.00 M in THF, 5.22 mmol, 1.00 equiv.), TMSCl (0.66 mL, 5.22 mmol, 1.00 equiv.), (4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)lithium solution (6.37 mmol, 1.20 equiv.), CH₂Cl₂ (26.1 mL), Et₃N (0.89 mL, 6.37 mmol, 1.20 equiv.) and NsCl (1.27 g, 5.74 mmol, 1.10 equiv.). Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 50:1 to 30:1 to 20:1) afforded *sulfinamidine* **3p** as a white solid (3.28 g, 4.96 mmol, 95%).

mp 95-97 °C;

*R*_f 0.45 (CH₂Cl₂/ethyl acetate, 30:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.22 (d, *J* = 8.8 Hz, 2H), 7.99 (d, *J* = 8.8 Hz, 2H), 7.61 (d, *J* = 8.9 Hz, 2H), 7.40 (d, *J* = 8.9 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 7.07 (d, *J* = 8.0 Hz, 2H), 6.71 (s, 1H), 4.46 (s, 1H), 2.37 (s, 3H), 1.66 (d, *J* = 15.0 Hz, 1H), 1.62 (d, *J* = 15.0 Hz, 1H), 1.50 (s, 3H), 1.44 (s, 3H), 0.98 (s, 9H);


^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 150.1, 149.3, 145.3, 144.2 (q, J = 38.5 Hz), 142.2, 140.0, 137.7, 129.8, 128.8, 128.0, 127.4, 125.78, 125.75, 124.1, 121.10 (q, J = 269.3 Hz), 106.5, 60.8, 55.8, 31.8, 31.7, 30.7, 29.2, 21.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = -62.4 (s);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1528, 1349, 1236, 1139, 1088, 969, 855, 732, 614;

HRMS (ESI^+) calcd. for $\text{C}_{31}\text{H}_{35}\text{F}_3\text{N}_5\text{O}_4\text{S}_2^+$ $[\text{M}+\text{H}]^+$: 662.2077, found: 662.2071.


2.2.3 General Procedure B for Sulfondiimidoyl Fluoride Synthesis



An oven-dried round-bottom flask was charged with sulfinamidine (1.00 equiv.) and NaH (60 % dispersion in mineral oil, 1.10 equiv.) at 0 °C and was purged with nitrogen gas. Anhydrous THF (0.5 M) was added. The reaction was stirred at 0 °C for 5 min before being warmed to room temperature and stirred for another 25 min. NFSI (1.50 equiv.) was then added under a positive pressure of nitrogen and the reaction was stirred at room temperature for 30 min before being quenched with sat. aq. NaCl solution. Ethyl acetate was added and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate twice. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a crude solid. Diethyl ether was added to the crude solid. The resulting suspension was shaken well before being filtered. The white filter cake was washed with diethyl ether and CH₂Cl₂. The combined filtrate was concentrated under reduced pressure to give a crude product containing a mixture of *N*-fluorinated product and *S*-fluorinated product. The crude mixture was allowed to stand at room temperature (open to air) for 1-8 days until all the *N*-fluorinated product had isomerized to the desired *S*-fluorinated product (as determined by TLC and ¹⁹F NMR). The crude product was then purified by flash column chromatography to afford the sulfondiimidoyl fluoride.

Notes:

1. The time taken for the *N*-fluorinated compound to isomerize into the *S*-fluorinated compound varies from substrate to substrate. ¹⁹F NMR can be used to monitor this isomerization and determine when it is complete. The chemical shifts of the fluorine atoms for *N*-fluorinated compounds in the ¹⁹F NMR are present at approximately -70 ppm and the chemical shifts of the fluorine atoms for *S*-fluorinated compounds in the ¹⁹F NMR are present at approximately 80 ppm. When monitoring by TLC, the *N*-fluorinated compound is usually more polar than *S*-fluorinated compound (in the eluent system of petrol and ethyl acetate).



- Even for different batches of the same substrate, the time taken for the *N*-fluorinated compound to isomerize into the *S*-fluorinated compound is not identical. It is recommended to monitor the isomerization every 12 h by ^{19}F NMR or TLC.
- Sulfondiimidoyl fluorides decompose gradually when stored in CDCl_3 . As such, it is recommended to remove the CDCl_3 or other deuterated solvent immediately after the NMR experiments for longer term storage. Storing them in pure form typically reduces their decomposition rate.
- Sulfondiimidoyl fluorides containing electron-withdrawing substituents on carbon e.g. **4d**, **4e**, **4h**, **4j** and **4o** can be susceptible to hydrolysis when stored at room temperature. For this reason, we suggest purification of all sulfondiimidoyl fluorides should be carried out as soon as possible upon the completion of isomerization. We also recommend using purified sulfondiimidoyl fluorides in the next amination step immediately in order to maximise yield.
- The *in-situ* generated sulfinamidine salt forms a viscous slurry in the reaction flask. When NFSI (solid) is added, the stirring is often difficult and some solid was found to stick to the upper part of the wall of the round-bottom flask, which led to insufficient reaction of the two reagents and reduced yield. When this happens, it is recommended to add additional anhydrous THF (sulfinamidine conc. 1.0 M) to flush the adhered solids from the wall to the bottom of round-bottom flask, and the addition of THF will not lead to a decrease in yield.
- Addition of 15-crown-5 (1.1 equiv.) to the reaction mixture at 0 °C after the addition of the anhydrous THF prevents the formation of the slurry, and the *in-situ* generated sulfinamidine salt dissolves to form a clear solution. Although the improved stirring gave a slight improvement of yield (70%), this additive was not used in any of the scope reactions.

4-Fluoro-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4a)



An oven-dried 50 mL round-bottom flask was charged with sulfinamidine **3a** (2.20 g, 4.84 mmol, 1.00 equiv.) and NaH (213 mg, 60 % dispersion in mineral oil, 5.32 mmol, 1.10 equiv.) at 0 °C and was purged with nitrogen gas. Anhydrous THF (9.70 mL) was added. The reaction was stirred at 0 °C for 5 min before being warmed to room temperature and stirred for another 25 min. NFSI (2.29 g, 7.26 mmol, 1.50 equiv.) was then added under a positive pressure of nitrogen and the reaction was stirred at room temperature for 30 min before being quenched with sat. aq. NaCl solution (250 mL). Ethyl acetate (150 mL) was added and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate (2 × 60 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a crude solid. Diethyl ether (100 mL) was added to the crude solid and the resulting suspension was shaken well before being filtered. The white filter cake was washed with diethyl ether (120 mL) and CH₂Cl₂ (20 mL). The combined filtrate was concentrated under reduced pressure to give a crude product containing a mixture of *N*-fluorinated product and *S*-fluorinated product. The crude mixture was allowed to stand at room temperature (open to air) for 16-20 h until all the *N*-fluorinated product had isomerized to the desired *S*-fluorinated product (as determined by TLC and ¹⁹F NMR). The crude product was then purified by flash column chromatography (petrol/ethyl acetate, 4:1) to afford *sulfondiimidoyl fluoride 4a* a pale-yellow solid (1.56 g, 3.30 mmol, 68%).

mp 57-59 °C;

R_f 0.59 (petrol/ethyl acetate, 6:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.32 (d, *J* = 8.9 Hz, 2H), 8.06 (d, *J* = 8.9 Hz, 2H), 8.04-7.98 (m, 2H), 7.26-7.19 (m, 2H), 1.67 (d, *J* = 14.7 Hz, 1H), 1.52 (d, *J* = 14.7 Hz, 1H), 1.48 (s, 3H), 1.43 (s, 3H), 0.96 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.1 (d, *J* = 258.8 Hz), 150.0, 148.3, 134.4 (dd, *J* = 25.1, 3.3 Hz), 130.6 (d, *J* = 9.8 Hz), 128.1, 124.2, 116.9 (d, *J* = 23.1 Hz), 63.5 (d, *J* = 4.6 Hz), 56.5 (d, *J* = 3.2 Hz), 31.84, 31.79 (d, *J* = 2.7 Hz), 31.52, 31.45 (d, *J* = 6.6 Hz) (note: for *gem*-dimethyl carbons in


tert-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.5 (s), -101.4 (tt, *J* = 7.8, 4.7 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1532, 1492, 1348, 1240, 1163, 1089, 1075;

HRMS (ESI⁺) calcd. for C₂₀H₂₅F₂N₃O₄S₂Na⁺ [M+Na]⁺: 496.1147, found: 496.1146.

4-Chloro-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4b)



Prepared according to **General Procedure B** using sulfinamidine **3b** (707 mg, 1.50 mmol, 1.00 equiv.), THF (3.00 mL), NaH (66 mg, 60 % dispersion in mineral oil, 1.65 mmol, 1.10 equiv.) and NFSI (709 mg, 2.25 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 16 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1) afforded *sulfondiimidoyl fluoride 4b* as a white solid (520 mg, 1.06 mmol, 71%).

mp 66-68 °C;

R_f 0.55 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.32 (d, *J* = 8.9 Hz, 2H), 8.06 (d, *J* = 8.9 Hz, 2H), 7.92 (d, *J* = 8.9 Hz, 2H), 7.52 (d, *J* = 8.9 Hz, 2H), 1.67 (d, *J* = 14.7 Hz, 1H), 1.53 (d, *J* = 14.7 Hz, 1H), 1.48 (s, 3H), 1.44 (s, 3H), 0.97 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.0, 148.2, 141.4, 136.9 (d, *J* = 25.3 Hz), 129.8, 129.0, 128.1, 124.2, 63.5 (d, *J* = 4.4 Hz), 56.5 (d, *J* = 3.4 Hz), 31.83, 31.81 (d, *J* = 2.5 Hz), 31.51, 31.46 (d, *J* = 5.9 Hz) (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.0 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1347, 1309, 1162, 1108, 1087, 1072, 1010, 745, 610;

HRMS (ESI⁺) calcd. for C₂₀H₂₅ClFN₃O₄S₂Na⁺ [M+Na]⁺: 512.0851, found: 512.0857.

3-Chloro-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4c)



Prepared according to **General Procedure B** using sulfinamidine **3c** (471 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1) afforded *sulfondiimidoyl fluoride 4c* as a pale-yellow oil (313 mg, 0.64 mmol, 64%).

R_f 0.70 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.29 (d, *J* = 8.9 Hz, 2H), 8.02 (d, *J* = 8.9 Hz, 2H), 7.87 (ddd, *J* = 8.1, 2.0, 1.0 Hz, 1H), 7.81 (t, *J* = 2.0 Hz, 1H), 7.61 (ddd, *J* = 8.1, 2.0, 1.0 Hz, 1H), 7.49 (t, *J* = 8.1 Hz, 1H), 1.68 (d, *J* = 14.7 Hz, 1H), 1.54 (d, *J* = 14.7 Hz, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 0.97 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.0, 148.0, 139.7 (d, *J* = 25.3 Hz), 135.5, 134.5, 130.7, 128.1, 127.4, 125.7, 124.2, 63.7 (d, *J* = 4.6 Hz), 56.4 (d, *J* = 3.3 Hz), 31.84 (d, *J* = 2.8 Hz), 31.78, 31.5, 31.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 85.8 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1347, 1310, 1163, 1131, 1088, 1071, 672, 616;

HRMS (ESI⁺) calcd. for C₂₀H₂₅ClFN₃O₄S₂Na⁺ [M+Na]⁺: 512.0851, found: 512.0854.

4-Cyanophenyl-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4d)



Prepared according to **General Procedure B** using sulfinamidine **3d** (693 mg, 1.50 mmol, 1.00 equiv.), THF (3.00 mL), NaH (66 mg, 60 % dispersion in mineral oil, 1.65 mmol, 1.10 equiv.) and NFSI (709 mg, 2.25 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfondiimidoyl fluoride* **4d** as a colourless oil (325 mg, 0.68 mmol, 45%).

R_f 0.50 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.34 (d, *J* = 8.8 Hz, 2H), 8.14 (d, *J* = 8.7 Hz, 2H), 8.08 (d, *J* = 8.8 Hz, 2H), 7.87 (d, *J* = 8.7 Hz, 2H), 1.66 (d, *J* = 14.7 Hz, 1H), 1.52 (d, *J* = 14.7 Hz, 1H), 1.47 (s, 3H), 1.43 (s, 3H), 0.95 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.1, 147.9, 142.5 (d, *J* = 26.3 Hz), 133.2, 128.2, 128.1, 124.3, 118.1, 116.8, 64.0 (d, *J* = 4.6 Hz), 56.3 (d, *J* = 3.3 Hz), 31.8, 31.78, 31.5, 31.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.3 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1532, 1350, 1303, 1164, 1133, 1107, 1089, 1071;

HRMS (ESI⁺) calcd. for C₂₁H₂₅FN₄O₄S₂Na⁺ [**M**+Na]⁺: 503.1193, found: 503.1194.

3-Cyanophenyl-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4e)



Prepared according to **General Procedure B** using sulfinamidine **3e** (693 mg, 1.50 mmol,

1.00 equiv.), THF (3.00 mL), NaH (66 mg, 60 % dispersion in mineral oil, 1.65 mmol, 1.10 equiv.) and NFSI (709 mg, 2.25 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfondiimidoyl fluoride* **4e** as a colourless oil (359 mg, 0.75 mmol, 50%).

R_f 0.55 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.33 (d, *J* = 8.9 Hz, 2H), 8.27-8.21 (m, 2H), 8.07 (d, *J* = 8.9 Hz, 2H), 7.96 (dt, *J* = 7.8, 1.3 Hz, 1H), 7.73 (t, *J* = 7.8 Hz, 1H), 1.67 (d, *J* = 14.8 Hz, 1H), 1.54 (d, *J* = 14.8 Hz, 1H), 1.48 (s, 3H), 1.44 (s, 3H), 0.95 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.1, 147.8, 140.1 (d, *J* = 26.9 Hz), 137.3, 131.3, 131.1, 130.6, 128.1, 124.3, 116.6, 114.2, 64.0 (d, *J* = 4.6 Hz), 56.3 (d, *J* = 3.3 Hz), 31.8, 31.7, 31.5, 31.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.7 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1532, 1349, 1306, 1164, 1109, 1087, 1073;

HRMS (ESI⁺) calcd. for C₂₁H₂₅FN₄O₄S₂Na⁺ [M+Na]⁺: 503.1193, found: 503.1188.

4-Methoxyphenyl-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (**4f**)



Prepared according to **General Procedure B** using sulfinamidine **3f** (467 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded xx *sulfondiimidoyl fluoride* **4f** a colourless oil (325 mg, 0.67 mmol, 67%).

R_f 0.54 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.25 (d, J = 8.7 Hz, 2H), 8.00 (d, J = 8.7 Hz, 2H), 7.84 (d, J = 9.0 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 3.83 (s, 3H), 1.65 (d, J = 14.8 Hz, 1H), 1.51 (d, J = 14.8 Hz, 1H), 1.48 (s, 3H), 1.43 (s, 3H), 0.95 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.2, 149.7, 148.4, 129.9, 129.2 (d, J = 24.0 Hz), 128.0, 124.0, 114.5, 62.9 (d, J = 4.4 Hz), 56.4 (d, J = 3.2 Hz), 55.9, 31.72, 31.69 (d, J = 2.7 Hz), 31.5, 31.3 (d, J = 6.2 Hz) (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.1 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1349, 1311, 1266, 1162, 1104, 1089;

HRMS (ESI⁺) calcd. for C₂₁H₂₈FN₃O₅S₂Na⁺ [M+Na]⁺: 508.1347, found: 508.1353.

***o*-Tolyl-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4g)**



Prepared according to **General Procedure B** using sulfinamidine **3g** (451 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 48 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfondiimidoyl fluoride 4g* a white solid (235 mg, 0.50 mmol, 50%).

mp 86-88 °C;

R_f 0.63 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.26 (d, J = 8.9 Hz, 2H), 7.98 (d, J = 8.9 Hz, 2H), 7.98-7.95 (m, 1H), 7.53 (td, J = 7.5, 1.3 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.29 (d, J = 7.5 Hz, 1H), 2.56 (s, 3H), 1.59 (d, J = 14.6 Hz, 1H), 1.50 (d, J = 14.6 Hz, 1H), 1.47 (s, 3H), 1.45 (s, 3H), 0.89 (s, 9H);


^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 149.8, 148.1, 137.6, 137.3 (d, $J = 19.5$ Hz), 134.2, 133.0 (d, $J = 1.8$ Hz), 128.2 (d, $J = 2.4$ Hz), 128.1, 126.6, 124.0, 63.5 (d, $J = 4.6$ Hz), 56.5 (d, $J = 3.0$ Hz), 31.7, 31.5 (d, $J = 3.1$ Hz), 31.4, 31.1 (d, $J = 6.6$ Hz), 20.1 (d, $J = 2.3$ Hz) (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = 81.2 (s);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1531, 1349, 1327, 1306, 1164, 1147, 1086, 1059, 686, 620;

HRMS (ESI^+) calcd. for $\text{C}_{21}\text{H}_{28}\text{FN}_3\text{O}_4\text{S}_2\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 492.1397, found: 492.1389.

3,5-Difluorophenyl-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4h)



Prepared according to **General Procedure B** using sulfinamidine **3h** (710 mg, 1.50 mmol, 1.00 equiv.), THF (3.00 mL), NaH (66 mg, 60 % dispersion in mineral oil, 1.65 mmol, 1.10 equiv.) and NFSI (709 mg, 2.25 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1) afforded *sulfondiimidoyl fluoride 4h* as a white solid (373 mg, 0.76 mmol, 51%).

mp 50-52 °C;

R_f 0.70 (petrol/ethyl acetate, 4:1);

^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.34 (d, $J = 8.9$ Hz, 2H), 8.08 (d, $J = 8.9$ Hz, 2H), 7.56-7.51 (m, 2H), 7.13 (tt, $J = 8.2, 2.3$ Hz, 1H), 1.68 (d, $J = 14.7$ Hz, 1H), 1.54 (d, $J = 14.7$ Hz, 1H), 1.49 (s, 3H), 1.45 (s, 3H), 0.97 (s, 9H);

^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 162.6 (dd, $J = 256.0, 11.8$ Hz), 150.1, 147.9, 141.2 (dt, $J = 28.4, 9.6$ Hz), 128.1, 124.3, 111.7-111.3 (second-order multiplet), 110.2 (t, $J = 24.9$ Hz), 64.0 (d,

$J = 4.6$ Hz), 56.3 (d, $J = 3.4$ Hz), 31.82, 31.80, 31.46 (d, $J = 6.1$ Hz), 31.45 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);


^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = 87.12 (s), -103.8- -103.9 (second-order multiplet);

The second-order multiplet in the ^{13}C and ^{19}F NMR spectra arise due to virtual coupling;

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1604, 1533, 1349, 1299, 1166, 1131, 1106, 1086;

HRMS (ESI^+) calcd. for $\text{C}_{20}\text{H}_{24}\text{F}_3\text{N}_3\text{O}_4\text{S}_2\text{Na}^+ [\text{M}+\text{Na}]^+$: 514.1053, found: 514.1053.

6-Methoxy-*N*-(4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)pyridine-3-sulfonyldiimidoyl fluoride (4i)



Prepared according to **General Procedure B** using sulfinamidine **3i** (468 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfonyldiimidoyl fluoride 4i* as a white solid (291 mg, 0.60 mmol, 60%).

mp 70-72 °C;

R_f 0.50 (petrol/ethyl acetate, 4:1);

^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.69 (d, $J = 2.7$ Hz, 1H), 8.29 (d, $J = 9.0$ Hz, 2H), 8.08-8.05 (m, 1H), 8.04 (d, $J = 9.0$ Hz, 2H), 6.81 (dd, $J = 9.0, 0.6$ Hz, 1H), 3.98 (s, 3H), 1.65 (d, $J = 14.7$ Hz, 1H), 1.50 (d, $J = 14.7$ Hz, 1H), 1.47 (s, 3H), 1.42 (s, 3H), 0.95 (s, 9H);


^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 167.2, 149.9, 148.2, 148.1, 137.3, 128.1, 127.7 (d, $J = 24.8$ Hz), 124.1, 111.6, 63.4 (d, $J = 4.4$ Hz), 56.4 (d, $J = 3.1$ Hz), 54.8, 31.8, 31.7 (d, $J = 2.6$ Hz), 31.5, 31.4 (d, $J = 6.3$ Hz) (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = 88.7 (s);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1588, 1532, 1484, 1381, 1348, 1310, 1288, 1163, 1086, 607;

HRMS (ESI^+) calcd. for $\text{C}_{20}\text{H}_{27}\text{FN}_4\text{O}_5\text{S}_2\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 509.1299, found: 509.1307.

***N*-((4-Nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)pyridine-3-sulfondiimidoyl fluoride (4j)**



Prepared according to **General Procedure B** using sulfinamidine **3j** (657 mg, 1.50 mmol, 1.00 equiv.), THF (3.00 mL), NaH (66 mg, 60 % dispersion in mineral oil, 1.65 mmol, 1.10 equiv.) and NFSI (709 mg, 2.25 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 72 h for the completion of isomerization. Purification by flash column chromatography (CH_2Cl_2 /ethyl acetate, 25:1 to 10:1) afforded *sulfondiimidoyl fluoride* **4j** as a colourless oil (275 mg, 0.60 mmol, 40%).

R_f 0.58 (CH_2Cl_2 /ethyl acetate, 20:1);

^1H NMR (400 MHz, CDCl_3): δ (ppm) = 9.10 (dd, J = 2.5, 0.8 Hz, 1H), 8.84 (dd, J = 4.9, 1.5 Hz, 1H), 8.31-8.27 (m, 1 H), 8.29 (d, J = 9.0 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), 7.50 (ddd, J = 8.3, 4.9, 0.8 Hz, 1H), 1.66 (d, J = 14.7 Hz, 1H), 1.52 (d, J = 14.7 Hz, 1H), 1.48 (s, 3H), 1.43 (s, 3H), 0.94 (s, 9H);


^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 154.5, 150.0, 148.1, 147.9, 135.5 (d, J = 24.9 Hz), 135.1, 128.0, 124.2, 123.8, 63.8 (d, J = 4.5 Hz), 56.3 (d, J = 3.2 Hz), 31.8, 31.7, 31.44, 31.39 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = 88.1 (s);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1532, 1473, 1462, 1382, 1251, 1162, 1085, 954;

HRMS (ESI^+) calcd. for $\text{C}_{19}\text{H}_{25}\text{FN}_4\text{O}_4\text{S}_2\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 479.1193, found: 479.1195.

***N*-((4-Nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)cyclopropanesulfondiimidoyl fluoride (**4k**)**



Prepared according to **General Procedure B** using sulfinamidine **3k** (401 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 8 days for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfondiimidoyl fluoride 4k* as a colourless oil (390 mg, 0.93 mmol, 93%).

R_f 0.63 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.34 (d, *J* = 8.9 Hz, 2H), 8.14 (d, *J* = 8.9 Hz, 2H), 3.50 (tq, *J* = 8.3, 4.3 Hz, 1H), 1.55-1.47 (m, 1H), 1.51 (d, *J* = 14.7 Hz, 1H), 1.43-1.36 (m, 1H), 1.39 (d, *J* = 14.7 Hz, 1H), 1.32 (s, 3H), 1.30-1.18 (m, 2H), 1.27 (s, 3H), 0.93 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.0, 148.7, 128.1, 124.2, 62.2 (d, *J* = 4.5 Hz), 56.5 (d, *J* = 2.5 Hz), 34.9 (d, *J* = 28.5 Hz), 31.7, 31.5, 31.4 (d, *J* = 2.7 Hz), 31.2 (d, *J* = 6.9 Hz), 8.2, 7.9 (d, *J* = 2.0 Hz);

Notes:


1. For *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;
2. For 2 secondary carbons in cyclopropane ring, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.0 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1349, 1334, 1299, 1160, 1071, 735, 686, 615;

HRMS (ESI⁺) calcd. for C₁₇H₂₆FN₃O₄S₂Na⁺ [M+Na]⁺: 442.1241, found: 442.1241.

***N*-((4-Nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)ethanesulfondiimidoyl fluoride (**4l**)**



Prepared according to **General Procedure B** using sulfinamidine **3l** (389 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 12 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1) afforded *sulfondiimidoyl fluoride* **4l** as a white solid (286 mg, 0.70 mmol, 70%).

mp 80-82 °C;

R_f 0.52 (petrol/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.30 (d, *J* = 9.0 Hz, 2H), 8.08 (d, *J* = 9.0 Hz, 2H), 3.90-3.69 (m, 2H), 1.53-1.47 (m, 4H), 1.36 (d, *J* = 14.7 Hz, 1H), 1.31 (s, 3H), 1.23 (s, 3H), 0.90 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): 149.8, 148.4, 128.0, 124.1, 62.1 (d, *J* = 4.7 Hz), 56.2 (d, *J* = 2.7 Hz), 52.5 (d, *J* = 17.0 Hz), 31.7, 31.39 (d, *J* = 2.7 Hz), 31.36, 31.1 (d, *J* = 6.8 Hz), 8.7 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 77.9 (t, *J* = 3.5 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1349, 1161, 1081, 1056, 739;

HRMS (ESI⁺) calcd. for C₁₆H₂₆FN₃O₄S₂Na⁺ [*M*+Na]⁺: 430.1241, found: 430.1240.

***N*-((4-Nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)butanesulfondiimidoyl fluoride (**4m**)**



Prepared according to **General Procedure B** using sulfinamidine **3m** (626 mg, 1.50 mmol, 1.00 equiv.), THF (3.00 mL), NaH (66 mg, 60 % dispersion in mineral oil, 1.65 mmol, 1.10 equiv.) and NFSI (709 mg, 2.25 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-

fluorinated compound was left at room temperature for 6 days for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 7:1 to 5:1) afforded *sulfondiimidoyl fluoride 4m* as a colourless oil (593 mg, 1.36 mmol, 91%).

R_f 0.47 (petrol/ethyl acetate, 8:1);

¹H NMR (400 MHz, CD₃CN): δ (ppm) = 8.34 (d, J = 8.9 Hz, 2H), 8.11 (d, J = 8.9 Hz, 2H), 3.88 (dddd, J = 13.8, 9.0, 6.2, 2.5 Hz, 1H), 3.76 (dddd, J = 13.8, 9.0, 6.2, 4.0 Hz, 1H), 1.93-1.84 (m, 2H), 1.58 (d, J = 14.6 Hz, 1H), 1.53-1.42 (m, 3H), 1.36 (s, 3H), 1.30 (s, 3H), 0.97 (s, 9H), 0.94 (t, J = 7.4 Hz, 3H);


¹³C NMR (101 MHz, CD₃CN): δ (ppm) = 151.2, 149.3, 128.9, 125.4, 62.9 (d, J = 4.9 Hz), 57.7 (d, J = 14.2 Hz), 56.8 (d, J = 3.1 Hz), 32.2, 31.8 (d, J = 3.1 Hz), 31.7, 31.5 (d, J = 6.8 Hz), 26.7, 21.5, 13.6 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CD₃CN): δ (ppm) = 81.2 (t, J = 3.4 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1348, 1307, 1160, 1071, 742, 686, 614;

HRMS (ESI⁺) calcd. for C₁₈H₃₀FN₃O₄S₂Na⁺ [M+Na]⁺: 458.1554, found: 458.1552.

***N*-((4-Nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)ethenesulfondiimidoyl fluoride (4n)**



Prepared according to **General Procedure B** using sulfinamidine **3n** (418 mg, 1.08 mmol, 1.00 equiv.), THF (3.60 mL), NaH (48 mg, 60 % dispersion in mineral oil, 1.20 mmol, 1.10 equiv.) and NFSI (510 mg, 1.62 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 3:1) afforded *sulfondiimidoyl fluoride 4n* as a colourless oil (210 mg, 0.52 mmol, 48%).

R_f 0.62 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.33 (d, J = 8.8 Hz, 2H), 8.11 (d, J = 8.8 Hz, 2H), 7.04 (ddd, J = 16.0, 9.6, 2.3 Hz, 1H), 6.55 (dd, J = 16.0, 1.5 Hz, 1H), 6.25 (ddd, J = 9.6, 4.5, 1.5 Hz, 1H), 1.59 (d, J = 14.7 Hz, 1H), 1.43 (d, J = 14.7 Hz, 1H), 1.37 (s, 3H), 1.32 (s, 3H), 0.93 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.9, 148.3, 134.1 (d, J = 29.0 Hz), 130.3, 128.1, 124.2, 62.6 (d, J = 4.6 Hz), 56.2 (d, J = 3.1 Hz), 31.7, 31.6 (d, J = 2.7 Hz), 31.5 (d, J = 6.3 Hz), 31.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = 86.5 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1348, 1312, 1161, 1082, 741, 616;

HRMS (ESI⁺) calcd. for C₁₆H₂₄FN₃O₄S₂Na⁺ [M+Na]⁺: 428.1084, found: 428.1084.

3-Cyano-4-ethoxy-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4o)



Prepared according to **General Procedure B** using sulfinamidine **3o** (3.84 g, 7.58 mmol, 1.00 equiv.), THF (15.2 mL), NaH (334 mg, 60 % dispersion in mineral oil, 8.35 mmol, 1.10 equiv.) and NFSI (3.58 g, 11.37 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 20 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 2:1) afforded *sulfondiimidoyl fluoride* **4o** as a white solid (1.91 g, 3.65 mmol, 48%).

mp 120-122 °C;

R_f 0.58 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.32 (d, J = 8.9 Hz, 2H), 8.15 (dd, J = 9.1, 2.6 Hz, 1H), 8.11 (d, J = 2.6 Hz, 1H), 8.06 (d, J = 8.9 Hz, 2H), 7.09 (d, J = 9.1 Hz, 1H), 4.26 (q, J = 7.0 Hz, 2H), 1.66 (d, J = 14.7 Hz, 1H), 1.54-1.49 (m, 4H), 1.46 (s, 3H), 1.42 (s, 3H), 0.95 (s, 9H);


^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 164.4, 150.0, 148.0, 133.83, 133.81, 130.2 (d, J = 26.9 Hz), 128.1, 124.2, 114.2, 112.7, 103.4, 66.3, 63.6 (d, J = 4.3 Hz), 56.3 (d, J = 3.1 Hz), 31.8, 31.7 (d, J = 2.8 Hz), 31.43, 31.37 (d, J = 6.2 Hz), 14.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = 87.8 (s);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1527, 1473, 1383, 1251, 1151, 1072, 955, 615;

HRMS (ESI^+) calcd. for $\text{C}_{23}\text{H}_{29}\text{FN}_4\text{O}_5\text{S}_2\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 547.1456, found: 547.1456.

4-(5-(*p*-Tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (4p**)**



Prepared according to **General Procedure B** using sulfinamidine **3p** (661 mg, 1.00 mmol, 1.00 equiv.), THF (2.00 mL), NaH (44 mg, 60 % dispersion in mineral oil, 1.10 mmol, 1.10 equiv.) and NFSI (473 mg, 1.50 mmol, 1.50 equiv.). The crude mixture of *N*-fluorinated compound and *S*-fluorinated compound was left at room temperature for 24 h for the completion of isomerization. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfondiimidoyl fluoride* **4p** as a colourless oil (350 mg, 0.52 mmol, 52%).

R_f 0.64 (petrol/ethyl acetate, 3:1);

^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.30 (d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.9 Hz, 2H), 7.98 (d, J = 8.9 Hz, 2H), 7.53 (d, J = 8.9 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 6.75 (s, 1H), 2.40 (s, 3H), 1.67 (d, J = 14.7 Hz, 1H), 1.53 (d, J = 14.7 Hz, 1H), 1.48 (s, 3H), 1.43 (s, 3H), 0.96 (s, 9H);


^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 149.9, 148.1, 145.5, 144.5 (q, J = 38.8 Hz), 143.8, 140.2, 137.3 (d, J = 25.1 Hz), 130.0, 128.8, 128.6, 128.1, 125.6, 125.2, 124.2, 121.0 (q, J = 269.2 Hz), 106.9, 63.5 (d, J = 4.2 Hz), 56.3 (d, J = 2.7 Hz), 31.78 (d, J = 2.2 Hz), 31.76, 31.43, 31.35 (d, J = 5.9 Hz), 21.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = 86.7 (s), -62.5 (s);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1530, 1348, 1237, 1161, 1135, 1107, 974, 744;

HRMS (ESI^+) calcd. for $\text{C}_{31}\text{H}_{33}\text{F}_4\text{N}_5\text{O}_4\text{S}_2\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 702.1802, found: 702.1799.


2.2.4 General Procedure C for Sulfondiimidamide Synthesis



Sulfondiimidoyl fluoride (1.00 equiv.), $\text{Ca(NTf}_2)_2$ (1.10 equiv.) and amine (2.20-6.00 equiv.) were added to an oven-dried round-bottom flask and dissolved in anhydrous *t*-AmylOH (0.5 M). The reaction was stirred at 60-80 °C until completion (judged by TLC, 10-36 h). The mixture was then diluted with CH_2Cl_2 and quenched with sat. aq. NaCl solution. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 twice. The combined organic layers were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford the desired sulfondiimidamide product.

Note: an emulsion may form during extraction in a large-scale reaction. In this case, 0.5 M aq. HCl solution is suggested to be used in aqueous workup stage instead of sat. aq. NaCl solution to facilitate easier separation.

N-((4-Fluorophenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5a**)



Sulfondiimidoyl fluoride **4a** (120 mg, 0.25 mmol, 1.00 equiv.), $\text{Ca(NTf}_2)_2$ (167 mg, 0.28 mmol, 1.10 equiv.) were added to an oven-dried 10 mL round-bottom flask and dissolved in anhydrous *t*-AmylOH (0.5 mL). Then morpholine (48 mg, 0.55 mmol, 2.20 equiv.) was added and the reaction was stirred at 60 °C for 24 h until completion (judged by TLC). The mixture was then diluted with CH_2Cl_2 (80 mL) and quenched with sat. aq. NaCl solution (120 mL). The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (2×50 mL). The combined organic layers were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) to afford *sulfondiimidamide* **5a** as a white solid (126 mg, 0.23 mmol, 93%).

Gram scale: Sulfondiimidoyl fluoride **4a** (4.40 g, 9.30 mmol, 1.00 equiv.), $\text{Ca(NTf}_2)_2$ (5.86 g, 9.77 mmol, 1.05 equiv.) were added to an oven-dried 100 mL round-bottom flask and dissolved in

anhydrous *t*-AmylOH (18.6 mL). Then morpholine (1.78 g, 20.43 mmol, 2.20 equiv.) was added and the reaction was stirred at 60 °C for 24 h until completion (judged by TLC). The mixture was then diluted with CH₂Cl₂ (250 mL) and quenched with 0.5 M aq. HCl solution (250 mL). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (2 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) to afford *sulfondiimidamide* **5a** as a white solid (4.51 g, 8.35 mmol, 90%). *mp* 55-57 °C;

R_f 0.50 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.19 (d, *J* = 8.8 Hz, 2H), 7.84 (d, *J* = 8.8 Hz, 2H), 7.71-7.64 (m, 2H), 7.09-7.02 (m, 2H), 3.68 (app. t, *J* = 4.5 Hz, 4H), 3.11 (dt, *J* = 12.0, 4.5 Hz, 2H), 3.04 (dt, *J* = 12.0, 4.5 Hz, 2H), 1.71 (d, *J* = 14.5 Hz, 1H), 1.59-1.51 (m, 4H), 1.48 (s, 3H), 1.05 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.1 (d, *J* = 256.1 Hz), 149.5, 149.3, 133.5 (d, *J* = 3.1 Hz), 130.7 (d, *J* = 9.2 Hz), 127.5, 123.8, 116.1 (d, *J* = 22.7 Hz), 66.6, 60.3, 57.6, 47.0, 32.1, 31.92, 31.87, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.1 (tt, *J* = 7.9, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1529, 1350, 1298, 1154, 1088, 1050, 921;

HRMS (ESI⁺) calcd. for C₂₄H₃₃FN₄O₅S₂Na⁺ [M+Na]⁺: 563.1769, found: 563.1766.

***N*-(4-Fluoro-*N*-(2,4,4-trimethylpentan-2-yl)phenylsulfonimidoyl)-4-nitrobenzenesulfonamide (5a')**



R_f 0.60 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.28 (d, *J* = 8.8 Hz, 2H), 8.09 (d, *J* = 8.8 Hz, 2H), 7.96-7.90 (m, 2H), 7.19-7.11 (m, 2H), 6.15 (s, 1H), 1.60 (d, *J* = 14.9 Hz, 1H), 1.49 (d, *J* = 14.9 Hz, 1H), 1.32 (s, 3H), 1.16 (s, 3H), 0.95 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.6 (d, J = 257.2 Hz), 149.8, 148.9, 137.4 (d, J = 3.2 Hz), 130.6 (d, J = 9.6 Hz), 128.2, 124.0, 116.5 (d, J = 22.9 Hz), 61.9, 56.1, 31.6, 31.5, 30.1, 28.2 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -103.1 (tt, J = 8.5, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1590, 1530, 1493, 1384, 1351, 1302, 1261, 1154, 1091, 1039, 1027;

HRMS (ESI⁺) calcd. for C₂₀H₂₇FN₃O₅S₂⁺ [M+H]⁺: 472.1371, found: 472.1371.

4-Morpholino-*N*-((4-nitrophenyl)sulfonyl)-*N*-(2,4,4-trimethylpentan-2-yl)benzenesulfondiimidoyl fluoride (5a'')



R_f 0.62 (petrol/ethyl acetate, 1:1);

¹H NMR (400 MHz, CD₃CN): δ (ppm) = 8.19 (d, J = 8.8 Hz, 2H), 7.87 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 9.3 Hz, 2H), 6.80 (d, J = 9.3 Hz, 2H), 3.77-3.69 (m, 4H), 3.29-3.21 (m, 4H), 1.69 (d, J = 14.6 Hz, 1H), 1.55 (d, J = 14.6 Hz, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 0.98 (s, 9H);


¹³C NMR (101 MHz, CD₃CN): δ (ppm) = 155.7, 150.8, 149.0, 130.4, 128.9, 125.1, 124.2 (d, J = 24.3 Hz), 113.7, 66.9, 63.3 (d, J = 4.4 Hz), 57.0 (d, J = 3.2 Hz), 47.5, 32.3, 32.2 (d, J = 2.5 Hz), 31.83, 31.77 (d, J = 6.4 Hz) (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CD₃CN): δ (ppm) = 84.9 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1590, 1530, 1349, 1332, 1304, 1247, 1161, 1089, 1053, 928;

HRMS (ESI⁺) calcd. for C₂₄H₃₃FN₄O₅S₂Na⁺ [M+ Na]⁺: 563.1769, found: 563.1771.

***N*-((4-Chlorophenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5b**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4b** (88 mg, 0.18 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (119 mg, 0.20 mmol, 1.10 equiv.), morpholine (35 mg, 0.40 mmol, 2.20 equiv.) and *t*-AmylOH (0.36 mL). The reaction was stirred at 60 °C for 24 h. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:2) afforded *sulfondiimidamide* **5b** as a white solid (95 mg, 0.17 mmol, 94%).

mp 128-130 °C;

R_f 0.61 (petrol/ethyl acetate, 2:1);


¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.19 (d, J = 8.9 Hz, 2H), 7.84 (d, J = 8.9 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.8 Hz, 2H), 3.70-3.65 (m, 4H), 3.11 (dt, J = 12.0, 4.5 Hz, 2H), 3.04 (dt, J = 12.0, 4.5 Hz, 2H), 1.71 (d, J = 14.5 Hz, 1H), 1.55 (s, 3H), 1.55 (d, J = 14.5 Hz, 1H), 1.48 (s, 3H), 1.05 (s, 9H);

¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 149.4, 149.3, 139.4, 136.1, 129.4, 129.2, 127.5, 123.8, 66.6, 60.3, 57.5, 47.0, 32.1, 31.92, 31.86, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1528, 1349, 1299, 1257, 1153, 1087, 1062, 1009, 919, 746;

HRMS (ESI^+) calcd. for $\text{C}_{24}\text{H}_{33}\text{ClN}_4\text{O}_5\text{S}_2\text{Na}^+$ [$\text{M}+\text{Na}$] $^+$: 579.1473, found: 579.1475.

***N*-((3-Chlorophenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5c**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4c** (160 mg, 0.33 mmol,

1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (216 mg, 0.36 mmol, 1.10 equiv.), morpholine (63 mg, 0.72 mmol, 2.20 equiv.) and *t*-AmylOH (0.65 mL). The reaction was stirred at 60 °C for 24 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide* **5c** as a white solid (162 mg, 0.29 mmol, 89%).

mp 112-114 °C;

R_f 0.73 (petrol/ethyl acetate, 1:1);


¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.16 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.8 Hz, 2H), 7.54 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.43 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.39 (t, J = 2.0 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 3.69-3.64 (m, 4H), 3.10 (dt, J = 12.0, 4.2 Hz, 2H), 3.03 (dt, J = 12.0, 4.2 Hz, 2H), 1.75 (d, J = 14.5 Hz, 1H), 1.61 (s, 3H), 1.57 (d, J = 14.5 Hz, 1H), 1.50 (s, 3H), 1.06 (s, 9H);

¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 149.3, 149.1, 139.0, 135.0, 132.6, 130.2, 127.6, 127.4, 126.3, 123.8, 66.5, 60.5, 57.4, 46.9, 32.0, 31.9, 31.8, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1528, 1349, 1296, 1255, 1153, 1112, 1088, 1049, 917, 733, 677;

HRMS (ESI^+) calcd. for $\text{C}_{24}\text{H}_{33}\text{ClN}_4\text{O}_5\text{S}_2\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 579.1473, found: 579.1469.

***N*-((4-Cyanophenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5d**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4d** (200 mg, 0.42 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (275 mg, 0.46 mmol, 1.10 equiv.), morpholine (80 mg, 0.92 mmol, 2.20 equiv.) and *t*-AmylOH (0.83 mL). The reaction was stirred at 60 °C for 12 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide* **5d** as a white solid (213 mg, 0.39 mmol, 93%).

mp 154-156 °C;

R_f 0.54 (petrol/ethyl acetate, 1:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.21 (d, J = 8.9 Hz, 2H), 7.87 (d, J = 8.9 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 3.66 (app. t, J = 4.8 Hz, 4H), 3.09 (dt, J = 12.0, 4.6 Hz, 2H), 3.01 (dt, J = 12.0, 4.6 Hz, 2H), 1.69 (d, J = 14.5 Hz, 1H), 1.54 (d, J = 14.5 Hz, 1H), 1.52 (s, 3H), 1.46 (s, 3H), 1.02 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.4, 149.1, 142.2, 132.7, 128.5, 127.4, 123.9, 117.1, 116.2, 66.4, 60.5, 57.3, 46.9, 31.9, 31.79, 31.75, 31.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1349, 1299, 1257, 1154, 1086, 1045, 917, 733;

HRMS (ESI⁺) calcd. for C₂₅H₃₃N₅O₅S₂Na⁺ [M+Na]⁺: 570.1815, found: 570.1812.

***N*-((3-Cyanophenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5e**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4e** (285 mg, 0.59 mmol, 1.00 equiv.), Ca(NTf₂)₂ (392 mg, 0.46 mmol, 1.10 equiv.), morpholine (114 mg, 1.31 mmol, 2.20 equiv.) and *t*-AmylOH (1.19 mL). The reaction was stirred at 60 °C for 12 h. Purification by flash column chromatography (petrol/ethyl acetate, 2:1 to 1:1) afforded *sulfondiimidamide 5e* as a white solid (300 mg, 0.55 mmol, 92%).

mp 160-162 °C;

R_f 0.60 (petrol/ethyl acetate, 1:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.24 (d, J = 8.8 Hz, 2H), 7.93-7.85 (m, 2H), 7.87 (d, J = 8.8 Hz, 2H), 7.80 (dt, J = 7.8, 1.3 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 3.73-3.68 (m, 4H), 3.12 (dt, J = 12.0, 4.6 Hz, 2H), 3.04 (dt, J = 12.0, 4.6 Hz, 2H), 1.74 (d, J = 14.7 Hz, 1H), 1.59 (d, J = 14.7 Hz, 1H), 1.58 (s, 3H), 1.50 (s, 3H), 1.06 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.6, 149.1, 139.4, 135.7, 131.73, 131.65, 130.1, 127.5, 124.1, 117.1, 113.7, 66.5, 60.8, 57.5, 47.1, 32.1, 31.91, 31.90, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1529, 1385, 1350, 1298, 1257, 1154, 1088, 1064, 922;

HRMS (ESI⁺) calcd. for C₂₅H₃₃N₅O₅S₂Na⁺ [M+Na]⁺: 570.1815, found: 570.1811.

***N*-((4-Methoxyphenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5f**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4f** (110 mg, 0.23 mmol, 1.00 equiv.), Ca(NTf₂)₂ (150 mg, 0.25 mmol, 1.10 equiv.), morpholine (44 mg, 0.51 mmol, 2.20 equiv.) and *t*-AmylOH (0.45 mL). The reaction was stirred at 60 °C for 24 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide 5f* as a white solid (115 mg, 0.21 mmol, 92%).

mp 132-134 °C;

R_f 0.59 (petrol/ethyl acetate, 1:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.10 (d, *J* = 8.9 Hz, 2H), 7.77 (d, *J* = 8.9 Hz, 2H), 7.50 (d, *J* = 9.0 Hz, 2H), 6.75 (d, *J* = 9.0 Hz, 2H), 3.77 (s, 3H), 3.68-3.63 (m, 4H), 3.10 (dt, *J* = 12.0, 4.1 Hz, 2H), 3.03 (dt, *J* = 12.0, 4.1 Hz, 2H), 1.70 (d, *J* = 14.5 Hz, 1H), 1.56 (s, 3H), 1.53 (d, *J* = 14.5 Hz, 1H), 1.47 (s, 3H), 1.04 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 162.9, 149.6, 149.1, 130.0, 128.5, 127.6, 123.6, 113.9, 66.6, 59.9, 57.6, 55.7, 46.8, 32.1, 31.9, 31.8, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1530, 1383, 1348, 1296, 1254, 1151, 1087, 1063, 914, 733;

HRMS (ESI⁺) calcd. for C₂₅H₃₇N₄O₆S₂⁺ [M+H]⁺: 553.2149, found: 553.2144.

***N*-(Morpholino(*o*-tolyl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (5g)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4g** (175 mg, 0.37 mmol, 1.00 equiv.), Ca(NTf₂)₂ (244 mg, 0.41 mmol, 1.10 equiv.), morpholine (129 mg, 1.48 mmol, 4.00 equiv.) and *t*-AmylOH (0.75 mL). The reaction was stirred at 75 °C for 18 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) afforded *sulfondiimidamide* **5g** as a white solid (149 mg, 0.28 mmol, 75%).

mp 114-116 °C;

R_f 0.46 (petrol/ethyl acetate, 2:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.09 (d, *J* = 8.9 Hz, 2H), 8.08-8.05 (m, 1H), 7.71 (d, *J* = 8.9 Hz, 2H), 7.36 (td, *J* = 7.5, 1.4 Hz, 1H), 7.26-7.21 (m, 1H), 7.06 (dt, *J* = 7.5, 1.4 Hz, 1H), 3.69-3.61 (m, 4H), 3.29 (ddd, *J* = 12.3, 6.0, 4.0 Hz, 2H), 3.16 (ddd, *J* = 12.3, 6.0, 4.0 Hz, 2H), 2.30 (s, 3H), 1.72 (d, *J* = 14.5 Hz, 1H), 1.66 (d, *J* = 14.5 Hz, 1H), 1.51 (s, 3H), 1.49 (s, 3H), 1.04 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.12, 149.10, 138.0, 137.0, 133.6, 132.6, 131.8, 127.5, 126.4, 123.6, 66.4, 60.4, 57.7, 45.3, 32.1, 31.9, 31.8, 31.5, 21.2 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1349, 1296, 1257, 1151, 1061, 1034, 919, 734;

HRMS (ESI⁺) calcd. for C₂₅H₃₆N₄O₅S₂Na⁺ [M+Na]⁺: 559.2019, found: 559.2010.

***N*-((3,5-Difluorophenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5h**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4h** (310 mg, 0.63 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (417 mg, 0.70 mmol, 1.10 equiv.), morpholine (121 mg, 1.39 mmol, 2.20 equiv.) and *t*-AmylOH (1.26 mL). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) afforded *sulfondiimidamide 5h* as a white solid (328 mg, 0.59 mmol, 93%).

mp 152-154 °C;

R_f 0.37 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.23 (d, J = 8.8 Hz, 2H), 7.88 (d, J = 8.8 Hz, 2H), 7.16-7.13 (m, 2H), 6.96 (tt, J = 8.2, 2.3 Hz, 1H), 3.69 (app. t, J = 4.7 Hz, 4H), 3.11 (dt, J = 12.0, 4.6 Hz, 2H), 3.04 (dt, J = 12.0, 4.6 Hz, 2H), 1.75 (d, J = 14.5 Hz, 1H), 1.58 (d, J = 14.5 Hz, 1H), 1.58 (s, 3H), 1.49 (s, 3H), 1.06 (s, 9H);

¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 162.6 (dd, J = 254.9, 11.7 Hz), 149.5, 149.1, 141.2 (t, J = 8.2 Hz), 127.5, 124.0, 111.6-111.3 (second-order multiplet), 108.3 (t, J = 25.1 Hz), 66.5, 60.8, 57.5, 47.0, 32.0, 31.90, 31.86, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);


¹⁹F NMR (377 MHz, CDCl_3): δ (ppm) = -105.22- -105.24 (second-order multiplet);

Note: The second-order multiplet in the ¹³C and ¹⁹F NMR spectra arise due to virtual coupling;

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1601, 1529, 1350, 1293, 1257, 1157, 1090, 1066, 920;

HRMS (ESI^+) calcd. for $\text{C}_{24}\text{H}_{32}\text{F}_2\text{N}_4\text{O}_5\text{S}_2\text{Na}^+$ [$\text{M}+\text{Na}$]⁺: 581.1674, found: 581.1664.

***N*-((6-Methoxypyridin-3-yl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5i**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4i** (290 mg, 0.60 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (394 mg, 0.66 mmol, 1.10 equiv.), morpholine (115 mg, 1.32 mmol, 2.20 equiv.) and *t*-AmylOH (1.20 mL). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide* **5i** as a white solid (307 mg, 0.56 mmol, 93%).

mp 140-142 °C;

R_f 0.44 (petrol/ethyl acetate, 2:1);


¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.29 (d, J = 2.6 Hz, 1H), 8.14 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.77 (dd, J = 8.9, 2.6 Hz, 1H), 6.65 (d, J = 8.9 Hz, 1H), 3.88 (s, 3H), 3.66 (app. t, J = 4.7 Hz, 4H), 3.12 (dt, J = 12.0, 4.5 Hz, 2H), 3.04 (dt, J = 12.0, 4.5 Hz, 2H), 1.69 (d, J = 14.5 Hz, 1H), 1.54 (s, 3H), 1.52 (d, J = 14.5 Hz, 1H), 1.45 (s, 3H), 1.02 (s, 9H);

¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 166.2, 149.4, 149.3, 148.0, 138.4, 127.5, 126.6, 123.8, 111.0, 66.5, 60.2, 57.5, 54.4, 46.8, 32.1, 31.84, 31.80, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1586, 1528, 1479, 1349, 1298, 1256, 1154, 1089, 1050, 1012, 919, 736;

HRMS (ESI^+) calcd. for $\text{C}_{24}\text{H}_{35}\text{N}_5\text{O}_6\text{S}_2\text{Na}^+$ [$\text{M}+\text{Na}$] $^+$: 576.1921, found: 576.1915.

***N*-(Morpholino(pyridin-3-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5j**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4j** (230 mg, 0.50 mmol,

1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (330 mg, 0.55 mmol, 1.10 equiv.), morpholine (96 mg, 1.10 mmol, 2.20 equiv.) and *t*-AmylOH (1.00 mL). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 2:1 to 1:2) afforded *sulfondiimidamide* **5j** as a white solid (240 mg, 0.46 mmol, 92%).

mp 126-128 °C;

R_f 0.33 (petrol/ethyl acetate, 1:2);


¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.74 (dd, J = 2.5, 0.8 Hz, 1H), 8.65 (dd, J = 4.8, 1.5 Hz, 1H), 8.14 (d, J = 8.9 Hz, 2H), 7.95 (ddd, J = 8.2, 2.5, 1.5 Hz, 1H), 7.78 (d, J = 8.9 Hz, 2H), 7.32 (ddd, J = 8.2, 4.8, 0.8 Hz, 1H), 3.67-3.61 (m, 4H), 3.11 (dt, J = 12.5, 4.7 Hz, 2H), 3.02 (dt, J = 12.5, 4.7 Hz, 2H), 1.70 (d, J = 14.5 Hz, 1H), 1.54 (s, 3H), 1.53 (d, J = 14.5 Hz, 1H), 1.46 (s, 3H), 1.01 (s, 9H);

¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 152.8, 149.3, 149.0, 148.5, 135.8, 134.3, 127.3, 123.9, 123.4, 66.4, 60.4, 57.3, 46.8, 32.0, 31.8, 31.7, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1528, 1350, 1297, 1257, 1154, 1110, 1089, 1062, 1011, 921, 742;

HRMS (ESI^+) calcd. for $\text{C}_{23}\text{H}_{33}\text{N}_5\text{O}_5\text{S}_2\text{Na}^+$ [$\text{M}+\text{Na}$] $^+$: 546.1815, found: 546.1808.

***N*-(Cyclopropyl(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5k**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4k** (390 mg, 0.93 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (614 mg, 1.02 mmol, 1.10 equiv.), morpholine (178 mg, 2.04 mmol, 2.20 equiv.) and *t*-AmylOH (1.86 mL). The reaction was stirred at 60 °C for 24 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide* **5k** as a white solid (413 mg, 0.85 mmol, 91%).

mp 125-127 °C;

R_f 0.23 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.25 (d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.9 Hz, 2H), 3.71-3.62 (m, 4H), 3.28 (ddd, J = 12.0, 6.0, 3.2 Hz, 2H), 3.19 (ddd, J = 12.0, 6.0, 3.2 Hz, 2H), 2.26 (tt, J = 7.6, 4.5 Hz, 1H), 1.44 (d, J = 14.5 Hz, 1H), 1.36 (s, 3H), 1.36 (d, J = 14.5 Hz, 1H), 1.29 (s, 3H), 1.26 (dt, J = 5.3, 2.7 Hz, 2H), 1.01-0.95 (m, 1H), 0.93-0.83 (m, 10H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.5, 149.2, 127.4, 123.9, 66.6, 59.5, 57.8, 47.2, 32.0, 31.7, 31.6, 31.3, 29.2, 7.6, 5.6;


Notes:

1. For *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;
2. For 2 secondary carbons in cyclopropane ring, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1349, 1293, 1256, 1149, 1091, 1057, 918, 733;

HRMS (ESI⁺) calcd. for C₂₁H₃₅N₄O₅S₂⁺ [M+H]⁺: 487.2043, found: 487.2045.

***N*-(Ethyl(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (5I)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4I** (160 mg, 0.39 mmol, 1.00 equiv.), Ca(NTf₂)₂ (259 mg, 0.43 mmol, 1.10 equiv.), *t*-AmylOH (0.79 mL) and morpholine (75 mg, 0.86 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 10 h. Ethyl acetate was used for extraction instead of CH₂Cl₂ because of the better aqueous solubility of this substrate. Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 20:1) afforded *sulfondiimidamide* **5I** as a colourless oil (96 mg, 0.20 mmol, 52%).

R_f 0.38 (petrol/ethyl acetate, 1:1);


¹H NMR (400 MHz, CD₃CN): δ (ppm) = 8.30 (d, J = 9.0 Hz, 2H), 8.07 (d, J = 9.0 Hz, 2H), 3.69-3.60 (m, 4H), 3.60-3.47 (m, 2H), 3.27 (t, J = 4.6 Hz, 4H), 1.56 (d, J = 14.4 Hz, 1H), 1.45 (d, J = 14.4 Hz, 1H), 1.41 (s, 3H), 1.36 (s, 3H), 1.20 (t, J = 7.4 Hz, 3H), 1.01 (s, 9H);

¹³C NMR (101 MHz, CD₃CN): δ (ppm) = 151.3, 150.5, 128.1, 125.2, 67.5, 59.8, 58.0, 50.7, 47.8, 32.5, 32.3, 32.1, 31.8, 9.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 1528, 1350, 1256, 1148, 1091, 1066, 924, 739;

HRMS (ESI⁺) calcd. for C₂₀H₃₄N₄O₅S₂Na⁺ [M+Na]⁺: 497.1863, found: 497.1856.

***N*-(Butyl(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5m**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4m** (216 mg, 0.50 mmol, 1.00 equiv.), Ca(NTf₂)₂ (328 mg, 0.55 mmol, 1.10 equiv.), *t*-AmylOH (1.0 mL) and morpholine (96 mg, 1.10 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 22 h. Ethyl acetate was used for extraction instead of CH₂Cl₂ because of the better aqueous solubility of this substrate. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) afforded *sulfondiimidamide* **5m** as a pale-yellow oil (110 mg, 0.22 mmol, 44%).

R_f 0.23 (CH₂Cl₂);


¹H NMR (400 MHz, CD₃CN): δ (ppm) = 8.30 (d, J = 8.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H), 3.69-3.59 (m, 4H), 3.57-3.38 (m, 2H), 3.29-3.23 (m, 4H), 1.72-1.60 (m, 1H), 1.59-1.50 (m, 2H), 1.45 (d, J = 14.4 Hz, 1H), 1.42 (s, 3H), 1.36 (s, 3H), 1.34-1.25 (m, 2H), 1.01 (s, 9H), 0.83 (t, J = 7.4 Hz, 3H);

¹³C NMR (101 MHz, CD₃CN): δ (ppm) = 151.4, 150.5, 128.1, 125.2, 67.5, 59.9, 58.0, 55.5, 47.8, 32.5, 32.3, 32.1, 31.9, 26.5, 22.0, 13.9 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1349, 1292, 1256, 1148, 1089, 1061, 923, 743, 633;

HRMS (ESI⁺) calcd. for C₂₂H₃₈N₄O₅S₂Na⁺ [M+Na]⁺: 525.2176, found: 525.2175.

***N*-((3-Cyano-4-ethoxyphenyl)(morpholino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5o**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4o** (510 mg, 0.97 mmol, 1.00 equiv.), Ca(NTf₂)₂ (642 mg, 1.07 mmol, 1.10 equiv.), morpholine (186 mg, 2.13 mmol, 2.20 equiv.) and *t*-AmylOH (1.94 mL). The reaction was stirred at 60 °C for 24 h. 0.5 M aq. HCl solution was used to quench the reaction (instead of sat. aq. NaCl solution) and the aqueous layers was extracted with ethyl acetate (instead of CH₂Cl₂). Purification by flash column chromatography (petrol/ethyl acetate, 1:1 to 1:2) afforded *sulfondiimidamide* **5o** as a white solid (546 mg, 0.92 mmol, 95%).

mp 183-185 °C;

R_f 0.58 (petrol/ethyl acetate, 2:3);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.23 (d, *J* = 8.8 Hz, 2H), 7.88 (d, *J* = 8.8 Hz, 2H), 7.84-7.78 (m, 2H), 6.92 (d, *J* = 8.9 Hz, 1H), 4.19 (q, *J* = 7.0 Hz, 2H), 3.72-3.67 (m, 4H), 3.10 (dt, *J* = 12.0, 4.6 Hz, 2H), 3.03 (dt, *J* = 12.0, 4.6 Hz, 2H), 1.71 (d, *J* = 14.5 Hz, 1H), 1.56 (d, *J* = 14.5 Hz, 1H), 1.55 (s, 3H), 1.51 (t, *J* = 7.0 Hz, 3H), 1.48 (s, 3H), 1.05 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 163.3, 149.5, 149.3, 134.2, 134.1, 129.6, 127.5, 124.0, 114.7, 112.1, 102.8, 66.6, 66.0, 60.6, 57.6, 47.0, 32.1, 31.92, 31.89, 31.5, 14.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 1529, 1349, 1294, 1256, 1152, 1063, 920, 735;

HRMS (ESI⁺) calcd. for C₂₇H₃₈N₅O₆S₂⁺ [M+H]⁺: 592.2258, found: 592.2261.

***N*-(Morpholino(4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5p**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4p** (401 mg, 0.59 mmol, 1.00 equiv.), Ca(NTf₂)₂ (390 mg, 0.65 mmol, 1.10 equiv.), morpholine (112 mg, 1.29 mmol, 2.20 equiv.) and *t*-AmylOH (1.18 mL). The reaction was stirred at 60 °C for 24 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide 5p* as a white solid (386 mg, 0.52 mmol, 88%).

mp 165-167 °C;

R_f 0.48 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.11 (d, *J* = 8.9 Hz, 2H), 7.82 (d, *J* = 8.9 Hz, 2H), 7.63 (d, *J* = 8.8 Hz, 2H), 7.37 (d, *J* = 8.8 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 6.72 (s, 1H), 3.65 (app. t, *J* = 4.5 Hz, 4H), 3.06 (dt, *J* = 11.8, 4.5 Hz, 2H), 2.99 (dt, *J* = 11.8, 4.5 Hz, 2H), 2.38 (s, 3H), 1.72 (d, *J* = 14.5 Hz, 1H), 1.58 (d, *J* = 14.5 Hz, 1H), 1.57 (s, 3H), 1.49 (s, 3H), 1.04 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.4, 149.3, 145.2, 144.1 (q, *J* = 38.5 Hz), 142.5, 139.9, 137.2, 129.8, 128.8, 128.7, 127.4, 125.8, 125.2, 123.8, 121.1 (q, *J* = 269.3 Hz), 106.5, 66.4, 60.4, 57.5, 46.9, 32.0, 31.81, 31.78, 31.5, 21.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -62.4 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1529, 1349, 1299, 1236, 1156, 1089, 1062, 918, 733;

HRMS (ESI⁺) calcd. for C₃₅H₄₂F₃N₆O₅S₂⁺ [M+H]⁺: 747.2605, found: 747.2604.

***N*-((4-Fluorophenyl)(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5q**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (220 mg, 0.47 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (307 mg, 0.51 mmol, 1.10 equiv.), *t*-AmylOH (0.94 mL) and 1,4-dioxa-8-azaspiro[4.5]decane (148 mg, 1.03 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide* **5q** as a white solid (254 mg, 0.43 mmol, 92%).

mp 86-88 °C;

R_f 0.45 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.15 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 7.65-7.60 (m, 2H), 7.03-6.97 (m, 2H), 3.89 (s, 4H), 3.26 (ddd, J = 11.9, 6.5, 4.5 Hz, 2H), 3.19 (ddd, J = 11.9, 6.5, 4.5 Hz, 2H), 1.76-1.66 (m, 5H), 1.58-1.52 (m, 4H), 1.48 (s, 3H), 1.04 (s, 9H);


¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 164.9 (d, J = 255.6 Hz), 149.6, 149.2, 134.3 (d, J = 3.1 Hz), 130.4 (d, J = 9.2 Hz), 127.5, 123.7, 116.0 (d, J = 22.6 Hz), 106.1, 64.6, 60.1, 57.6, 44.9, 34.9, 31.93, 31.85, 31.8, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl_3): δ (ppm) = -105.6 (tt, J = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1529, 1349, 1300, 1226, 1153, 1088, 1040;

HRMS (ESI^+) calcd. for $\text{C}_{27}\text{H}_{37}\text{FN}_4\text{O}_6\text{S}_2\text{Na}^+$ [$\text{M}+\text{Na}$] $^+$: 619.2031, found: 619.2027.

***N*-((6,7-Dihydrothieno[3,2-*c*]pyridin-5(4*H*)-yl)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5r**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (115 mg, 0.24 mmol, 1.00 equiv.), Ca(NTf₂)₂ (160 mg, 0.27 mmol, 1.10 equiv.), *t*-AmylOH (0.48 mL) and 4,5,6,7-tetrahydrothieno[3,2-*c*]pyridine (74 mg, 0.53 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 3:1) afforded *sulfondiimidamide 5r* as a pale-yellow oil (117 mg, 0.20 mmol, 81%).

R_f 0.45 (petrol/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.13 (d, *J* = 8.8 Hz, 2H), 7.78 (d, *J* = 8.8 Hz, 2H), 7.74-7.68 (m, 2H), 7.12 (d, *J* = 5.2 Hz, 1H), 7.04-6.97 (m, 2H), 6.68 (d, *J* = 5.2 Hz, 1H), 4.35 (d, *J* = 15.1 Hz, 1H), 4.20 (d, *J* = 15.1 Hz, 1H), 3.59 (ddd, *J* = 12.0, 6.8, 4.9 Hz, 1H), 3.50 (dt, *J* = 12.0, 5.5 Hz, 1H), 2.94-2.73 (m, 2H), 1.68 (d, *J* = 14.5 Hz, 1H), 1.57 (d, *J* = 14.5 Hz, 1H), 1.54 (s, 3H), 1.46 (s, 3H), 1.06 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.0 (d, *J* = 256.2 Hz), 149.5, 149.2, 135.0 (d, *J* = 3.1 Hz), 132.8, 131.1, 130.7 (d, *J* = 9.2 Hz), 127.5, 124.8, 124.2, 123.7, 116.0 (d, *J* = 22.6 Hz), 60.2, 57.6, 46.5, 44.1, 31.94, 31.90, 31.8, 31.6, 25.6 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.2 (tt, *J* = 8.0, 5.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 2889, 1383, 1252, 1153, 1088, 955;

HRMS (ESI⁺) calcd. for C₂₇H₃₃FN₄O₄S₃Na⁺ [**M**+Na]⁺: 615.1540, found: 615.1536.

***N*-((4-(6-Fluorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (5s)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (180 mg, 0.38 mmol, 1.00 equiv.), Ca(NTf₂)₂ (251 mg, 0.42 mmol, 1.10 equiv.), *t*-AmylOH (0.76 mL) and 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole (184 mg, 0.84 mmol, 2.20 equiv.). The reaction was stirred at 60 °C

for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 2:1) afforded *sulfondiimidamide* **5s** as a white solid (220 mg, 0.33 mmol, 86%).

mp 78-80 °C;

R_f 0.77 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.16 (d, *J* = 8.8 Hz, 2H), 7.82 (d, *J* = 8.8 Hz, 2H), 7.73-7.68 (m, 2H), 7.54 (dd, *J* = 8.7, 5.0 Hz, 1H), 7.21 (dd, *J* = 8.4, 2.1 Hz, 1H), 7.07-7.01 (m, 3H), 4.09-4.02 (m, 1H), 3.89-3.83 (m, 1H), 3.10 (tt, *J* = 11.0, 3.9 Hz, 1H), 2.83 (td, *J* = 11.5, 2.5 Hz, 1H), 2.53 (td, *J* = 11.5, 2.5 Hz, 1H), 2.21-2.11 (m, 2H), 2.09-1.92 (m, 2H), 1.70 (d, *J* = 14.5 Hz, 1H), 1.56 (d, *J* = 14.5 Hz, 1H), 1.56 (s, 3H), 1.50 (s, 3H), 1.05 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.9 (d, *J* = 255.9 Hz), 164.3 (d, *J* = 251.5 Hz), 163.9 (d, *J* = 13.5 Hz), 159.9, 149.6, 149.2, 134.2 (d, *J* = 2.3 Hz), 130.5 (d, *J* = 9.1 Hz), 127.5, 123.8, 122.0 (d, *J* = 11.2 Hz), 117.1, 116.1 (d, *J* = 22.5 Hz), 112.8 (d, *J* = 25.5 Hz), 97.6 (d, *J* = 26.9 Hz), 60.1, 57.6, 47.8, 44.9, 33.5, 31.90, 31.86, 31.8, 31.5, 30.5, 29.8;

Notes:


1. For *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom;
2. For 4 secondary carbons in piperidine ring, 4 peaks were found instead of 2 due to the loss of symmetry caused by chiral sulfur atom;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.3 (tt, *J* = 8.0, 4.9 Hz), -108.8 (td, *J* = 8.6, 5.1 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1349, 1298, 1269, 1229, 1153, 1087, 1050, 913, 839, 736;

HRMS (ESI⁺) calcd. for C₃₂H₃₈F₂N₅O₅S₂⁺ [M+H]⁺: 674.2277, found: 674.2272.

N-((4-(Benzo[*d*]isothiazol-3-yl)piperazin-1-yl)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5t**)



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (180 mg, 0.38 mmol, 1.00 equiv.), Ca(NTf₂)₂ (251 mg, 0.42 mmol, 1.10 equiv.), *t*-AmylOH (0.76 mL) and 3-(piperazin-1-yl)benzo[*d*]isothiazole (184 mg, 0.84 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 4:1 to 2:1) afforded *sulfondiimidamide 5t* as a pale-yellow solid (238 mg, 0.35 mmol, 93%).

mp 66-68 °C;

R_f 0.54 (petrol/ethyl acetate, 2:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.20 (d, *J* = 8.8 Hz, 2H), 7.86 (d, *J* = 8.8 Hz, 2H), 7.81 (dt, *J* = 8.1, 1.0 Hz, 1H), 7.79 (dt, *J* = 8.1, 1.0 Hz, 1H), 7.75-7.70 (m, 2H), 7.47 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 1H), 7.34 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 1H), 7.10-7.05 (m, 2H), 3.60 (ddd, *J* = 12.7, 6.5, 3.3 Hz, 2H), 3.54 (ddd, *J* = 12.7, 6.5, 3.3 Hz, 2H), 3.39 (ddd, *J* = 10.0, 6.4, 3.3 Hz, 2H), 3.33 (ddd, *J* = 10.0, 6.4, 3.3 Hz, 2H), 1.75 (d, *J* = 14.5 Hz, 1H), 1.60 (s, 3H), 1.60 (d, *J* = 14.5 Hz, 1H), 1.54 (s, 3H), 1.08 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.0 (d, *J* = 256.0 Hz), 163.0, 152.9, 149.5, 149.3, 133.8 (d, *J* = 3.1 Hz), 130.6 (d, *J* = 9.2 Hz), 127.9, 127.6, 127.5, 124.3, 123.8, 123.5, 120.8, 116.1 (d, *J* = 22.6 Hz), 60.3, 57.6, 49.9, 46.5, 32.0, 31.94, 31.87, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.1 (tt, *J* = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1489, 1383, 1349, 1302, 1261, 1230, 1153, 1087, 1052, 925, 737; **HRMS** (ESI⁺) calcd. for C₃₁H₃₈FN₆O₄S₃⁺ [M+H]⁺: 673.2095, found: 673.2093.

***N*-((4-Fluorophenyl)(4-(pyrimidin-2-yl)piperazin-1-yl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (5u)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (86 mg, 0.18 mmol,

1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (120 mg, 0.20 mmol, 1.10 equiv.), *t*-AmylOH (0.36 mL) and 2-(piperazin-1-yl)pyrimidine (66 mg, 0.40 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 2:1 to 1:1) afforded *sulfondiimidamide 5u* as a white solid (99 mg, 0.16 mmol, 88%).

mp 176-178 °C;

R_f 0.31 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.25 (d, J = 4.8 Hz, 2H), 8.17 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 7.69-7.63 (m, 2H), 7.05-6.98 (m, 2H), 6.50 (t, J = 4.8 Hz, 1H), 3.90-3.82 (m, 4H), 3.22-3.08 (m, 4H), 1.72 (d, J = 14.5 Hz, 1H), 1.58 (s, 3H), 1.57 (d, J = 14.5 Hz, 1H), 1.51 (s, 3H), 1.06 (s, 9H);


¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 165.0 (d, J = 256.1 Hz), 161.3, 157.8, 149.5, 149.3, 133.7 (d, J = 3.1 Hz), 130.6 (d, J = 9.2 Hz), 127.5, 123.8, 116.1 (d, J = 22.7 Hz), 110.9, 60.3, 57.6, 46.7, 43.6, 32.0, 31.93, 31.87, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl_3): δ (ppm) = -105.2 (tt, J = 8.0, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1585, 1528, 1486, 1349, 1300, 1260, 1227, 1153, 1086, 1053, 950, 901, 732;

HRMS (ESI^+) calcd. for $\text{C}_{28}\text{H}_{37}\text{FN}_7\text{O}_4\text{S}_2^+$ $[\text{M}+\text{H}]^+$: 618.2327, found: 618.2319.

***N*-((4-(2-Chlorodibenzo[*b,f*][1,4]oxazepin-11-yl)piperazin-1-yl)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (5v)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (238 mg, 0.50 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (332 mg, 0.55 mmol, 1.10 equiv.), *t*-AmylOH (1.0 mL) and Amoxapine (345 mg, 1.10 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 24 h. Purification by flash

column chromatography (petrol/ethyl acetate, 5:1 to 4:1) afforded *sulfondiimidamide* **5v** as a pale-yellow solid (350 mg, 0.46 mmol, 91%).

mp 68-70 °C;

R_f 0.50 (petrol/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.19 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 8.8 Hz, 2H), 7.72 -7.66 (m, 2H), 7.39 (dd, J = 8.6, 2.6 Hz, 1H), 7.23-7.01 (m, 8H), 3.59 (app. br. s, 4H), 3.25 (app. br. s, 4H), 1.74 (d, J = 14.5 Hz, 1H), 1.59 (s, 3H), 1.59 (d, J = 14.5 Hz, 1H), 1.53 (s, 3H), 1.08 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.1 (d, J = 256.3 Hz), 159.5, 158.6, 151.9, 149.5, 149.3, 139.1, 133.9 (d, J = 2.3 Hz), 133.3, 130.6, 130.5 (d, J = 9.5 Hz), 128.9, 127.5, 127.1, 126.0, 125.6, 124.3, 123.9, 123.1, 120.3, 116.3 (d, J = 22.6 Hz), 60.4, 57.6, 47.6, 46.5, 32.02, 31.96, 31.9, 31.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -104.9 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 2888, 1383, 1251, 1153, 1086, 954;

HRMS (ESI⁺) calcd. for C₃₇H₄₁ClFN₆O₅S₂⁺ [M+H]⁺: 767.2247, found: 767.2237.

***N*-(((Cyclohexylmethyl)(methyl)amino)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5w**)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (153 mg, 0.32 mmol, 1.00 equiv.), Ca(NTf₂)₂ (213 mg, 0.36 mmol, 1.10 equiv.), *t*-AmylOH (0.65 mL) and 1-cyclohexyl-*N*-methylethanamine (90 mg, 0.71 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 36 h. Purification by flash column chromatography (petrol/ethyl acetate, 5:1 to 4:1) afforded *sulfondiimidamide* **5w** as a pale-yellow solid (180 mg, 0.31 mmol, 96%).

mp 87-89 °C;

R_f 0.67 (petrol/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.17 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H), 7.70-7.64 (m, 2H), 7.06-6.98 (m, 2H), 3.32 (dd, J = 13.0, 8.0 Hz, 1H), 2.87 (dd, J = 13.0, 6.4 Hz, 1H), 2.56 (s, 3H), 1.77-1.61 (m, 6H), 1.59-1.51 (m, 1H), 1.57 (d, J = 14.5 Hz, 1H), 1.54 (s, 3H), 1.46 (s, 3H), 1.26-1.12 (m, 3H), 1.05 (s, 9H), 0.95-0.83 (m, 2H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.8 (d, J = 255.4 Hz), 149.9, 149.2, 135.4 (d, J = 3.2 Hz), 130.7 (d, J = 9.2 Hz), 127.3, 123.7, 115.9 (d, J = 22.6 Hz), 59.9, 58.9, 57.6, 37.0, 34.7, 31.93, 31.90, 31.88, 31.7, 31.3, 31.0, 26.4, 25.9, 25.8;

Notes:


1. For *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);
2. For 5 secondary carbons in cyclohexane ring, 5 peaks were found instead of 3 due to the loss of symmetry caused by chiral sulfur atom;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -106.0 (tt, J = 8.1, 5.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 1528, 1349, 1230, 1152, 1088, 1051;

HRMS (ESI⁺) calcd. for C₂₈H₄₁FN₄O₄S₂Na⁺ [M+Na]⁺: 603.2445, found: 603.2435.

***N*-((4-Fluorophenyl)(pyridin-3-ylamino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (5x)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (146 mg, 0.31 mmol, 1.00 equiv.), Ca(NTf₂)₂ (205 mg, 0.34 mmol, 1.10 equiv.), *t*-AmylOH (0.62 mL) and 3-aminopyridine (64 mg, 0.68 mmol, 2.20 equiv.). The reaction was stirred at 60 °C for 30 h. Purification by flash column chromatography (petrol/ethyl acetate, 1:1) afforded *sulfondiimidamide* **5x** as a pale-yellow oil (136 mg, 0.25 mmol, 81%).

R_f 0.25 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.47 (dd, J = 2.7, 0.7 Hz, 1H), 8.23-8.18 (m, 2H), 8.15 (dd, J = 4.8, 1.4 Hz, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.82 (d, J = 8.9 Hz, 2H), 7.44 (ddd, J = 8.2, 2.7, 1.4 Hz, 1H), 7.23-7.16 (m, 2H), 7.09 (ddd, J = 8.2, 4.8, 0.7 Hz, 1H), 6.11 (br. s, 1H), 1.41 (d, J = 15.0 Hz, 1H), 1.37 (d, J = 15.0 Hz, 1H), 1.16 (s, 3H), 1.10 (s, 3H), 0.85 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.7 (d, J = 258.0 Hz), 149.5, 148.0, 143.5, 142.0, 140.2, 136.2 (d, J = 3.3 Hz), 131.6 (d, J = 9.5 Hz), 130.9, 128.2, 123.9, 123.6, 116.7 (d, J = 22.8 Hz), 61.6, 56.5, 31.6, 31.5, 29.3, 28.7 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -103.1 (tt, J = 8.0, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1349, 1305, 1235, 1156, 1087, 733;

HRMS (ESI⁺) calcd. for C₂₅H₃₁FN₅O₄S₂⁺ [M+H]⁺: 548.1796, found: 548.1792.

***N*-(((Bis(dimethylamino)methylene)amino)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (5y)**



Prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (132 mg, 0.28 mmol, 1.00 equiv.), Ca(NTf₂)₂ (184 mg, 0.31 mmol, 1.10 equiv.), *t*-AmylOH (0.70 mL) and 1,1,3,3-tetramethylguanidine (97 mg, 0.84 mmol, 3.00 equiv.). The reaction was stirred at 80 °C for 24 h. Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1 to 1:3) afforded *sulfondiimidamide* **5y** as a colourless oil (135 mg, 0.24 mmol, 85%).

R_f 0.50 (petrol/ethyl acetate, 1:2);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.12 (d, J = 8.9 Hz, 2H), 7.91-7.84 (m, 4H), 6.94-6.87 (m, 2H), 2.91 (s, 12H), 1.43 (d, J = 14.4 Hz, 1H), 1.34 (d, J = 14.4 Hz, 1H), 1.27 (s, 3H), 1.20 (s, 3H), 0.83 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 163.8 (d, J = 252.6 Hz), 161.5, 151.4, 148.7, 143.8 (d, J = 2.5 Hz), 129.0 (d, J = 8.8 Hz), 127.6, 123.3, 114.9 (d, J = 22.3 Hz), 59.3, 57.8, 41.1, 31.8, 31.7, 31.6, 31.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -108.6 (tt, J = 8.6, 5.2 Hz);


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1521, 1396, 1348, 1218, 1143, 1088, 1039, 729;

HRMS (ESI⁺) calcd. for C₂₅H₃₈FN₆O₄S₂⁺ [M+H]⁺: 569.2374, found: 569.2370.




Sulfondiimidamides **5z** and **5z'** were prepared according to **General Procedure C** using sulfondiimidoyl fluoride **4a** (380 mg, 0.80 mmol, 1.00 equiv.), Ca(NTf₂)₂ (530 mg, 0.88 mmol, 1.10 equiv.), *t*-AmylOH (1.60 mL) and (*S*)-(+)-2-(methoxymethyl)pyrrolidine (203 mg, 1.76 mmol, 2.20 equiv.). The reaction was stirred at 70 °C for 36 h. Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 20:1 to 15:1) afforded *diastereoisomer 5z* as a white solid (204 mg, 0.36 mmol, 45%) and *diastereoisomer 5z'* as a colourless oil (206 mg, 0.36 mmol, 45%). (Sulfur stereochemistry of these two compounds remains unknown)

***N*-((*R*)-(4-Fluorophenyl)((*S*)-2-(methoxymethyl)pyrrolidin-1-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide**



***N*-((*S*)-(4-Fluorophenyl)((*S*)-2-(methoxymethyl)pyrrolidin-1-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide**



Diastereoisomer 1 (Sulfur stereochemistry is unknown)

mp 108-110 °C;

R_f 0.60 (CH₂Cl₂/ethyl acetate, 15:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.08 (d, *J* = 8.8 Hz, 2H), 7.82-7.75 (m, 2H), 7.54 (d, *J* = 8.8 Hz, 2H), 7.03-6.96 (m, 2H), 4.32 (ddt, *J* = 8.0, 5.5, 2.8 Hz, 1H), 3.47 (dd, *J* = 9.3, 5.4 Hz, 1H), 3.34 (dd, *J* = 9.3, 2.6 Hz, 1H), 3.23-3.15 (m, 1H), 3.20 (s, 3H), 2.73-2.67 (m, 1H), 2.03-1.82 (m, 4H), 1.68 (d, *J* = 14.5 Hz, 1H), 1.62 (s, 3H), 1.58 (d, *J* = 14.5 Hz, 1H), 1.49 (s, 3H), 1.04 (s, 9H);

¹³C NMR (101 MHz, (CD₃)₂CO): δ (ppm) = 165.7 (d, *J* = 252.7 Hz), 150.8, 150.0, 137.0 (d, *J* = 2.9 Hz), 132.5 (d, *J* = 9.5 Hz), 128.0, 124.5, 116.5 (d, *J* = 23.0 Hz), 75.3, 61.0, 59.9, 59.0, 58.1, 46.9, 32.6, 32.4, 32.3, 32.2, 29.7, 24.7 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -106.1 (tt, *J* = 8.0, 5.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1718, 1529, 1489, 1349, 1300, 1228, 1155, 1088, 1052, 1030, 997;

HRMS (ESI⁺) calcd. for C₂₆H₃₈FN₄O₅S₂⁺ [M+H]⁺: 569.2262, found: 569.2264;

[α]_D²⁵: -126.4° (c = 1.0, CHCl₃).

Diastereoisomer 2 (Sulfur stereochemistry is unknown)

R_f 0.46 (CH₂Cl₂/ethyl acetate, 15:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.14 (d, *J* = 8.8 Hz, 2H), 7.77 (d, *J* = 8.8 Hz, 2H), 7.69-7.63 (m, 2H), 7.00-6.94 (m, 2H), 4.14 (tt, *J* = 7.2, 3.6 Hz, 1H), 3.57 (dd, *J* = 9.2, 3.3 Hz, 1H), 3.38 (dd, *J* = 9.2, 6.8 Hz, 1H), 3.28 (s, 3H), 3.17-3.10 (m, 1H), 3.00-2.93 (m, 1H), 1.93-1.78 (m, 3H), 1.67 (d, *J* = 14.5 Hz, 1H), 1.56 (s, 3H), 1.55 (d, *J* = 14.5 Hz, 1H), 1.47 (s, 3H), 1.46-1.39 (m, 1H), 1.03 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.7 (d, J = 255.4 Hz), 149.9, 149.1, 136.3 (d, J = 3.1 Hz), 130.4 (d, J = 9.2 Hz), 127.3, 123.7, 115.8 (d, J = 22.6 Hz), 75.4, 62.9, 60.1, 59.0, 57.5, 47.7, 31.9, 31.8, 31.4, 31.3, 28.8, 24.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);


¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.9 (tt, J = 8.0, 5.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1589, 1529, 1489, 1350, 1300, 1229, 1154, 1089, 1056, 1030;

HRMS (ESI⁺) calcd. for C₂₆H₃₈FN₄O₅S₂⁺ [M+H]⁺: 569.2262, found: 569.2256;

[α]_D²⁵: +17.0° (c = 1.0, CHCl₃).

***N*-((4-Fluorophenyl)(1*H*-imidazol-1-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5aa**)**



Sulfondiimidoyl fluoride **4a** (735 mg, 1.55 mmol, 1.00 equiv.), Ca(NTf₂)₂ (1.02 g, 1.71 mmol, 1.10 equiv.) and imidazole (633 mg, 9.30 mmol, 6.0 equiv.) were added in an oven-dried 25 mL round-bottom flask and dissolved in anhydrous *t*-AmylOH (3.10 mL). The reaction was sealed and stirred at 65 °C for 12 h. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 4:1 to 2:1 to 1:2) without an aqueous workup to afford *sulfondiimidamide* **5aa** as a white solid (710 mg, 1.36 mmol, 88%).

Note:

Continuous monitoring of this reaction is important as the desired product tends to hydrolyse under this reaction conditions. 12 h seems to maximise the yield with only around 5% of hydrolysed product (shown in ¹⁹F NMR). Extended reaction times led to larger amounts of hydrolysed product.

mp 160-162 °C;

R_f 0.62 (petrol/ethyl acetate, 1:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.20 (d, J = 9.0 Hz, 2H), 8.04 (t, J = 1.1 Hz, 1H), 7.77 (d, J = 9.0 Hz, 2H), 7.61-7.57 (m, 2H), 7.13 (t, J = 1.5 Hz, 1H), 7.09-7.03 (m, 3H), 1.76 (d, J = 14.8 Hz, 1H), 1.62 (s, 3H), 1.59 (d, J = 14.8 Hz, 1H), 1.33 (s, 3H), 1.08 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.7 (d, J = 259.3 Hz), 149.8, 148.3, 137.9, 135.1 (d, J = 3.2 Hz), 131.6, 130.3 (d, J = 9.8 Hz), 127.5, 124.1, 117.6, 116.8 (d, J = 23.1 Hz), 63.1, 57.2, 31.9, 31.8, 31.3, 30.9 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -101.7 (tt, J = 7.7, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1530, 1350, 1305, 1158, 1085, 1024, 735;


HRMS (ESI⁺) calcd. for C₂₃H₂₈FN₅O₄S₂Na⁺ [M+Na]⁺: 544.1459, found: 544.1461.

2.2.5 General Procedure D for Sulfondiimidamide Synthesis



An oven-dried round-bottom flask containing sulfondiimidamide **5aa** (1.00 equiv.) was sealed and subjected to three N₂ evacuation/refill cycles before anhydrous CH₂Cl₂ (0.3 M) was added. The solution was cooled to 0 °C before MeOTf (1.05 equiv.) was added. The reaction was warmed to room temperature and stirred for 30 min. Then amine (2.10 equiv.) was added and the reaction was stirred at room temperature for another 30 min before being quenched with sat. aq. NaCl solution. CH₂Cl₂ was added and the organic layer was separated. The aqueous layers was extracted with CH₂Cl₂ twice. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford the desire sulfondiimidamide.

N-((Butylamino)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (**5ab**)



An oven-dried 10 mL round-bottom flask containing sulfondiimidamide **5aa** (107 mg, 0.21 mmol, 1.00 equiv.) was sealed and subjected to three N₂ evacuation/refill cycles before anhydrous CH₂Cl₂ (0.70 mL) was added. The solution was cooled to 0 °C before MeOTf (25 μL, 0.22 mmol, 1.05 equiv.) was added. The reaction was warmed to room temperature and stirred for 30 min. Then *n*-butyl amine (32 mg, 0.43 mmol, 2.10 equiv.) was added and the reaction was stirred at room temperature for another 30 min before being quenched with sat. aq. NaCl solution (50 mL). CH₂Cl₂ (20 mL) was added and the organic layer was separated. The aqueous layers was extracted with CH₂Cl₂ (2 × 20 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1) to afford *sulfondiimidamide* **5ab** as a white solid (105 mg, 0.20 mmol, 97%).

mp 81-83 °C;

R_f 0.63 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.13 (d, *J* = 8.9 Hz, 2H), 7.85-7.78 (m, 4H), 7.03-6.97 (m, 2H), 6.10-5.30 (br. s, 1H), 2.98 (dt, *J* = 12.2, 7.3 Hz, 1H), 2.64 (dt, *J* = 12.2, 7.3 Hz, 1H), 1.64 (d, *J* = 14.5 Hz, 1H), 1.56-1.43 (m, 9H), 1.33-1.23 (m, 2H), 1.02 (s, 9H), 0.84 (t, *J* = 7.3 Hz, 3H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.9 (d, *J* = 255.9 Hz), 149.3, 149.2, 135.4 (d, *J* = 2.0 Hz), 130.7 (d, *J* = 9.2 Hz), 127.7, 123.7, 116.0 (d, *J* = 22.7 Hz), 60.2, 57.6, 41.6, 31.87, 31.86, 31.6, 31.5, 31.3, 20.1, 13.7 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.5 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1529, 1348, 1290, 1268, 1233, 1146, 1091, 1025, 1006, 731;

HRMS (ESI⁺) calcd. for C₂₄H₃₆FN₄O₄S₂⁺ [M+H]⁺: 527.2157, found: 527.2156.

***N*-((Cyclopropylamino)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfanylidene)-4-nitrobenzenesulfonamide (**5ac**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (98 mg, 0.19 mmol, 1.00 equiv.), CH₂Cl₂ (0.62 mL), MeOTf (22 μL, 0.20 mmol, 1.05 equiv.) and cyclopropylamine (23 mg, 0.39 mmol, 2.10 equiv.). Purification by flash column chromatography (petrol/ethyl acetate, 3:1) afforded *sulfondiimidamide* **5ac** as a pale-yellow solid (89 mg, 0.17 mmol, 93%).

mp 88-90 °C;

R_f 0.50 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.18 (d, *J* = 8.8 Hz, 2H), 7.93-7.87 (m, 2H), 7.85 (d, *J* = 8.8 Hz, 2H), 7.09-7.02 (m, 2H), 6.40-5.12 (br. s, 1H), 2.47 (app. br. s, 1H), 1.66 (d, *J* = 14.7 Hz, 1H), 1.58 (d, *J* = 14.7 Hz, 1H), 1.50 (s, 3H), 1.46 (s, 3H), 1.03 (s, 9H), 0.66-0.53 (m, 2H), 0.50-0.41 (m, 1H), 0.27 (app. br. s, 1H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.0 (d, J = 256.0 Hz), 149.4, 149.0, 136.2 (d, J = 2.0 Hz), 131.0 (d, J = 9.3 Hz), 127.7, 123.7, 115.9 (d, J = 22.7 Hz), 60.3, 57.3, 31.88, 31.85, 31.2, 25.0, 6.3, 1.1 (note: or 2 secondary carbons in cyclopropane ring, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.3 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 1383, 1252, 1149, 1088, 955;

HRMS (ESI⁺) calcd. for C₂₃H₃₁FN₄O₄S₂Na⁺ [M+Na]⁺: 533.1663, found: 533.1656.

***N*-((Allylamino)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5ad**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (96 mg, 0.18 mmol, 1.00 equiv.), CH₂Cl₂ (0.60 mL), MeOTf (22 μ L, 0.19 mmol, 1.05 equiv.) and allylamine (22 mg, 0.39 mmol, 2.10 equiv.). Purification by flash column chromatography (petrol/ethyl acetate, 3:1) afforded *sulfondiimidamide 5ad* as a white solid (75 mg, 0.15 mmol, 80%).

mp 95-97 °C;

R_f 0.43 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.13 (d, J = 8.9 Hz, 2H), 7.88-7.78 (m, 2H), 7.81 (d, J = 8.9 Hz, 2H), 7.05-6.98 (m, 2H), 6.15-5.50 (m, 2H), 5.22 (d, J = 17.0 Hz, 1H), 5.14 (dd, J = 10.3, 1.3 Hz, 1H), 3.74-3.57 (m, 1H), 3.35 (app. br. s, 1H), 1.67-1.37 (m, 8H), 1.01 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.0 (d, J = 256.1 Hz), 149.3, 149.2, 135.5, 132.6, 130.7 (d, J = 9.3 Hz), 127.7, 123.7, 118.1, 116.1 (d, J = 22.7 Hz), 60.4, 57.5, 44.3, 31.9, 31.8, 31.2;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.1 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 1528, 1349, 1230, 1148, 1088, 1004, 731;

HRMS (ESI⁺) calcd. for C₂₃H₃₁FN₄O₄S₂Na⁺ [M+Na]⁺: 533.1663, found: 533.1660.

***N*-((*tert*-Butylamino)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5ae**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (97 mg, 0.19 mmol, 1.00 equiv.), CH₂Cl₂ (0.62 mL), MeOTf (22 μ L, 0.20 mmol, 1.05 equiv.) and *tert*-butylamine (29 mg, 0.39 mmol, 2.10 equiv.). Purification by flash column chromatography (petrol/ethyl acetate, 3:1) afforded *sulfondiimidamide* **5ae** as a white solid (80 mg, 0.15 mmol, 82%).

mp 106-108 °C;

R_f 0.50 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.22 (d, *J* = 8.8 Hz, 2H), 7.98-7.94 (m, 2H), 7.90 (d, *J* = 8.8 Hz, 2H), 7.08-7.03 (m, 2H), 6.50-5.50 (br. s, 1H), 1.66-1.57 (m, 2H), 1.48-1.23 (m, 15H), 1.00 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.9 (d, *J* = 255.5 Hz), 149.6, 149.4, 140.2, 130.6 (d, *J* = 9.3 Hz), 127.5, 123.9, 115.9 (d, *J* = 22.6 Hz), 60.8, 57.3, 56.4, 31.9, 31.8, 31.1, 30.6;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -106.4 (tt, *J* = 8.2, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1531, 1348, 1286, 1227, 1144, 1091, 1045, 965, 744;

HRMS (ESI⁺) calcd. for C₂₄H₃₅FN₄O₄S₂Na⁺ [M+Na]⁺: 549.1976, found: 549.1974.

***N*-((4-Fluorophenyl)((5-methylisoxazol-3-yl)amino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5af**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (113 mg, 0.22 mmol, 1.00 equiv.), CH₂Cl₂ (0.72 mL), MeOTf (26 μ L, 0.23 mmol, 1.05 equiv.) and a solution of 3-amino-5-methylisoxazole (45 mg, 0.46 mmol, 2.10 equiv) in CH₂Cl₂ (0.72 mL). Purification by flash column

chromatography (petrol/ethyl acetate, 3:1) afforded *sulfondiimidamide 5af* as a white solid (98 mg, 0.18 mmol, 82%).

mp 132-134 °C;

R_f 0.33 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.25-8.18 (m, 2H), 8.10 (d, *J* = 8.9 Hz, 2H), 7.92 (d, *J* = 8.9 Hz, 2H), 7.26-7.19 (m, 2H), 5.58 (d, *J* = 0.9 Hz, 1H), 5.53 (br. s, 1H), 2.21 (d, *J* = 0.9 Hz, 3H), 1.47 (d, *J* = 14.9 Hz, 1H), 1.41 (d, *J* = 14.9 Hz, 1H), 1.22 (s, 3H), 1.14 (s, 3H), 0.93 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 169.4, 165.8 (d, *J* = 257.9 Hz), 160.9, 149.5, 148.3, 135.9 (d, *J* = 3.2 Hz), 131.7 (d, *J* = 9.5 Hz), 128.4, 123.5, 116.7 (d, *J* = 22.9 Hz), 98.5, 62.0, 56.6, 31.7, 31.6, 29.3, 28.6, 12.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -103.1 (tt, *J* = 8.6, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 2888, 1383, 1251, 1154, 1089, 955;

HRMS (ESI⁺) calcd. for C₂₄H₃₁FN₅O₅S₂⁺ [M+H]⁺: 552.1745, found:552.1736.

***N*-((4-Fluorophenyl)(isoxazol-3-ylamino)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (5ag)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (162 mg, 0.31 mmol, 1.00 equiv.), CH₂Cl₂ (1.03 mL), MeOTf (37 μL, 0.33 mmol, 1.05 equiv.) and 3-aminoisoxazole (55 mg, 0.65 mmol, 2.10 equiv.). Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) afforded *sulfondiimidamide 5ag* as a white solid (158 mg, 0.29 mmol, 95%).

mp 118-120 °C;

R_f 0.50 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.25-8.19 (m, 2H), 8.09 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 1.7 Hz, 1H), 7.91 (d, J = 8.8 Hz, 2H), 7.25-7.19 (m, 2H), 6.01 (d, J = 1.6 Hz, 1H), 5.66 (s, 1H), 1.45 (d, J = 14.9 Hz, 1H), 1.40 (d, J = 14.9 Hz, 1H), 1.19 (s, 3H), 1.13 (s, 3H), 0.90 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.8 (d, J = 258.0 Hz), 160.3, 158.6, 149.6, 148.1, 135.7 (d, J = 3.2 Hz), 131.7 (d, J = 9.6 Hz), 128.3, 123.5, 116.7 (d, J = 22.9 Hz), 101.6, 62.0, 56.4, 31.6, 31.5, 29.1, 28.7 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -102.9 (tt, J = 8.1, 4.1 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1561, 1529, 1462, 1350, 1301, 1154, 1090, 1062, 977, 741;

HRMS (ESI⁺) calcd. for C₂₃H₂₉FN₅O₅S₂⁺ [M+H]⁺: 538.1589, found: 538.1580.

***N*-((4-Fluorophenyl)(pyridin-2-ylamino)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5ah**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (156 mg, 0.30 mmol, 1.00 equiv.), CH₂Cl₂ (1.0 mL), MeOTf (36 μ L, 0.32 mmol, 1.05 equiv.) and a solution of 2-aminopyridine (59 mg, 0.63 mmol, 2.10 equiv) in CH₂Cl₂ (1.0 mL). Purification by flash column chromatography (petrol/ethyl acetate, 1:1) afforded *sulfondiimidamide* **5ah** as a white solid (160 mg, 0.29 mmol, 98%).

mp 128-130 °C;

R_f 0.50 (petrol/ethyl acetate, 1:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.54-6.42 (br. s, 1H), 8.22-8.16 (m, 2H), 7.98 (d, J = 8.9 Hz, 2H), 7.92-7.82 (m, 3H), 7.39 (ddd, J = 8.2, 7.3, 2.0 Hz, 1H), 7.22-7.15 (m, 2H), 6.72 (ddd, J = 7.3, 5.1, 1.0 Hz, 1H), 6.62 (dt, J = 8.2, 1.0 Hz, 1H), 1.48 (s, 2H), 1.25 (s, 3H), 1.18 (s, 3H), 0.95 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.5 (d, J = 256.8 Hz), 157.3, 149.2, 149.1, 146.3, 138.2, 137.6 (d, J = 2.8 Hz), 131.4 (d, J = 9.5 Hz), 128.2, 123.3, 118.0, 117.0, 116.4 (d, J = 22.9 Hz), 61.6, 56.9, 31.7, 31.6, 29.4, 29.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -103.9 (tt, J = 8.2, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1589, 1527, 1348, 1299, 1232, 1149, 1087, 1029, 1008, 732;

HRMS (ESI⁺) calcd. for C₂₅H₃₁FN₅O₄S₂⁺ [M+H]⁺: 548.1796, found: 548.1793.

***N*-((2,3-Dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-1-yl)(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (5ai)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (93 mg, 0.18 mmol, 1.00 equiv.), CH₂Cl₂ (0.60 mL), MeOTf (21 μ L, 0.19 mmol, 1.05 equiv.) and a solution of 2,3-dihydro-7-azaindole (45 mg, 0.38 mmol, 2.10 equiv) in CH₂Cl₂ (0.60 mL). Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) afforded *sulfondiimidamide 5ai* as a white solid (88 mg, 0.15 mmol, 85%).

mp 118-120 °C;

R_f 0.40 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.09 (d, J = 8.8 Hz, 2H), 7.83-7.78 (m, 2H), 7.74 (ddd, J = 5.2, 1.8, 0.9 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.34 (dq, J = 7.3, 1.3 Hz, 1H), 6.96-6.89 (m, 2H), 6.69 (dd, J = 7.3, 5.2 Hz, 1H), 4.51 (td, J = 10.5, 6.5 Hz, 1H), 4.26 (td, J = 10.5, 7.3 Hz, 1H), 3.21-3.01 (m, 2H), 1.63 (d, J = 14.5 Hz, 1H), 1.57 (s, 3H), 1.49 (d, J = 14.5 Hz, 1H), 1.35 (s, 3H), 1.02 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.8 (d, J = 255.3 Hz), 156.3, 149.8, 149.1, 146.5, 136.6 (d, J = 3.1 Hz), 133.1, 130.9 (d, J = 9.2 Hz), 127.4, 124.4, 123.6, 117.7, 115.5 (d, J = 23.0 Hz), 60.7,


57.2, 51.0, 31.83, 31.81, 31.75, 31.4, 25.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -105.8 (tt, *J* = 8.1, 5.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1415, 1349, 1301, 1230, 1152, 1088, 1043, 949, 736;

HRMS (ESI⁺) calcd. for C₂₇H₃₃FN₅O₄S₂⁺ [M+H]⁺: 574.1953, found: 574.1946.

***N*-((4-Fluorophenyl)(1*H*-indol-1-yl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (**5aj**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (313 mg, 0.60 mmol, 1.00 equiv.), CH₂Cl₂ (2.00 mL), MeOTf (71 μL, 0.65 mmol, 1.05 equiv.) and a solution of 5-bromoindoline (250 mg, 1.26 mmol, 2.10 equiv) in CH₂Cl₂ (2.00 mL). Purification by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) afforded *sulfondiimidamide 5aj* as a colourless oil (319 mg, 0.49 mmol, 82%).

R_f 0.38 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.13-8.06 (m, 2H), 7.71-7.61 (m, 4H), 7.23 (s, 1H), 7.04 (d, *J* = 8.7 Hz, 1H), 7.00-6.93 (m, 2H), 6.73 (d, *J* = 8.6 Hz, 1H), 4.40-4.28 (m, 1H), 4.18-4.07 (m, 1H), 3.01 (t, *J* = 8.6 Hz, 2H), 1.66 (d, *J* = 14.7 Hz, 1H), 1.63 (s, 3H), 1.54 (d, *J* = 14.6 Hz, 1H), 1.35 (s, 3H), 1.06 (s, 9H).;


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.1 (d, *J* = 256.8 Hz), 149.4, 149.2, 140.8, 135.2 (d, *J* = 3.2 Hz), 134.4, 130.7 (d, *J* = 9.3 Hz), 130.1, 128.5, 127.3, 123.7, 116.2 (d, *J* = 22.7 Hz), 116.0, 115.9, 61.0, 57.2, 52.8, 31.89, 31.85, 31.7, 31.4, 27.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(CH₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -104.2 (tt, *J* = 7.8, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1591, 1529, 1469, 1349, 1304, 1235, 1154, 1088, 1044;

HRMS (ESI⁺) calcd. for C₂₈H₃₃⁷⁹BrFN₄O₄S₂⁺ [M+H]⁺: 651.1105, found: 651.1104; calcd. for C₂₈H₃₃⁸¹BrFN₄O₄S₂⁺ [M+H]⁺: 653.1086, found: 653.1079.

***N*-((4-Fluorophenyl)(2-oxooxazolidin-3-yl)((2,4,4-trimethylpentan-2-yl)imino)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (**5ak**)**



Prepared according to **General Procedure D** using sulfondiimidamide **5aa** (156 mg, 0.30 mmol, 1.00 equiv.), CH₂Cl₂ (1.00 mL), MeOTf (36 μL, 0.31 mmol, 1.05 equiv.) and 2-oxazolidinone (55 mg, 0.63 mmol, 2.10 equiv.). The reaction was stirred at room temperature for 2 h. Purification by flash column chromatography (petrol/ethyl acetate, 2:1 to 1:1) afforded *sulfondiimidamide* **5ak** as a colourless oil (141 mg, 0.26 mmol, 87%).

R_f 0.41 (petrol/ethyl acetate, 1:1);


¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.20 (d, *J* = 9.0 Hz, 2H), 7.86 (d, *J* = 9.0 Hz, 2H), 7.85-7.80 (m, 2H), 7.08-7.02 (m, 2H), 4.36-4.28 (m, 3H), 4.21-4.12 (m, 1H), 1.73 (d, *J* = 14.5 Hz, 1H), 1.65 (d, *J* = 14.5 Hz, 1H), 1.58 (s, 3H), 1.52 (s, 3H), 1.07 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.5 (d, *J* = 257.5 Hz), 151.9, 149.6, 148.8, 135.4 (d, *J* = 3.1 Hz), 131.0 (d, *J* = 9.7 Hz), 127.6, 124.0, 116.3 (d, *J* = 23.0 Hz), 62.2, 61.8, 57.0, 47.4, 31.9, 31.8, 31.7, 31.4 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -103.5 (tt, *J* = 8.0, 4.9 Hz);


IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1773, 1529, 1349, 1303, 1154, 1123, 1086, 1031, 1004, 837, 728, 647;

HRMS (ESI⁺) calcd. for C₂₃H₂₉FN₄O₆S₂Na⁺ [M+Na]⁺: 563.1405, found: 563.1406.




Sulfondiimidamides **5al** and **5al'** were prepared according to **General Procedure D** using sulfondiimidamide **5aa** (300 mg, 0.58 mmol, 1.00 equiv.), CH₂Cl₂ (1.9 mL), MeOTf (69 μ L, 0.61 mmol, 1.05 equiv.) and (*S*)-(+)-2-pyrrolidinemethanol (123 mg, 1.22 mmol, 2.10 equiv.). The reaction was stirred at room temperature for 1 h. Purification by flash column chromatography (CH₂Cl₂/ethyl acetate, 3:1) afforded *diastereoisomer 5al* as a white solid (132 mg, 0.24 mmol, 41%) and *diastereoisomer 5al'* as a white solid (133 mg, 0.24 mmol, 41%). (Sulfur stereochemistry of these two compounds remains unknown)

***N*-((*R*)-(4-Fluorophenyl)((*S*)-2-(hydroxymethyl)pyrrolidin-1-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide**



***N*-((*S*)-(4-Fluorophenyl)((*S*)-2-(hydroxymethyl)pyrrolidin-1-yl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide**



Diastereoisomer 1 (Sulfur stereochemistry is unknown)

mp 44-46 °C;

R_f 0.53 (CH₂Cl₂/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.15 (d, *J* = 8.9 Hz, 2H), 7.83-7.78 (m, 2H), 7.75 (d, *J* = 8.9 Hz, 2H), 7.07-7.02 (m, 2H), 4.38 (tt, *J* = 8.4, 3.8 Hz, 1H), 3.84-3.04 (br. s, 1H), 3.77 (dd, *J* = 11.0, 4.3 Hz, 1H), 3.58 (dd, *J* = 11.0, 5.3 Hz, 1H), 3.05 (dt, *J* = 10.0, 7.0 Hz, 1H), 2.75 (ddd, *J* = 10.0, 7.0, 5.1 Hz, 1H), 2.04-1.93 (m, 1H), 1.92-1.80 (m, 2H), 1.76-1.67 (m, 1H), 1.65 (d,

$J = 14.5$ Hz, 1H), 1.57 (d, $J = 14.5$ Hz, 1H), 1.48 (s, 3H), 1.46 (s, 3H), 1.00 (s, 9H);

^{13}C NMR (101 MHz, CDCl_3): δ (ppm) = 165.0 (d, $J = 256.1$ Hz), 149.4, 149.3, 136.8 (d, $J = 3.1$ Hz), 131.2 (d, $J = 9.2$ Hz), 127.4, 123.8, 116.2 (d, $J = 22.6$ Hz), 65.9, 62.8, 60.3, 57.7, 46.7, 32.2, 31.9, 31.8, 31.5, 28.9, 24.5 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

^{19}F NMR (377 MHz, CDCl_3): δ (ppm) = -105.3 (tt, $J = 8.5, 5.1$ Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1529, 1383, 1349, 1298, 1234, 1152, 1086, 1051, 969;

HRMS (ESI⁺) calcd. for $\text{C}_{25}\text{H}_{36}\text{FN}_4\text{O}_5\text{S}_2^+$ $[\text{M}+\text{H}]^+$: 555.2106, found: 555.2097;

$[\alpha]_{\text{D}}^{25}$: -76.0° ($c = 1.0$, CHCl_3).

Diastereoisomer 2 (Sulfur stereochemistry is unknown)

mp 117-120 °C;

R_f 0.47 (CH_2Cl_2 /ethyl acetate, 3:1);

^1H NMR (400 MHz, CDCl_3): δ (ppm) = 8.20 (d, $J = 8.8$ Hz, 2H), 7.87 (d, $J = 8.8$ Hz, 2H), 7.76-7.71 (m, 2H), 7.07-7.01 (m, 2H), 4.30 (tt, $J = 8.6, 4.5$ Hz, 1H), 4.05-3.55 (br. s, 1H), 3.71 (dd, $J = 10.9, 7.2$ Hz, 1H), 3.62 (dd, $J = 10.9, 4.6$ Hz, 1H), 3.12-3.00 (m, 2H), 2.04-1.94 (m, 1H), 1.78 (dt, $J = 12.0, 6.6$ Hz, 1H), 1.72-1.63 (m, 2H), 1.58 (d, $J = 14.5$ Hz, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 1.45-1.36 (m, 1H), 1.03 (s, 9H);

^{13}C NMR (101 MHz, $(\text{CD}_3)_2\text{CO}$): δ (ppm) = 165.6 (d, $J = 252.6$ Hz), 150.8, 150.0, 136.8 (d, $J = 3.1$ Hz), 131.7 (d, $J = 9.5$ Hz), 128.2, 124.6, 116.5 (d, $J = 23.0$ Hz), 66.6, 65.8, 60.4, 58.2, 48.2, 32.4, 32.3, 32.0, 31.8, 29.0, 24.9 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);


^{19}F NMR (377 MHz, $(\text{CD}_3)_2\text{CO}$): δ (ppm) = -108.4 (tt, $J = 8.6, 5.1$ Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1589, 1529, 1489, 1350, 1299, 1265, 1230, 1152, 1087, 1047, 977;

HRMS (ESI⁺) calcd. for $\text{C}_{25}\text{H}_{36}\text{FN}_4\text{O}_5\text{S}_2^+$ $[\text{M}+\text{H}]^+$: 555.2106, found: 555.2106;

$[\alpha]_{\text{D}}^{25}$: +37.5° ($c = 1.0$, CHCl_3).

***N*-(Amino(4-fluorophenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**5am**)**



An oven-dried 10 mL round-bottom flask containing sulfondiimidamide **5aa** (167 mg, 0.32 mmol, 1.00 equiv.) was sealed and subjected to three N₂ evacuation/refill cycles before anhydrous CH₂Cl₂ (1.07 mL) was added. The solution was cooled to 0 °C before MeOTf (38 μ L, 0.34 mmol, 1.05 equiv.) was added. The reaction was warmed to room temperature and was stirred for 30 min. Then ammonia solution (0.64 mL, 2 M in *i*-PrOH, 1.28 mmol, 4.00 equiv.) was added and the reaction was stirred at room temperature for another 30 min. The reaction was then concentrated under reduced pressure and crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1 to 1:1) to afford *sulfondiimidamide* **5am** as a white solid (108 mg, 0.23 mmol, 72%).

mp 93-95 °C;

R_f 0.33 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.16 (d, *J* = 8.9 Hz, 2H), 8.03-7.98 (m, 2H), 7.94 (d, *J* = 8.9 Hz, 2H), 7.11-7.04 (m, 2H), 5.66-4.75 (br. s, 1H), 3.85-2.88 (br. s, 1H), 1.56 (d, *J* = 14.9 Hz, 1H), 1.44 (d, *J* = 14.9 Hz, 1H), 1.31 (s, 3H), 1.15 (s, 3H), 0.96 (s, 9H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.3 (d, *J* = 256.8 Hz), 149.5, 149.3, 137.4, 130.4 (d, *J* = 9.4 Hz), 128.0, 123.8, 116.2 (d, *J* = 22.7 Hz), 61.0, 56.4, 31.71, 31.70, 29.8, 28.9 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);


¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -104.4 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1349, 1281, 1153, 1096, 1059, 991, 962;

HRMS (ESI⁺) calcd. for C₂₀H₂₇FN₄O₄S₂Na⁺ [M+Na]⁺: 493.1350, found: 493.1350.

2.2.6 Functionalisation of Primary Sulfondiimidamide **5am**

***N*-((4-Fluorophenyl)(phenylacetamido)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**6a**)**



To an oven-dried 25 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **5am** (180 mg, 0.38 mmol, 1.00 equiv.) in anhydrous CH_2Cl_2 (2.5 mL) at room temperature. Et_3N (80 μL , 0.57 mmol, 1.50 equiv.) was then added, followed by the addition of phenylacetyl chloride (70 mg, 0.46 mmol, 1.20 equiv.). After being stirred at room temperature for 30 min, the reaction mixture was quenched with sat. aq. NaCl solution (100 mL). The product was extracted with CH_2Cl_2 (3×40 mL). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) to afford *sulfondiimidamide 6a* as a white solid (158 mg, 0.27 mmol, 70%).

mp 78-80 °C;

R_f 0.50 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.13 (d, J = 8.9 Hz, 2H), 7.95 (d, J = 8.9 Hz, 2H), 7.88-7.83 (m, 2H), 7.59 (br. s, 1H), 7.23-7.16 (m, 3H), 7.12-7.06 (m, 4H), 3.42 (s, 2H), 1.56 (d, J = 15.0 Hz, 1H), 1.47 (d, J = 15.0 Hz, 1H), 1.36 (s, 3H), 1.13 (s, 3H), 0.93 (s, 9H);


¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 179.3, 165.9 (d, J = 258.7 Hz), 149.7, 148.8, 136.6 (d, J = 3.3 Hz), 134.8, 130.6 (d, J = 9.6 Hz), 129.5, 128.6, 128.2, 127.1, 123.9, 116.9 (d, J = 23.0 Hz), 62.9, 56.6, 47.2, 31.8, 31.6, 29.4, 29.2 (note: for *gem*-dimethyl carbons in *tert*-octyl group, $\text{NC}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{CH}_3)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl_3): δ (ppm) = -102.1 (tt, J = 7.8, 4.5 Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1529, 1349, 1304, 1234, 1157, 1086;

HRMS (ESI⁺) calcd. for $\text{C}_{28}\text{H}_{33}\text{FN}_4\text{O}_5\text{S}_2\text{Na}^+$ [$\text{M}+\text{Na}$]⁺: 611.1769; found: 611.1768.

***N*-((4-Fluorophenyl)(3-phenylureido)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**6b**)**



Sulfondiimidamide **5am** (86 mg, 0.18 mmol, 1.00 equiv.) and NaH (11 mg, 60 % dispersion in mineral oil, 0.28 mmol, 1.50 equiv.) were added to an oven-dried 25 mL round-bottom flask at room temperature and the flask was purged with nitrogen gas. Anhydrous THF (1.80 mL) was then added. The reaction was stirred at room temperature for 15 min. Phenyl isocyanate (26 mg, 0.22 mmol, 1.20 equiv.) was then added and the reaction was stirred at room temperature for another 30 min. The reaction was quenched with sat. aq. NaCl solution (50 mL). Ethyl acetate (30 mL) was added and the organic layers was separated. The aqueous layer was further extracted with ethyl acetate (2 \times 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was then purified by flash column chromatography (petrol/ethyl acetate, 3:1) to afford sulfondiimidamide **6b** as a pale-yellow solid (88 mg, 0.15 mmol, 82%).

mp 146-148 °C;

R_f 0.50 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, (CD₃)₂SO): δ (ppm) = 9.33 (s, 1H), 8.18-8.06 (m, 5H), 7.87 (d, J = 8.8 Hz, 2H), 7.48 (t, J = 8.8 Hz, 2H), 7.34-7.30 (m, 2H), 7.17 (t, J = 7.9 Hz, 2H), 6.91 (t, J = 7.3 Hz, 1H), 1.53 (d, J = 14.7 Hz, 1H), 1.48 (d, J = 14.7 Hz, 1H), 1.19 (s, 3H), 1.10 (s, 3H), 0.87 (s, 9H);

¹³C NMR (101 MHz, (CD₃)₂SO): δ (ppm) = 164.7 (d, J = 253.2 Hz), 154.1, 148.8, 148.4, 139.7, 137.5 (d, J = 2.3 Hz), 131.2 (d, J = 9.8 Hz), 128.4, 128.1, 123.7, 122.0, 117.9, 116.3 (d, J = 23.0 Hz), 60.7, 54.6, 31.19, 31.15, 28.5, 28.3 (note: for *gem*-dimethyl carbons in *tert*-octyl group, NC(**CH**₃)₂CH₂C(CH₃)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);


¹⁹F NMR (377 MHz, (CD₃)₂SO): δ (ppm) = -105.8 (tt, J = 8.7, 4.2 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1349, 1301, 1223, 1156, 1087, 1056, 840, 739;

HRMS (ESI⁺) calcd. for C₂₇H₃₃FN₅O₅S₂⁺ [M+H]⁺: 590.1902; found: 590.1894.

2.2.7 *t*-Octyl Deprotection of Sulfondiimidamide 5a

N-((4-Fluorophenyl)(imino)(morpholino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (6c)



To a solution of sulfondiimidamide **5a** (4.50 g, 8.33 mmol, 1.00 equiv.) in CH₂Cl₂ (83.3 mL) in an oven-dried 250 mL round-bottom flask was added TFA (3.21 mL, 41.70 mmol, 5.00 equiv.) at room temperature. The mixture was stirred at room temperature for 15 min before being concentrated *in vacuo* and diluted with ethyl acetate (200 mL). Then the mixture was basified to pH 10-11 using 1 M aq. NaOH solution (300 mL). The aqueous phase was extracted with ethyl acetate (2 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 1:1 to 1:2) to afford *sulfondiimidamide 6c* as a white solid (3.39 g, 7.92 mmol, 95%).

mp 64-66 °C;

R_f 0.50 (petrol/ethyl acetate, 1:2);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.24 (d, *J* = 9.0 Hz, 2H), 8.08 (d, *J* = 9.0 Hz, 2H), 7.98-7.93 (m, 2H), 7.23-7.17 (m, 2H), 3.72 (app. t, *J* = 4.7 Hz, 4H), 3.28 (br. s, 1H), 3.15-3.02 (m, 4H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.9 (d, *J* = 257.8 Hz), 149.7, 149.3, 130.4 (d, *J* = 9.5 Hz), 129.3 (d, *J* = 3.2 Hz), 127.9, 124.1, 116.7 (d, *J* = 22.9 Hz), 66.2, 46.8;


¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -102.9 (tt, *J* = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1528, 1351, 1300, 1154, 1089, 1067, 1052, 920;

HRMS (ESI⁺) calcd. for C₁₆H₁₈FN₄O₅S₂⁺ [M+H]⁺: 429.0697, found: 429.0695.

2.2.8 Functionalisation of Sulfondiimidamide 6c

N-((Cyanoimino)(4-fluorophenyl)(morpholino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (6d)



To an oven-dried 250 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6c** (3.05 g, 7.13 mmol, 1.00 equiv.) in anhydrous CH₃CN (35.7 mL) at room temperature. Et₃N (1.99 mL, 14.3 mmol, 2.00 equiv.) was then added, followed by the addition of BrCN solution (2.14 mL, 5.0 M in CH₃CN, 10.7 mmol, 1.50 equiv.). After being stirred at room temperature for 30 min, the reaction mixture was quenched with sat. aq. NaHCO₃ solution (500 mL). The product was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 8:1 to 4:1) to afford *sulfondiimidamide 6d* as a white solid (3.16 g, 6.98 mmol, 98%).

mp 50-53 °C;

*R*_f 0.58 (CH₂Cl₂/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.38 (d, *J* = 8.9 Hz, 2H), 8.22 (d, *J* = 8.9 Hz, 2H), 8.05-8.00 (m, 2H), 7.39-7.33 (m, 2H), 3.82 (app. t, *J* = 4.7 Hz, 4H), 3.40 (dt, *J* = 11.7, 4.6 Hz, 2H), 3.25 (dt, *J* = 11.7, 4.6 Hz, 2H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 167.1 (d, *J* = 262.0 Hz), 150.5, 147.3, 131.6 (d, *J* = 10.1 Hz), 128.7, 127.5 (d, *J* = 3.3 Hz), 124.6, 118.1 (d, *J* = 23.1 Hz), 109.3, 65.9, 46.7;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -98.3 (tt, *J* = 7.8, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2360, 2208, 1530, 1350, 1166, 1107, 1084, 930, 846;

HRMS (ESI⁺) calcd. for C₁₇H₁₆FN₅O₅S₂Na⁺ [M+Na]⁺: 476.0469, found: 476.0469.

***N*-((4-Fluorophenyl)(imino)(morpholino)- λ^6 -sulfaneylidene)cyanamide (6e)**



To an oven-dried 50 mL round-bottom flask was dissolved sulfondiimidamide **6d** (650 mg, 1.43 mmol, 1.00 equiv.) in anhydrous CH₃CN (14.3 mL) at room temperature. Then 1-dodecanethiol (0.86 mL, 3.58 mmol, 2.50 equiv.) was added, followed by the addition of DBU (0.54 mL, 3.58 mmol, 2.50 equiv.). After being stirred at room temperature for 15 min (judged by TLC), the reaction was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 4:1 to 1:1 to 0:1) without an aqueous workup to afford *sulfondiimidamide 6e* as a colourless oil (278 mg, 1.04 mmol, 73%).

R_f 0.38 (ethyl acetate);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.03-7.98 (m, 2H), 7.30-7.25 (m, 2H), 3.78-3.72 (m, 4H), 3.12-3.03 (m, 5H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.1 (d, J = 258.1 Hz), 130.9 (d, J = 9.5 Hz), 128.6 (d, J = 3.1 Hz), 117.1 (d, J = 22.9 Hz), 113.0, 66.2, 46.8;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -102.5 (tt, J = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2186, 1588, 1490, 1226, 1109, 924, 839;

HRMS (ESI⁺) calcd. for C₁₁H₁₄FN₄OS⁺ [M+H]⁺: 269.0867, found: 269.0869.

***N*-((4-Fluorophenyl)((methylsulfonyl)imino)(morpholino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (6f)**



To an oven-dried 25 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6c** (190 mg, 0.44 mmol, 1.00 equiv.) in anhydrous CH₂Cl₂ (2.2 mL) at room temperature. Et₃N (92 μ L, 0.66 mmol, 1.50 equiv.) was then added, followed by the addition of MsCl (61 mg, 0.53 mmol, 1.20 equiv.) and DMAP (11 mg, 0.09 mmol, 0.20 equiv.). After being stirred at room temperature for 30 min, the reaction mixture was quenched with sat. aq. NaCl solution (100 mL).

The product was extracted with CH₂Cl₂ (3 × 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 5:1) to afford *sulfondiimidamide* **6f** as a white solid (181 mg, 0.36 mmol, 81%).

mp 56-58 °C;

R_f 0.47 (CH₂Cl₂/ethyl acetate, 5:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.23 (d, *J* = 8.9 Hz, 2H), 8.05 (d, *J* = 8.9 Hz, 2H), 7.96-7.91 (m, 2H), 7.24-7.17 (m, 2H), 3.73-3.68 (m, 4H), 3.25 (dt, *J* = 12.1, 4.8 Hz, 2H), 3.19 (dt, *J* = 11.0, 4.3 Hz, 2H), 3.15 (s, 3H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.5 (d, *J* = 260.3 Hz), 150.0, 147.6, 131.5 (d, *J* = 9.9 Hz), 129.5 (d, *J* = 3.1 Hz), 128.2, 124.1, 117.4 (d, *J* = 23.1 Hz), 65.9, 46.4, 44.0;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -100.2 (tt, *J* = 8.2, 4.7 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1530, 1351, 1307, 1169, 1084, 926, 741;

HRMS (ESI⁺) calcd. for C₁₇H₂₀FN₄O₇S₃⁺ [M+H]⁺: 507.0473, found: 507.0470.

N-((4-Fluorophenyl)(imino)(morpholino)-λ⁶-sulfaneylidene)methanesulfonamide (**6g**)



To an oven-dried 25 mL round-bottom flask was dissolved sulfondiimidamide **6f** (152 mg, 0.30 mmol, 1.00 equiv.) in anhydrous CH₃CN (3.0 mL) at room temperature. Then 1-dodecanethiol (0.36 mL, 1.50 mmol, 5.0 equiv.) was added, followed by the addition of DBU (0.21 mL, 1.43 mmol, 4.75 equiv.). After being stirred at room temperature for 15 min (judged by TLC), the reaction mixture was quenched with sat. aq. NaCl solution (100 mL). The product was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (ethyl acetate/MeOH, 1:0 to 9:1) to afford *sulfondiimidamide* **6g** as a colourless oil (68 mg, 0.21 mmol, 71%).

R_f 0.50 (ethyl acetate/MeOH, 9:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 7.92-7.86 (m, 2H), 7.12-7.06 (m, 2H), 3.61-3.53 (m, 4H), 3.15 (s, 1H), 3.01-2.94 (m, 2H), 2.94-2.85 (m, 5H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.7 (d, J = 257.0 Hz), 130.3 (d, J = 9.4 Hz), 129.9 (d, J = 3.1 Hz), 116.6 (d, J = 22.7 Hz), 66.3, 46.9, 44.6;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -103.7 (tt, J = 8.0, 5.1 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1590, 1490, 1292, 1137, 1092, 1051, 1009, 913, 725;

HRMS (ESI⁺) calcd. for C₁₁H₁₇FN₃O₃S₂⁺ [M+H]⁺: 322.0690, found: 322.0685.

***N*-((4-Fluorophenyl)(morpholino)(((4-nitrophenyl)sulfonyl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzamide (**6h**)**



To an oven-dried 25 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6c** (164 mg, 0.38 mmol, 1.00 equiv.) in anhydrous CH₂Cl₂ (1.9 mL) at room temperature. Et₃N (80 μ L, 0.57 mmol, 1.50 equiv.) was then added, followed by the addition of 4-nitrobenzoyl chloride (78 mg, 0.42 mmol, 1.10 equiv.). After being stirred at room temperature for 1 h, the reaction mixture was quenched with sat. aq. NaCl solution (100 mL). The product was extracted with CH₂Cl₂ (3 \times 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 7:1 to 4:1) to afford *sulfondiimidamide 6h* as a white solid (207 mg, 0.36 mmol, 94%).

mp 222-224 °C;

R_f 0.75 (CH₂Cl₂/ethyl acetate, 5:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.18 (d, J = 9.0 Hz, 2H), 8.14-8.09 (m, 2H), 8.04-7.97 (m, 4H), 7.94 (d, J = 9.0 Hz, 2H), 7.34-7.28 (m, 2H), 3.87-3.81 (m, 4H), 3.63-3.56 (m, 2H), 3.45-3.39 (m, 2H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 169.1, 166.5 (d, J = 260.0 Hz), 150.5, 149.8, 147.4, 139.6, 131.6 (d, J = 9.9 Hz), 130.2, 129.8 (d, J = 3.2 Hz), 128.6, 123.9, 123.5, 117.6 (d, J = 23.0 Hz), 66.2, 46.2;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -100.4 (tt, J = 7.7, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1525, 1349, 1272, 1107, 1083, 1066, 936, 839, 720;

HRMS (ESI⁺) calcd. for C₂₃H₂₁FN₅O₈S₂⁺ [M+H]⁺: 578.0810, found: 578.0809.

***N*-((4-Fluorophenyl)(imino)(morpholino)- λ^6 -sulfaneylidene)-4-nitrobenzamide (**6i**)**



To an oven-dried 25 mL round-bottom flask was dissolved sulfondiimidamide **6h** (202 mg, 0.35 mmol, 1.00 equiv.) in anhydrous CH₃CN (3.5 mL) at room temperature. Then 1-dodecanethiol (0.42 mL, 1.75 mmol, 5.00 equiv.) was added, followed by the addition of DBU (0.25 mL, 1.66 mmol, 4.75 equiv.). After being stirred at room temperature for 30 min (judged by TLC), the reaction mixture was quenched with sat. aq. NaCl solution (120 mL). The product was extracted with ethyl acetate (3 \times 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 1:1 to 1:2) to afford *sulfondiimidamide 6i* as colourless oil (94 mg, 0.24 mmol, 69%).

R_f 0.39 (CH₂Cl₂/ethyl acetate, 1:2);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.25-8.16 (m, 4H), 8.13-8.08 (m, 2H), 7.27-7.21 (m, 2H), 3.72-3.66 (m, 4H), 3.50 (s, 1H), 3.13 (dt, J = 12.0, 4.8 Hz, 2H), 3.04 (dt, J = 12.0, 4.8 Hz, 2H);


¹³C NMR (101 MHz, (CD₃)₂CO): δ (ppm) = 171.4, 166.2 (d, J = 252.8 Hz), 150.8, 143.3, 132.2 (d, J = 1.7 Hz), 131.5 (d, J = 9.5 Hz), 130.9, 124.0, 117.1 (d, J = 23.0 Hz), 66.9, 47.2;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -104.0 (tt, J = 8.0, 4.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1627, 1590, 1522, 1490, 1287, 1258, 1138, 1110, 918, 721;

HRMS (ESI⁺) calcd. for C₁₇H₁₈FN₄O₄S⁺ [M+H]⁺: 393.1027, found: 393.1024.

***N*-(((3,5-Bis(trifluoromethyl)phenyl)carbamoyl)imino)(4-fluorophenyl)(morpholino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (6j)**



To an oven-dried 25 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6c** (255 mg, 0.60 mmol, 1.00 equiv.) in anhydrous CH₃CN (6.0 mL) at room temperature. DBU (0.13 mL, 0.90 mmol, 1.50 equiv.) was then added, followed by the addition of 3,5-bis(trifluoromethyl)phenyl isocyanate (230 mg, 0.90 mmol, 1.50 equiv.). After being stirred at room temperature for 30 min, the reaction mixture was quenched with sat. aq. NaCl solution (120 mL). The product was extracted with ethyl acetate (3 \times 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 1:1 to 2:3) to afford sulfondiimidamide **6j** as a white solid (322 mg, 0.47 mmol, 79%).

mp 196-198 °C;

R_f 0.39 (petrol/ethyl acetate, 1:1);

¹H NMR (400 MHz, (CD₃)₂SO): δ (ppm) = 10.01 (s, 1H), 8.18-8.13 (m, 2H), 8.08 (app. br. s, 4H), 7.85 (app. br. s, 2H), 7.59-7.51 (m, 3H), 3.69 (app. t, J = 4.5 Hz, 4H), 3.34-3.22 (m, 4H);


¹³C NMR (101 MHz, (CD₃)₂SO): δ (ppm) = 165.5 (d, J = 254.9 Hz), 154.2, 148.9, 147.5, 141.2, 131.9 (d, J = 10.1 Hz), 130.7 (q, J = 32.7 Hz), 130.1 (d, J = 2.8 Hz), 128.7, 123.8, 123.2 (q, J = 272.6 Hz), 117.2, 117.1 (d, J = 23.2 Hz), 114.7, 65.3, 45.6;

¹⁹F NMR (377 MHz, (CD₃)₂SO): δ (ppm) = -62.0 (s), -103.6 (tt, J = 9.0, 5.1 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1665, 1533, 1277, 1224, 1161, 1132, 1085, 940;

HRMS (ESI⁺) calcd. for C₂₅H₂₀F₇N₅O₆S₂Na⁺ [M+Na]⁺: 706.0635, found: 706.0629.

1-(3,5-Bis(trifluoromethyl)phenyl)-3-((4-fluorophenyl)(imino)(morpholino)-λ⁶-sulfaneylidene)urea (6k)



To an oven-dried 25 mL round-bottom flask was dissolved sulfondiimidamide **6j** (180 mg, 0.26 mmol, 1.00 equiv.) in anhydrous CH₃CN (2.6 mL) at 0 °C. Then 1-dodecanethiol (0.32 mL, 1.32 mmol, 5.00 equiv.) was added, followed by the addition of DBU (0.19 mL, 1.25 mmol, 4.75 equiv.). After being stirred at 0 °C for 20 min (judged by TLC), the reaction mixture was quenched with sat. aq. NaCl solution (120 mL). The product was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 1:1 to 1:2) to afford *sulfondiimidamide 6k* as a colorless oil (95 mg, 0.19 mmol, 72%).

R_f 0.50 (petrol/ethyl acetate, 1:2);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.07-8.02 (m, 2H), 7.93 (s, 2H), 7.85-7.41 (br. s, 1H), 7.46 (s, 1H), 7.24-7.18 (m, 2H), 3.71 (app. t, *J* = 4.7 Hz, 4H), 3.43 (s, 1H), 3.10 (dt, *J* = 11.7, 4.7 Hz, 2H), 3.03 (dt, *J* = 11.7, 4.7 Hz, 2H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.7 (d, *J* = 256.6 Hz), 158.2, 141.1, 132.2 (q, *J* = 33.1 Hz), 130.2 (d, *J* = 9.3 Hz), 130.0 (d, *J* = 2.8 Hz), 123.4 (q, *J* = 272.6 Hz), 118.5, 116.6 (d, *J* = 22.6 Hz), 115.8, 66.4, 46.6;


¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -63.0 (s), -104.3 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1638, 1541, 1492, 1474, 1434, 1387, 1277, 1236, 1176, 1129, 924;

HRMS (ESI⁺) calcd. for C₁₉H₁₈F₇N₄O₂S⁺ [M+H]⁺: 499.1033, found: 499.1029.

2.2.9 Functionalisation of Sulfondiimidamide 6e

N-((4-Fluorophenyl)(morpholino)(phenylimino)- λ^6 -sulfaneylidene)cyanamide (6l)



Sulfondiimidamide **6e** (83 mg, 0.31 mmol, 1.00 equiv.), phenylboronic acid (94 mg, 0.77 mmol, 2.50 equiv.), $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (58 mg, 0.16 mmol, 0.50 equiv.), *N*-methylpiperidine (277 mg, 2.79 mmol, 9.00 equiv.) were dissolved in anhydrous CH_3CN (3.1 mL) in an oven-dried 25 mL round-bottom flask and under oxygen atmosphere. The reaction was stirred at room temperature for 3 h until completion (judged by TLC). Then the reaction mixture was quenched with sat. aq. NaCl solution (80 mL). The product was extracted with ethyl acetate (3×30 mL). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH_2Cl_2 /ethyl acetate, 8:1 to 4:1) to afford *sulfondiimidamide 6l* as a white solid (81 mg, 0.24 mmol, 76%).

mp 107-109°C;

R_f 0.58 (CH_2Cl_2 /ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl_3): δ (ppm) = 8.07-8.02 (m, 2H), 7.32-7.22 (m, 6H), 7.07 (tt, $J = 7.2, 1.5$ Hz, 1H), 3.74-3.62 (m, 4H), 3.20-3.10 (m, 4H);


¹³C NMR (101 MHz, CDCl_3): δ (ppm) = 166.0 (d, $J = 258.1$ Hz), 140.6, 131.2 (d, $J = 9.6$ Hz), 129.5, 128.7 (d, $J = 3.3$ Hz), 124.1, 123.9, 117.2 (d, $J = 22.9$ Hz), 112.8, 66.0, 46.8;

¹⁹F NMR (377 MHz, CDCl_3): δ (ppm) = -102.3 (tt, $J = 8.0, 5.0$ Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 2980, 2190, 1588, 1487, 1259, 1238, 1110, 927, 843, 759;

HRMS (ESI^+) calcd. for $\text{C}_{17}\text{H}_{18}\text{FN}_4\text{OS}^+$ [$\text{M}+\text{H}$] $^+$: 345.1180, found: 345.1181.

Phenyl ((cyanoimino)(4-fluorophenyl)(morpholino)- λ^6 -sulfaneylidene)carbamate (6m)



To an oven-dried 25 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6e** (132 mg, 0.49 mmol, 1.00 equiv.) in anhydrous CH₂Cl₂ (2.5 mL) at room temperature. Et₃N (0.14 mL, 0.98 mmol, 2.0 equiv.) was then added, followed by the addition of phenyl chloroformate (115 mg, 0.73 mmol, 1.50 equiv.) and DMAP (12 mg, 0.098 mmol, 0.20 equiv.). After being stirred at room temperature for 10 min, the reaction mixture was quenched with sat. aq. NaCl solution (100 mL). The product was extracted with CH₂Cl₂ (3 × 40 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 8:1 to 4:1) to afford sulfondiimidamide **6m** as a white solid (177 mg, 0.46 mmol, 93%).

mp 132-134 °C;

R_f 0.50 (CH₂Cl₂/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.12-8.07 (m, 2H), 7.38-7.30 (m, 4H), 7.24-7.19 (m, 1H), 7.18-7.14 (m, 2H), 3.80 (app. t, *J* = 4.7 Hz, 4H), 3.39 (dt, *J* = 12.2, 5.0 Hz, 2H), 3.32 (dt, *J* = 12.8, 5.0 Hz, 2H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.5 (d, *J* = 260.3 Hz), 154.5, 151.1, 131.4 (d, *J* = 9.9 Hz), 129.3, 127.6 (d, *J* = 3.0 Hz), 125.8, 121.3, 117.6 (d, *J* = 23.1 Hz), 110.4, 65.8, 46.2;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -99.8 (tt, *J* = 7.9, 4.7 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2202, 1697, 1588, 1489, 1237, 1184, 1158, 1107, 928, 838, 728;

HRMS (ESI⁺) calcd. for C₁₈H₁₈FN₄O₃S⁺ [M+H]⁺: 389.1078, found: 389.1078.

***N*-((4-Fluorophenyl)(morpholino)(prop-2-yn-1-ylimino)-λ⁶-sulfaneylidene)cyanamide (**6n**)**



To an oven-dried 10 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6e** (54.9 mg, 0.20 mmol, 1.00 equiv.) in anhydrous CH₃CN (2.1 mL) at room temperature. DBU (92 μL, 0.62 mmol, 3.00 equiv.) was then added and the reaction was stirred at room temperature for 5 min, followed by the addition of propargyl bromide solution (76 mg, 80% wt

in toluene, 0.51 mmol, 2.50 equiv.). The reaction was stirred at room temperature for 16 h until completion (judged by TLC). The reaction was quenched with sat. aq. NaCl solution (100 mL). The product was extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂ /ethyl acetate, 10:1 to 4:1) to afford *sulfondiimidamide 6n* as a white solid (48.3 mg, 0.16 mmol, 77%).

mp 128-131 °C;

R_f 0.54 (CH₂Cl₂/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 7.99-7.94 (m, 2H), 7.30-7.24 (m, 2H), 4.14 (dd, *J* = 17.4, 2.5 Hz, 1H), 4.02 (dd, *J* = 17.4, 2.5 Hz, 1H), 3.78-3.72 (m, 4H), 3.17 (dt, *J* = 11.9, 4.8 Hz, 2H), 3.07 (dt, *J* = 11.3, 4.2 Hz, 2H), 2.28 (t, *J* = 2.5 Hz, 1H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.0 (d, *J* = 257.9 Hz), 131.0 (d, *J* = 9.6 Hz), 128.4 (d, *J* = 3.2 Hz), 117.1 (d, *J* = 22.8 Hz), 112.9, 81.2, 71.5, 66.1, 47.0, 31.8;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -102.5 (tt, *J* = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2190, 1586, 1489, 1260, 1188, 1110, 928;

HRMS (ESI⁺) calcd. for C₁₄H₁₆FN₄OS⁺ [M+H]⁺: 307.1023, found: 307.1021.

***N*-((Benzylimino)(4-fluorophenyl)(morpholino)-λ⁶-sulfaneylidene)cyanamide (6o)**



To an oven-dried 25 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6e** (120 mg, 0.45 mmol, 1.00 equiv.) in anhydrous CH₃CN (4.5 mL) at room temperature. DBU (0.20 mL, 1.35 mmol, 3.00 equiv.) was then added and the reaction was stirred at room temperature for 5 min, followed by the addition of BnBr (192 mg, 1.12 mmol, 2.50 equiv.). The reaction was stirred at room temperature for 3 h until completion (judged by TLC). The reaction was quenched with sat. aq. NaCl solution (120 mL). The product was extracted with ethyl acetate

(3 × 40 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 9:1 to 4:1) to afford *sulfondiimidamide* **6o** as a colourless oil (131 mg, 0.37 mmol, 81%).

R_f 0.63 (CH₂Cl₂/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.00-7.95 (m, 2H), 7.47-7.42 (m, 2H), 7.38-7.32 (m, 2H), 7.30-7.24 (m, 3H), 4.56 (d, *J* = 14.4 Hz, 1H), 4.38 (d, *J* = 14.4 Hz, 1H), 3.65 (ddd, *J* = 11.8, 6.3, 3.2 Hz, 2H), 3.57 (ddd, *J* = 11.8, 6.3, 3.2 Hz, 2H), 3.03 (ddd, *J* = 11.9, 6.5, 3.2 Hz, 2H), 2.93 (ddd, *J* = 11.9, 6.5, 3.2 Hz, 2H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.8 (d, *J* = 257.5 Hz), 139.4, 130.8 (d, *J* = 9.5 Hz), 128.7 (d, *J* = 3.2 Hz), 128.5, 127.8, 127.2, 116.9 (d, *J* = 22.7 Hz), 113.3, 65.9, 46.8, 46.3;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -102.9 (tt, *J* = 8.0, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2187, 1586, 1489, 1185, 1110, 928, 838;

HRMS (ESI⁺) calcd. for C₁₈H₂₀FN₄OS⁺ [M+H]⁺: 359.1336, found: 359.1336.

***N*-((4-Fluorophenyl)(morpholino)(((trifluoromethyl)thio)imino)-λ⁶-sulfaneylidene)cyanamide (6p)**



To an oven-dried 10 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **6e** (170 mg, 0.63 mmol, 1.00 equiv.) in anhydrous CH₃CN (1.26 mL) at room temperature. NBS (112 mg, 0.63 mmol, 1.00 equiv.) was then added. The reaction was stirred at room temperature for 30 min, followed by the addition of a solution of AgSCF₃ (158 mg, 0.76 mmol, 1.20 equiv.) in anhydrous CH₃CN (1.9 mL). After being stirred at room temperature for another 30 min, the reaction mixture was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 50:1 to 20:1 to 10:1) to afford *sulfondiimidamide* **6p** as a colourless oil (119 mg, 0.32 mmol, 51%).

R_f 0.57 (CH₂Cl₂/ethyl acetate, 10:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 7.99-7.94 (m, 2H), 7.35-7.29 (m, 2H), 3.80-3.71 (m, 4H), 3.24-3.12 (m, 4H);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 166.5 (d, J = 260.3 Hz), 131.5 (d, J = 9.9 Hz), 130.0 (q, J = 312.0 Hz), 127.2 (d, J = 3.2 Hz), 117.7 (d, J = 23.0 Hz), 110.6, 65.9, 46.9;


¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -49.8 (s), -100.1 (tt, J = 7.8, 4.7 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2200, 1586, 1490, 1159, 1108, 1085, 1007, 930, 841,.

HRMS (ESI⁺) calcd. for C₁₂H₁₃F₄N₄OS₂⁺ [M+H]⁺: 369.0461, found: 369.0467.

2.2.10 Sulfondiimidamide Synthesis using Tri-isopropylsilyl Sulfinylamine

Triisopropylsilyl amine



Triisopropylsilyl chloride (13.50 g, 70.0 mmol, 1.00 equiv.) was dissolved in anhydrous diethyl ether (140 mL) in an oven-dried 500 mL round-bottom flask. The reaction mixture was cooled to -78 °C. Anhydrous ammonia gas was bubbled through this solution for 2 h, resulting in the formation of a white precipitate. The reaction was then warmed to 0 °C and stirred for another 3 h to remove excess ammonia. Filtration over anhydrous Na₂SO₄ (washed with diethyl ether) and removal of solvent under reduced pressure afforded triisopropylsilyl amine as a colourless oil (12.0 g, 69.4 mmol, 99%).


¹H NMR (400 MHz, C₆D₆): δ (ppm) = 1.05-1.00 (m, 18H), 0.95-0.85 (m, 3H), -0.12 (s, 2H);

¹³C NMR (101MHz, C₆D₆): δ (ppm) = 18.4, 12.5;

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2864, 1546, 1463, 1382, 1245, 1011, 882, 817, 658;

HRMS (ESI⁺) calcd. for C₉H₂₄NSi⁺ [M+H]⁺: 174.1673; mass not found.

Triisopropylsilyl Sulfinylamine (7)



Triisopropylsilyl amine (5.20 g, 30.0 mmol, 1.00 equiv.) was dissolved in anhydrous diethyl ether (600 mL) in an oven-dried 1 L round-bottom flask. The reaction was cooled to 0 °C and anhydrous Et₃N (8.41 mL, 61.8 mmol, 2.06 equiv.) was added. Freshly distilled thionyl chloride (2.25 mL, 30.9 mmol, 1.03 equiv.) was then added dropwise. The reaction was stirred at 0 °C for 1.5 h. Filtration over Na₂SO₄ (washed with diethyl ether) and removal of solvent under reduced pressure afforded triisopropylsilyl sulfinylamine **7** as a pale-yellow oil (6.56 g, 30.0 mmol, 100%).

Notes

1. Tri-*isopropylsilyl* sulfinylamine should be stored in the freezer (-20 °C) and can be used without loss of performance for at least 1 month.
2. **CAUTION: Hydrolysis of sulfinylamines results in the formation of toxic sulfur dioxide gas.** Evolution of SO₂ from TIPS-NSO has not been observed in the normal course of use, but

avoidance of contact with water or prolonged storage at room temperature is advised.

3. During the workup stage diethyl ether was removed in a rotary evaporator with the bath temperature set to 30 °C or lower.


¹H NMR (400 MHz, C₆D₆): δ (ppm) = 1.19-0.96 (m, 21H);

¹³C NMR (101MHz, C₆D₆): δ (ppm) = 18.0, 12.4;

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2980, 1463, 1385, 1308, 1128, 882, 682, 664;

HRMS (ESI⁺) calcd. for C₉H₂₂NOSSi⁺ [M+H]⁺: 220.1186; mass not found.

***N*-(*S*-(4-Fluorophenyl)-*N*-(triisopropylsilyl)sulfinimidoyl)-4-nitrobenzenesulfonamide (10)**



Triisopropylsilyl sulfinylamine **7** (1.73 g, 7.90 mmol, 1.00 equiv.) was dissolved in anhydrous THF (15.8 mL) in an oven-dried 250 mL round-bottom flask and was purged with nitrogen gas. The mixture was cooled to -30 °C before LiHMDS solution (7.90 mL, 1.00 M in THF, 7.90 mmol, 1.00 equiv.) was added. After being stirred at -30 °C for 5 min, the reaction was warmed to 0 °C and stirred for another 5 min. TMSCl (1.00 mL, 7.90 mmol, 1.00 equiv.) was added and the reaction was stirred at 0 °C for 10 min. 4-Fluorophenylmagnesium bromide solution (10.53 mL, 0.90 M in THF, 9.48 mmol, 1.20 equiv.) was then added and the reaction was stirred at 0 °C for 10 min. The reaction mixture was then quenched with sat. aq. tetrasodium EDTA solution (250 mL). Ethyl acetate (150 mL) was added and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate (2 × 80 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude mixture was dissolved in anhydrous CH₂Cl₂ (39.5 mL) in an oven-dried 250 mL round-bottom flask at 0 °C before Et₃N (1.32 mL, 9.48 mmol, 1.20 equiv.) and NsCl (1.75 g, 7.90 mmol, 1.00 equiv.) were added. The reaction was stirred at 0 °C for 20 min and then was quenched with sat. aq. NaCl solution (150 mL) and extracted with CH₂Cl₂ (3 × 80 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 100:1 to 30:1 to 20:1) to afford *sulfinamidine* **10** as a white solid (3.52 g, 7.05 mmol, 89%).

mp 148-150 °C;

R_f 0.64 (CH₂Cl₂/ethyl acetate, 25:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.18 (d, *J* = 8.9 Hz, 2H), 7.87 (d, *J* = 8.9 Hz, 2H), 7.63-7.58 (m, 2H), 7.13-7.07 (m, 2H), 4.53 (s, 1H), 1.32-1.20 (m, 3H), 1.13-1.06 (m, 18H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 164.7 (d, *J* = 254.8 Hz), 150.3, 149.2, 136.6 (d, *J* = 3.2 Hz), 128.8 (d, *J* = 9.1 Hz), 127.4, 123.8, 116.8 (d, *J* = 22.7 Hz), 17.94, 17.90, 12.0 (note: for dimethyl carbons in tri-*isopropylsilyl* group, NSi (CH(CH₃)₂)₃, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -106.7 (tt, *J* = 8.1, 4.9 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1527, 1490, 1389, 1347, 1299, 1227, 1149, 1088, 954, 786, 608;

HRMS (ESI⁺) calcd. for C₂₁H₃₁FN₃O₄S₂Si⁺ [M+H]⁺: 500.1504, found: 500.1504;

4-Fluoro-*N*-((4-nitrophenyl)sulfonyl)-*N*-(triisopropylsilyl)benzenesulfondiimidoyl fluoride (**11**)



An oven-dried 50 mL round-bottom flask was charged with sulfinamidine **10** (998 mg, 2.00 mmol, 1.00 equiv.) and NaH (88 mg, 60 % dispersion in mineral oil, 2.20 mmol, 1.10 equiv.) at 0 °C and was purged with nitrogen gas. Anhydrous THF (4.00 mL) was added. The reaction was stirred at 0 °C for 5 min before being warmed to room temperature and stirred for another 25 min. NFSI (945 mg, 3.00 mmol, 1.50 equiv.) was then added under a positive pressure of nitrogen and the reaction was stirred at room temperature for 30 min before being quenched with sat. aq. NaCl solution (150 mL). Ethyl acetate (100 mL) was added and the organic layer was separated. The aqueous layer was further extracted with ethyl acetate (2 × 40 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a crude solid. Diethyl ether (150 mL) was added to the crude solid and the resulting suspension was shaken well before being filtered. The white filter cake was washed with diethyl ether (80 mL) and CH₂Cl₂ (80 mL). The combined filtrate was concentrated under reduced pressure to give a crude product. The crude product was then purified by flash column chromatography (petrol/ethyl acetate, 6:1) to afford *sulfondiimidoyl fluoride* **11** as a

colourless oil (941 mg, 1.82 mmol, 91%).

R_f 0.42 (petrol/ethyl acetate, 6:1);

$^1\text{H NMR}$ (400 MHz, CD_3CN): δ (ppm) = 8.27 (d, J = 9.0 Hz, 2H), 8.00-7.94 (m, 4H), 7.34-7.28 (m, 2H), 1.23-1.13 (m, 3H), 1.05 (d, J = 2.9 Hz, 9H), 1.03 (d, J = 2.9 Hz, 9H);


$^{13}\text{C NMR}$ (101 MHz, CD_3CN): δ (ppm) = 167.0 (d, J = 256.4 Hz), 151.1, 148.8, 136.2 (dd, J = 28.5, 3.1 Hz), 131.3 (d, J = 10.2 Hz), 128.8, 125.3, 118.0 (d, J = 23.5 Hz), 18.3, 18.2, 13.4 (d, J = 1.9 Hz) (note: for dimethyl carbons in tri-*isopropylsilyl* group, $\text{NSi}(\text{CH}(\text{CH}_3)_2)_3$, 2 peaks were found instead of 1 due to the loss of symmetry caused by chiral sulfur atom);

$^{19}\text{F NMR}$ (377 MHz, CD_3CN): δ (ppm) = 87.6 (s), -103.3 (tt, J = 8.7, 4.8 Hz);

IR (ATR): $\tilde{\nu}$ (cm^{-1}) = 1531, 1403, 1348, 1251, 1163, 1113, 1090, 855, 683, 614;

HRMS (ESI^+) calcd. for $\text{C}_{21}\text{H}_{29}\text{F}_2\text{N}_3\text{O}_4\text{S}_2\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 540.1229, found: 540.1228.

***N*-((4-Fluorophenyl)(morpholino)((triisopropylsilyl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**12**)**



Sulfondiimidoyl fluoride **11** (305 mg, 0.59 mmol, 1.00 equiv.), $\text{Ca}(\text{NTf}_2)_2$ (389 mg, 0.65 mmol, 1.10 equiv.) were added to an oven-dried 10 mL round-bottom flask and dissolved in anhydrous *t*-AmylOH (1.18 mL). Then morpholine (113 mg, 1.30 mmol, 2.20 equiv.) was added and the reaction was stirred at 60 °C for 45 h until completion (judged by TLC). The mixture was then diluted with ethyl acetate (100 mL) and quenched with sat. aq. NaCl solution (250 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2×100 mL). The combined organic layers were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) to afford *sulfondiimidamide* **12** as a colourless oil (252 mg, 0.43 mmol, 73%).

R_f 0.41 (petrol/ethyl acetate, 3:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.26 (d, J = 8.9 Hz, 2H), 8.04 (d, J = 8.9 Hz, 2H), 7.87-7.82 (m, 2H), 7.18-7.12 (m, 2H), 3.71-3.66 (m, 4H), 3.15 (dt, J = 11.8, 4.6 Hz, 2H), 3.03 (dt, J = 11.8, 4.6 Hz, 2H), 1.07-0.96 (m, 21H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 165.2 (d, J = 256.3 Hz), 149.8, 149.4, 135.8 (d, J = 3.2 Hz), 130.2 (d, J = 9.2 Hz), 127.6, 123.8, 116.3 (d, J = 22.6 Hz), 66.3, 46.5, 18.3, 13.2;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -104.7 (tt, J = 8.0, 5.0 Hz);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1529, 1374, 1297, 1153, 1086, 1064, 1011, 922, 738, 680;

HRMS (ESI⁺) calcd. for C₂₅H₃₇FN₄O₅S₂SiNa⁺ [M+Na]⁺: 607.1851, found: 607.1849.


***N*-((4-Fluorophenyl)(imino)(morpholino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (**6c**)**



To a solution of sulfondiimidamide **12** (222 mg, 0.38 mmol, 1.00 equiv.) in anhydrous THF (3.80 mL) in an oven-dried 25 mL round-bottom flask was added TBAF solution (0.42 mL, 1.00 M in THF, 0.42 mmol, 1.10 equiv.) at 0 °C. After being stirred at 0 °C for 10 min, the reaction mixture was quenched with sat. aq. NaCl solution (120 mL). The product was extracted with ethyl acetate (3 × 60 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (CH₂Cl₂/ethyl acetate, 3:1 to 2:1) to afford *sulfondiimidamide* **6c** as a white solid (158 mg, 0.37 mmol, 97%).

2.2.11 Synthesis of Sulfondiimidamide Analogue of Celecoxib

***N*-((Diallylamino)(4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)((2,4,4-trimethylpentan-2-yl)imino)- λ^6 -sulfaneylidene)-4-nitrobenzenesulfonamide (13 (i))**



Sulfondiimidoyl fluoride **4p** (370 mg, 0.54 mmol, 1.00 equiv.), Ca(NTf₂)₂ (356 mg, 0.59 mmol, 1.10 equiv.) were added to an oven-dried 10 mL round-bottom flask and dissolved in anhydrous *t*-AmylOH (1.10 mL). Then diallyl amine (262 mg, 2.70 mmol, 5.00 equiv.) was added and the reaction was stirred at 70 °C for 18 h. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 4:1) without an aqueous workup to afford *sulfondiimidamide* **13 (i)** as a white solid (306 mg, 0.40 mmol, 75%).

mp 140-142 °C;

R_f 0.50 (petrol/ethyl acetate, 4:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.09 (d, *J* = 8.8 Hz, 2H), 7.74 (d, *J* = 8.8 Hz, 2H), 7.66 (d, *J* = 8.8 Hz, 2H), 7.33 (d, *J* = 8.8 Hz, 2H), 7.19 (d, *J* = 8.5 Hz, 2H), 7.12 (d, *J* = 8.5 Hz, 2H), 6.73 (s, 1H), 5.51 (dddd, *J* = 16.3, 10.2, 7.5, 5.9 Hz, 2H), 5.14-5.04 (m, 4H), 3.94 (dd, *J* = 15.1, 5.9 Hz, 2H), 3.74 (dd, *J* = 15.1, 7.6 Hz, 2H), 2.38 (s, 3H), 1.72 (d, *J* = 14.5 Hz, 1H), 1.61 (d, *J* = 14.5 Hz, 1H), 1.59 (s, 3H), 1.50 (s, 3H), 1.06 (s, 9H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 149.6, 149.2, 145.2, 144.2 (q, *J* = 38.5 Hz), 142.2, 141.3, 139.9, 132.5, 129.8, 128.9, 128.8, 127.3, 125.9, 125.2, 123.7, 121.1 (q, *J* = 269.4 Hz), 120.0, 106.4, 60.3, 57.5, 50.1, 31.88, 31.85, 31.5, 31.4, 21.4;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -62.4 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1530, 1473, 1382, 1237, 1155, 1089, 1012, 954;

HRMS (ESI⁺) calcd. for C₃₇H₄₄F₃N₆O₄S₂⁺ [M+H]⁺: 757.2812, found: 757.2802.

***N*-((Diallylamino)(imino)(4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (**13** (ii))**



To a solution of sulfondiimidamide **13** (i) (275 mg, 0.36 mmol, 1.00 equiv.) in CH₂Cl₂ (3.60 mL) in an oven-dried 25 mL round-bottom flask was added TFA (0.14 mL, 1.82 mmol, 5.00 equiv.) at room temperature. The mixture was stirred at room temperature for 15 min before being concentrated *in vacuo* and diluted with ethyl acetate (50 mL). Then the mixture was basified to pH 10-11 using 1 M aq. NaOH solution (60 mL). The aqueous phase was extracted with ethyl acetate (2 × 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 4:1 to 2:1) to afford *sulfondiimidamide* **13** (ii) as a colourless oil (212 mg, 0.33 mmol, 91%).

R_f 0.54 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CD₃CN): δ (ppm) = 8.21 (d, *J* = 8.8 Hz, 2H), 8.00 (d, *J* = 8.8 Hz, 2H), 7.93 (d, *J* = 8.9 Hz, 2H), 7.41 (d, *J* = 8.9 Hz, 2H), 7.17 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.2 Hz, 2H), 6.89 (s, 1H), 5.60 (ddt, *J* = 16.6, 10.2, 6.3 Hz, 2H), 5.22-5.06 (m, 4H), 3.91 (ddt, *J* = 15.5, 6.2, 1.6 Hz, 2H), 3.84 (ddt, *J* = 15.5, 6.4, 1.3 Hz, 2H), 3.70 (s, 1H), 2.32 (s, 3H);


¹³C NMR (101 MHz, CD₃CN): δ (ppm) = 150.6, 150.4, 146.6, 144.2 (q, *J* = 38.1 Hz), 143.8, 140.8, 139.9, 133.3, 130.4, 129.9, 129.2, 128.8, 126.8, 126.7, 125.0, 122.5 (q, *J* = 268.2 Hz), 120.0, 107.1 (q, *J* = 2.1 Hz), 50.6, 21.4;

¹⁹F NMR (377 MHz, CD₃CN): δ (ppm) = -62.7 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 1529, 1473, 1462, 1382, 1239, 1154, 1088, 1011, 954;

HRMS (ESI⁺) calcd. for C₂₉H₂₈F₃N₆O₄S₂⁺ [M+H]⁺: 645.1560, found: 645.1555.

***N*-(((Cyanoimino)(diallylamino)(4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)phenyl)-λ⁶-sulfaneylidene)-4-nitrobenzenesulfonamide (**13**)**



To an oven-dried 50 mL round-bottom flask under nitrogen atmosphere was dissolved sulfondiimidamide **13** (**ii**) (800 mg, 1.24 mmol, 1.00 equiv.) in anhydrous CH₃CN (6.2 mL) at room temperature. Et₃N (0.35 mL, 2.50 mmol, 2.00 equiv.) was then added, followed by the addition of BrCN solution (0.37 mL, 5.0 M in CH₃CN, 1.85 mmol, 1.50 equiv.). After being stirred at room temperature for 10 min, the reaction mixture was quenched with sat. aq. NaHCO₃ solution (100 mL). The product was extracted with ethyl acetate (3 × 60 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 3:1 to 2:1) to afford *sulfondiimidamide* **13** as a pale-yellow oil (780 mg, 1.17 mmol, 94%).

R_f 0.51 (petrol/ethyl acetate, 2:1);

¹H NMR (400 MHz, CDCl₃): δ (ppm) = 8.30 (d, *J* = 8.9 Hz, 2H), 8.16 (d, *J* = 8.9 Hz, 2H), 7.95 (d, *J* = 9.0 Hz, 2H), 7.57 (d, *J* = 9.0 Hz, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.10 (d, *J* = 8.0 Hz, 2H), 6.73 (s, 1H), 5.66 (ddt, *J* = 16.8, 10.2, 6.6 Hz, 2H), 5.30-5.20 (m, 4H), 4.05 (dd, *J* = 15.5, 6.4 Hz, 2H), 3.94 (dd, *J* = 15.5, 6.8 Hz, 2H), 2.36 (s, 3H);


¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 150.1, 147.3, 145.6, 144.51, 144.50 (q, *J* = 38.7 Hz), 140.2, 133.9, 130.1, 129.9, 129.2, 128.6, 128.4, 125.6, 125.3, 124.3, 121.8, 120.8 (q, *J* = 269.4 Hz), 109.4, 107.0, 50.1, 21.2;

¹⁹F NMR (377 MHz, CDCl₃): δ (ppm) = -62.5 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2360, 2208, 1531, 1473, 1462, 1382, 1239, 1162, 1081, 954;

HRMS (ESI⁺) calcd. for C₃₀H₂₇F₃N₇O₄S₂⁺ [M+H]⁺: 670.1513, found: 670.1522.

***N,N*-diallyl-*N'*-cyano-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfondiimidamide (**14 (i)**)**



To an oven-dried 50 mL round-bottom flask was dissolved sulfondiimidamide **13** (463 mg, 0.69 mmol, 1.00 equiv.) in anhydrous CH₃CN (6.90 mL) at 0 °C. Then 1-dodecanethiol (0.83 mL, 3.47 mmol, 5.00 equiv.) was added, followed by the addition of DBU (0.50 mL, 3.28 mmol, 4.75 equiv.). After being stirred at 0 °C for 5 min (judged by TLC), the reaction mixture was quenched with sat. aq. NaCl solution (100 mL). The product was extracted with ethyl acetate (3 × 60 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petrol/ethyl acetate, 2:1 to 1:1) to afford *sulfondiimidamide* **14 (i)** as a pale-yellow oil (301 mg, 0.62 mmol, 90%).

R_f 0.40 (petrol/ethyl acetate, 3:2);

¹H NMR (400 MHz, CD₃CN): δ (ppm) = 8.02 (d, *J* = 8.8 Hz, 2H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.20 (d, *J* = 8.2 Hz, 2H), 7.16 (d, *J* = 8.2 Hz, 2H), 6.92 (s, 1H), 5.65 (ddt, *J* = 17.2, 10.1, 6.3 Hz, 2H), 5.24-5.14 (m, 4H), 3.98-3.83 (m, 5H), 2.34 (s, 3H);

¹³C NMR (101 MHz, CD₃CN): δ (ppm) = 146.7, 144.2 (q, *J* = 37.8 Hz), 144.0, 140.8, 139.1, 133.1, 130.4, 129.9, 129.4, 127.0, 126.6, 122.4 (q, *J* = 268.2 Hz), 120.1, 114.0, 107.1 (q, *J* = 2.1 Hz), 50.6, 21.3;

¹⁹F NMR (377 MHz, CD₃CN): δ (ppm) = -62.8 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2188, 1495, 1471, 1373, 1235, 1160, 1133, 1097, 974, 808;

HRMS (ESI⁺) calcd. for C₂₄H₂₄F₃N₆S⁺ [M+H]⁺: 485.1730, found: 485.1732.

Cc1ccc(cc1)c2cc(C(F)(F)F)cnn2-c3ccc(cc3)S(=N)(=N)N(C=C)CC=C


R_f 0.57 (petrol/ethyl acetate, 2:1);

¹³C NMR (101 MHz, CDCl₃): δ (ppm) = 145.8, 145.1, 144.9 (q, J = 38.9 Hz), 140.5, 132.0, 130.1, 129.7, 129.4, 128.8, 125.9, 125.4, 122.5, 120.9 (q, J = 269.4 Hz), 109.0, 107.3 (q, J = 2.2 Hz), 50.1, 21.4;

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2204, 1592, 1471, 1372, 1236, 1161, 1135, 1096, 973, 888;

S105

***N'*-cyano-*N''*-cyano-4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfondiimidamide (15)**



Sulfondiimidamide **14** (426 mg, 0.84 mmol, 1.00 equiv.), 1,3-dimethylbarbituric acid (783 mg, 5.02 mmol, 6.00 equiv.), Pd(PPh₃)₄ (194 mg, 0.17 mmol, 0.20 equiv.) were dissolved in anhydrous, degassed CH₂Cl₂ (4.20 mL) in an oven-dried 25 mL round-bottom flask and under nitrogen atmosphere. The reaction was stirred at 35 °C for 2 h. The crude product was purified by flash column chromatography (ethyl acetate/ethanol, 1:0 to 3:1) without an aqueous workup to afford *sulfondiimidamide* **15** as a white solid (336 mg, 0.78 mmol, 93%).

mp 208-210 °C;

R_f 0.50 (ethyl acetate/ethanol, 4:1);

¹H NMR (400 MHz, (CD₃)₂SO): δ (ppm) = 8.01 (d, *J* = 8.7 Hz, 2H), 7.52 (d, *J* = 8.7 Hz, 2H), 7.20 (s, 4H), 7.11 (s, 1H), 4.80-2.90 (m, 2H), 2.30 (s, 3H);

¹³C NMR (101 MHz, (CD₃)₂SO): δ (ppm) = 145.4, 144.8, 142.4 (q, *J* = 37.7 Hz), 141.1, 139.3, 129.6, 128.8, 127.1, 125.8, 125.4, 121.4 (q, *J* = 269.0 Hz), 116.5, 106.1, 20.9;


¹⁹F NMR (377 MHz, (CD₃)₂SO): δ (ppm) = -61.0 (s);

IR (ATR): $\tilde{\nu}$ (cm⁻¹) = 2162, 1472, 1377, 1238, 1162, 1053, 1025, 1006, 821;



HRMS (ESI⁺) calcd. for C₁₉H₁₅F₃N₇S⁺ [M+H]⁺: 430.1056, found: 430.1055.

3. Calculated Physical Properties

Calculated using the SwissADME platform.³



celecoxibN-CN



SMILES N#CN=S(=O)(c1ccc(cc1)n1nc(cc1c1ccc(cc1)C)C(F)(F)F)N

Physicochemical Properties

Formula	C18H14F3N5OS
Molecular weight	405.40 g/mol
Num. heavy atoms	28
Num. arom. heavy atoms	17
Fraction Csp3	0.11
Num. rotatable bonds	4
Num. H-bond acceptors	8
Num. H-bond donors	1
Molar Refractivity	97.32
TPSA	105.44 Å²

Lipophilicity

Log P_{ow} (ILOP)	0.00
Log P_{ow} (XLOGP3)	4.23
Log P_{ow} (WLOGP)	6.07
Log P_{ow} (MLOGP)	3.21
Log P_{ow} (SILICOS-IT)	3.14
Consensus Log P_{ow}	3.33

Water Solubility	
Log S (ESOL)	-5.20
Solubility	2.54e-03 mg/ml ; 6.26e-06 mol/l
Class	Moderately soluble
Log S (Ali)	-6.15
Solubility	2.84e-04 mg/ml ; 7.00e-07 mol/l
Class	Poorly soluble
Log S (SILICOS-IT)	-6.43
Solubility	1.50e-04 mg/ml ; 3.70e-07 mol/l
Class	Poorly soluble

Pharmacokinetics

GI absorption	Low
BBB permeant	No
P-gp substrate	Yes
CYP1A2 inhibitor	No
CYP2C19 inhibitor	Yes
CYP2C9 inhibitor	No
CYP2D6 inhibitor	No
CYP3A4 inhibitor	No
Log K_p (skin permeation)	-5.77 cm/s



Druglikeness

Lipinski	Yes; 0 violation
Ghose	No; 1 violation: WLOGP>5.6
Veber	Yes
Egan	No; 1 violation: WLOGP>5.88
Muegge	Yes
Bioavailability Score	0.55

Medicinal Chemistry

PAINS	0 alert
Brenk	1 alert: cyanate_aminonitrile_thiocyanate
Leadlikeness	No; 2 violations: MW>350, XLOGP3>3.5
Synthetic accessibility	3.67

celecoxibN-CNN-CN



SMILES N#CN=S(=NC#N)(c1ccc(cc1)n1nc(cc1c1ccc(cc1)C)C(F)(F)F)N

Physicochemical Properties

Formula	C19H14F3N7S
Molecular weight	429.42 g/mol
Num. heavy atoms	30
Num. arom. heavy atoms	17
Fraction Csp3	0.11
Num. rotatable bonds	4
Num. H-bond acceptors	9
Num. H-bond donors	1
Molar Refractivity	104.67
TPSA	124.52 Å²

Lipophilicity

Log P_{ow} (ILOP)	0.00
Log P_{ow} (XLOGP3)	5.12
Log P_{ow} (WLOGP)	6.39
Log P_{ow} (MLOGP)	2.57
Log P_{ow} (SILICOS-IT)	3.02
Consensus Log P_{ow}	3.42

Water Solubility	
Log S (ESOL)	-5.88
Solubility	5.62e-04 mg/ml ; 1.31e-06 mol/l
Class	Moderately soluble
Log S (Ali)	-7.48
Solubility	1.42e-05 mg/ml ; 3.32e-08 mol/l
Class	Poorly soluble
Log S (SILICOS-IT)	-6.64
Solubility	9.81e-05 mg/ml ; 2.29e-07 mol/l
Class	Poorly soluble

Pharmacokinetics

GI absorption	Low
BBB permeant	No
P-gp substrate	No
CYP1A2 inhibitor	No
CYP2C19 inhibitor	No
CYP2C9 inhibitor	No
CYP2D6 inhibitor	No
CYP3A4 inhibitor	No
Log K_p (skin permeation)	-5.28 cm/s

Druglikeness

Lipinski	Yes; 0 violation
Ghose	No; 1 violation: WLOGP>5.6
Veber	Yes
Egan	No; 1 violation: WLOGP>5.88
Muegge	No; 1 violation: XLOGP3>5
Bioavailability Score	0.55

Medicinal Chemistry

PAINS	0 alert
Brenk	1 alert: cyanate_aminonitrile_thiocyanate
Leadlikeness	No; 2 violations: MW>350, XLOGP3>3.5
Synthetic accessibility	3.35

4. References

- 1 Zhang, Z. X., Davies, T. Q., and Willis, M. C. (2019). Modular sulfondiimine synthesis using a stable sulfinylamine reagent. *J. Am. Chem. Soc.* *141*, 13022-13027. 10.1021/jacs.9b06831.
- 2 Love, B. E., and Jones, E. G. (1999). The use of salicylaldehyde phenylhydrazone as an indicator for the titration of organometallic reagents.. *J. Org. Chem.* *64(10)*, 3755-3756. 10.1021/jo982433e.
- 3 Daina, A., Michielin, O., and Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* *7*, 42717. 10.1038/srep42717.